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ABSTRACT 
Mycobacterium tuberculosis is ostensibly an intracellular pathogen, which may form pellicle-
like biofilms in the peripheries of tuberculosis cavities. Environment-induced cell wall 
modifications and extracellular polymeric substance production may alter host-pathogen 
interactions. Specifically, expectorated mycobacteria from cavities, which establish infection 
in new hosts, may have distinct phenotypic adaptations to impair early clearance by the innate 
immune system. M. tuberculosis H37Rv biofilm extracellular polymeric substance was 
identified using scanning electron microscopy. Biofilm phenotype non-covalently-bound 
extracts of cell wall lipids and carbohydrates were compared to planktonic phenotype and a 
relative reduction in the proportion of constituent glucose in biofilm carbohydrate extracts 
was discovered, indicative of a reduction in α-glucan prevalence. Comparison of carbohydrate 
extracts’ potency in stimulating cytokine and chemokine secretion in whole blood and 
complement activation elucidated reduced C3b/iC3b deposition onto biofilm carbohydrate 
extracts. Labelling live dispersed M. tuberculosis planktonic and biofilm samples with 
fluorescent antibodies showed C3b/iC3b, C5b-9, MBL and C1q deposition was reduced on 
biofilm phenotype cells, using flow cytometry. The relative contribution of each major 
pathway of complement activation was investigated and greater dependence on classical 
pathway activation by M. tuberculosis biofilm cells compared to planktonic cells was 
observed. Implications of these findings in M. tuberculosis pathogenesis are discussed.  
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1 INTRODUCTION 
 
1.1 Overview 
Biofilms are environment-adapted single or multi-species aggregates of microorganisms 
embedded in a self-secreted matrix of extracellular polymeric substance (EPS), which 
attaches the organisms to each other and/or to a surface (Vert et al., 2012). EPS is the 
amalgamation of extracellular hydrated biopolymers such as polysaccharides, proteins nucleic 
acids and lipids (Flemming and Wingender, 2010). This thesis investigates the importance of 
M. tuberculosis biofilm formation in the modulation of the innate human immune response, 
using in vitro techniques to characterise M. tuberculosis biofilms and measure their effect on 
human cytokine/chemokine production and complement activation. Before these findings are 
presented it is pertinent to review tuberculosis pathogenesis, drawing particular attention to 
the role of the innate immune response in host-pathogen interaction and incorporating 
advances in research into M. tuberculosis biofilms and the M. tuberculosis cell wall. 
1.2 What is Tuberculosis? 
Tuberculosis (TB) is an airborne disease that infected an estimated 10.4 million people in 
2015 including 1 million children. In that same year 1.4 million people died as a result of TB 
(Anderson et al., 2016). The causative agent of TB is Mycobacterium tuberculosis, a rod 
shaped bacteria first discovered by Robert Koch in 1882 (Koch, 1882). TB is treatable with a 
multidrug regimen including isoniazid, rifampicin, pyrazinamide and ethambutol over 6 
months (Pai et al., 2016). However, the length of treatment increases the risk of patient non-
compliance. More concerning are incidences of rifampicin and multidrug resistant 
tuberculosis, which together accounted for almost 600 000 cases in 2015 (Anderson et al., 
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2016). Tuberculosis causes a significant disease burden in developing countries with India, 
Indonesia, China, Nigeria, Pakistan and South Africa accounting for 60% of all new 
infections. It also remains a problem in many developed countries for example in the United 
Kingdom, reducing tuberculosis incidence was named as one of the top 7 priorities for Public 
Health England (PHE, 2014). TB cases in London are reported at 26 per 100 000 of the 
population (PHE, 2016), which is greater than the average of the 30 highest-burden TB 
countries in the world at 25 per 100 000 of the population (Anderson et al., 2016). 
Bacillus Calmette-Guérin (BCG) vaccine is currently the only licenced vaccine against 
tuberculosis and it is approaching 100 years since the first human ‘trial’ (Luca and Mihaescu, 
2013). The vaccine is effective against extrapulmonary TB in infants (Trunz et al., 2006) but 
shows wildly variable efficacy against pulmonary TB in adults ranging from 0 to 80% 
(Andersen and Doherty, 2005). This is particularly problematic since 80% of clinical cases 
and nearly 100% of M. tuberculosis transmission is due to pulmonary TB, triggered after a 
period of non-symptomatic latent infection (Hunter, 2011).  
1.3 Part I Transmission 
M. tuberculosis bacteria are expectorated in aerosolised droplets from the lungs of infected 
individual with active tuberculosis. Aerosols have been shown to harbour viable bacteria 
predominantly when particle size ranges from 0.65 – 4.7 µm in aerodynamic diameter 
(Fennelly et al., 2004; Fennelly and Jones-López, 2015). M. tuberculosis bacterium are rod-
shaped, on average 2 - 4 µm in length (Eum et al., 2010) and around 0.44 µm in diameter 
(Takade et al., 2003) suggesting single or small aggregates of mycobacteria are primarily 
responsible for transmission. Sputum samples from tuberculosis patients are predominately 
composed of viable but non-culturable M. tuberculosis bacteria, which are undetected by 
conventional culture but may still be transmissible (Mukamolova et al., 2010).  
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1.4  Part II Air to Alveolus 
M. tuberculosis bacteria are inhaled deep into the respiratory tract but are unable to cross the 
respiratory epithelium which poses a physical barrier between host and pathogen (Stevenson 
et al., 2006). Furthermore, an M. tuberculosis bacterium must contend with its first adversary 
in the war of attrition between host and pathogen, the airway surface liquid (ASL). ASL 
consists of two layers: The aqueous layer immerses cilia in the airway epithelium and enables 
them to beat efficiently, resulting in the gradual upward movement of the ASL to the throat. 
Floating on top of this is a viscous mucus layer, which can trap inhaled bacteria. This process 
of capture and gradual removal is known as mucocilliary clearance (Stevenson et al., 2006). 
Antimicrobial proteins and peptides that are also present in the ASL include lysozyme 
(Fleming, 1922), beta-defensin-1 (hBD-1) (Singh et al., 1998) and LL-37 (Bals et al., 1998). 
Lysozyme is only weakly active against M. tuberculosis (Kanetsuna, 1980) and the 
concentration of hBD-1 required to kill virulent M. tuberculosis is higher than the 
concentration found in the lung (Fattorini et al., 2004). While two studies have shown 
bactericidal activity of of LL-37 against M. tuberculosis (Rivas-Santiago et al., 2013; 
Sonawane et al., 2011) another research group found minimal inhibitory activity of LL-37 
against M. tuberculosis (Jiang et al., 2011). 
M. tuberculosis bacteria that avoid the ASL travel deep into the lung through bronchioles to 
the alveoli. Each alveolus is a spherical construct of type I epithelial cells. The importance of 
type I epithelial cells in M. tuberculosis infection has not yet been determined however type II 
epithelial cells, present at cell junctions as well as resident alveolar macrophages, dendritic 
cells can be infected with M. tuberculosis as illustrated in Figure 1.4.1(Lerner et al., 2015). 
Before phagocytosis of M. tuberculosis is described, it is necessary to review the intricate 
structure of the M. tuberculosis cell wall. 
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Figure 1.4.1: Alveolus structure. Adapted from Lerner et al., 2015, (permission to reuse via 
Creative Commons Attribution License) each alveolus is structured from Type I epithelial 
cells with type II epithelial cells at cell junctions. M. tuberculosis (black rods) is able to infect 
type II epithelial cells, alveolar macrophages (AMs), dendritic cells (DCs) as well as recruited 
neutrophils while recruited natural killer (NK) cells are able to lyse infected cells.    
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1.5 The M. tuberculosis cell wall 
In the absence of biofilm formation, the M. tuberculosis cell wall is the host-pathogen 
interface and contains a variety of immunomodulatory molecules. The thick envelope 
surrounding the bacterium has low permeability and is also thought to be responsible for M. 
tuberculosis’ antibiotic tolerance (Brennan and Nikaido, 1995; Lopez-Marin, 2012). M. 
tuberculosis is classed in the order Actinomycetales and the sub-order Corynebacterineae 
which specifically produce mycolic acids (Verschoor et al., 2012).  
Mycobacteria produce mycolic acyl acid chains ranging from 60 to 90 carbons in length, the 
longest fatty acids known in nature (Lopez-Marin, 2012; Portevin et al., 2004; Verschoor et 
al., 2012; Vilcheze et al., 2000). There are three classes, α-mycolates, methoxy-mycolates and 
keto-mycolates, all of which contain cyclopropane rings in their carbon chains. α-mycolates 
tend to only form an extended ‘U’ shape, keto mycolates tend to form a ‘W’ shape and 
methoxy-mycolates are found in ‘W’ shape and intermediate semi-folded ‘sZ’ shape forms 
(Figure 1.5.1) (Minnikin et al., 2015). The majority of mycolic acids are covalently attached 
via ester linkages to the arabinogalactan, which is in turn covalently attached to peptidoglycan 
forming the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (McNeil et al., 1991, 
1990). This structure forms the core of the mycobacterial cell wall (Brennan, 2003). 
Importantly these mycolic acids form the inner leaflet of an outer membrane (OM). 
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Figure 1.5.1: M. tuberculosis mycolic acids. Adapted from (Minnikin et al., 2015)  
(permission to reuse via Creative Commons Attribution License) A. α-mycolate. B. methoxy-
mycolate in two alternative conformations. C. keto-mycolate 
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Between the mycobacterial inner membrane (IM) and the mAGP complex are 
phosphatidylinositol-anchored lipoglycans lipoarabinomannan (LAM) and lipomannan (LM) 
(Figure 1.5.2). LAM and LM are extensions of phosphatidyl-myo-inositol mannosides 
(PIMS). PIMs are glycolipids with fatty acids attached to glycerol, linked by a phosphodiester 
moiety to myo-inositol. Mycobacterium species can have mono or diacyl PIMs (AC1 and AC2 
respectively) (Minnikin et al., 2015). Furthermore PIMs can be dimannoside or 
hexamannoside (Minnikin et al., 2015; Mishra et al., 2011; Vilkas and Lederer, 1956). 21-34 
α-D-mannopyranosyl residues form the backbone of LM. With LAM, this is further extended 
by an additional highly branched arabinan domain and this is capped with around seven 
residues of mannose per molecule of LAM (Mishra et al., 2011).  
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Figure 1.5.2: Structural topography of M. tuberculosis lipomannan and lipoarabinomannan. 
Adapted from (Minnikin et al., 2015) (permission to reuse via Creative Commons Attribution 
License) MPI is manno-phosphatidylinositol. 
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The mycolic acids terminus of the mAGP complex has been shown to form the inner leaflet of 
a second bilayer surrounding the bacilli, an outer membrane analogous to that of Gram 
negative bacteria but more complex. The 3D ultrastructure of the outer membrane has yet to 
be fully established. The outer leaflet of the outer membrane is composed of non-covalently 
attached free lipids (Bansal-Mutalik and Nikaido, 2014; Hoffmann et al., 2008; Zuber et al., 
2008). 
Recently cell wall lipids have been quantified in M. smegmatis using a method known as 
reverse micellar solution (RMS) extraction. This method completely and selectively removes 
non-covalently bound outer membrane (OM) lipids in the Corynebacteria–Mycobacteria–
Nocardia group (Bansal-Mutalik and Nikaido, 2014, 2011). The OM inner leaflet was found 
to contain covalently bound mycolic acids (4.6% dcm). The OM outer leaflet comprised of 
mostly glycopeptidolipids (GPLs) 5.56% dcm, triacylglycerols (TAG) 2.54%, free mycolic 
acids and fatty acids (MA and FA) 2.06% dcm, diacyl glycerols 0.45% dcm, unidentified 
apolar lipids 0.28% dcm, trehalose dimycolate (TDM) 0.23% dcm and trace amounts of 
sulpholipid (SL). These lipids were found to be more than sufficient to form a complete 
bilayer. Notably the authors reason that a surplus of free mycolic acid required to form the 
outer-membrane is probably due to contamination of the RMS extract with extracellular 
material (Bansal-Mutalik and Nikaido, 2014). This contamination is due to mycobacterial 
biofilm formation, which will be discussed later in section 1.11. It would be interesting to see 
the same method applied to M. tuberculosis to identify the lipid constituents of the outer 
membrane and to identify which outer leaflet lipids form the complete bilayer. A recent model 
of the cell envelope as proposed by Minnikin et al., (2015) is shown in Figure 1.5.3. 
Surrounding the OM is a capsule layer rich in the polysaccharides α-glucan, arabino-D-
mannan, and D-mannan (Lemassu and Daffé, 1994; Ortalo-Magne et al., 1996; Ortalo-Magné 
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et al., 1995). This fragile layer can be stripped by culturing with detergents such as Tween-80, 
agitation alone and agitation with glass beads (Ortalo-Magné et al., 1995; Sani et al., 2010). 
Notably the discovery of the M. tuberculosis capsule was dependent on the culture of M. 
tuberculosis biofilms (surface pellicles). It is therefore possible that the mycobacterial 
extracellular polymeric substance (EPS) also contains the polysaccharides of the M. 
tuberculosis capsule in addition to the presence of free mycolic acids (Ojha et al., 2008) see 
section 1.11 for a review of M. tuberculosis biofilms.
11 
 
 
Figure 1.5.3: The cell envelope of M. tuberculosis. Schematic of the M. tuberculosis cell wall 
adapted from (Minnikin et al., 2015) (Permission to reuse via Creative Commons Attribution 
License). Dimensions correlate to cryo-electron microscopy and cell wall proteins are not 
shown. Depicts the mycobacterial inner membrane (MIM), arabinogalactan peptidoglycan 
(AGP), the mycobacterial outer membrane (MOM). The capsule is not shown. DAT, 
diacyltrehaloses; SGL, Sulfoglycolipid; PDIM, phthiocerol dimycocerosates; PAT, Pentaacyl 
trehalose; αu, fully extended α-mycolate; Kw and Mw, folded keto and methoxy-mycolate 
respectively; Ms, semi-folded methoxymycolate; AG, arabinogalactan; PG, peptidoglycan; 
LAM, lipoarabinomannan; LM, lipomannan; Ac1/Ac2PIM6, acyl/diacyl phosphatidylinositol 
hexamannosides respectively; DPG, diphosphatidylglycerol; PE, phatidylethanolamine; PI, 
phosphatidylinositol; Ac1/Ac2PIM2 acyl/diacyl phosphatidylinositol dimannosides 
respectively. 
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1.6 Part III Pathogen recognition proteins in the alveolus 
Residing in the alveolus are soluble pattern recognition receptors (PRRs) such as complement 
protein C1q (Watford et al., 2000), Ficolin-1 (Liu et al., 2005) Ficolin-3 (Plovsing et al., 
2016) and surfactant proteins A and D (Ferguson et al., 1999; Watford et al., 2001). These 
soluble PRRs interact with pathogen associated molecular patterns (PAMPs) on the surface of 
M. tuberculosis bacteria and opsonise the bacteria. However, uptake of M. tuberculosis can 
occur in the presence or absence of opsonins via PRRs present on host immune cells.  
Soluble PRRs present in the alveolus recognise PAMPs on the M. tuberculosis cell wall such 
as capsular polysaccharides: mannans, α-glucans and arabinomannans as well as OM lipids 
and extracellular proteins. Surfactant proteins SP-A and SP-D are members of the collectin 
family (calcium dependent lectins) unlike SP-B and SP-C which are the other main 
mammalian surfactant proteins (Bernhard, 2016). Surfactant proteins SP-A and SP-D show 
saccharide selectivity, SP-A preferentially binds to mannose over glucose (Jakel et al., 2013). 
This suggests it would preferentially bind to M. tuberculosis capsular mannans and Man-
AMs over capsular α-glucans. Whereas SP-D preferentially binds to maltose but shows an 
equal but less potent binding preference to glucose and mannose (Jakel et al., 2013) 
suggesting it interacts with all M. tuberculosis capsular polysaccharide components, 
mannans, α-glucans and Man-AMs, with similar affinity. Surprisingly, ficolin-3 does not bind 
to Man-LAM but instead to the secreted mycobacterial protein antigen 85 complex (Świerzko 
et al., 2016). Uptake of SP-A opsonised M. tuberculosis shows a decrease in the expression 
of reactive nitrogen intermediates (RNIs) (Pasula et al., 1997) whereas SP-D opsonisation of 
M. tuberculosis inhibits uptake by macrophages and independently causes agglutination 
(Ferguson et al., 2002). Incubation of M. tuberculosis with sub-agglutinating concentrations 
of SP-D reduces the adherence of bacteria to macrophages by 62.7% (Ferguson et al., 2002, 
1999). Trying to piece together the role of alveolus resident soluble PRRs interacting M. 
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tuberculosis is further complicated by observation that SP-A binds to complement protein 
C1q and prevents the formation of active C1 complexes (Watford et al., 2001). Ferguson et 
al. speculate that exclusion of M. tuberculosis from their intracellular niche by SP-D may be 
a protective response. Notably, SP-A levels are increased in HIV-infected patients: 
Bronchoalveolar lavages of HIV-infected individuals with corresponding raised SP-A levels 
led to a 3-fold increase in M. tuberculosis attachment to alveolar macrophages compared 
control non-HIV infected individuals (Downing et al., 1995). Tsolaki suggests the relative 
levels of SP-A and SP-D may correlate with risk of infection (Tsolaki, 2009). The effect of 
bacterial agglutination on M. tuberculosis pathogenesis is unknown but is thought to aid 
mucociliary clearance (Ferguson et al., 2002). Notably SP-A and SP-D were both found to be 
dispensable in the immune control of tuberculosis in mice (Lemos et al., 2011). This may be 
because there is redundancy in the mechanisms M. tuberculosis utilises to enter cells as it can 
gain access to phagocytes via PRRs expressed on their cell surface regardless of prior 
opsonisation (Hossain and Norazmi, 2013).  
Many sPRRs such as C1q and MBL are initiators of the complement cascade, which is a 
major mechanism M. tuberculosis utilises to gain access to its intracellular niche. The 
complement system also regulates inflammation and can directly kill some Gram negative 
bacteria through the deposition of the C5b-9 membrane attack complex which forms pores on 
the bacterial membrane. The cascade is triggered by multiple pathways and converges on 
deposition of C3b, which is quickly degraded to iC3b (Figure 1.6.1) (Murphy, 2012). 
Complement deposition onto M. tuberculosis complex can be initiated through opsonisation 
via antibodies or direct binding of C1q, (the classical pathway) (Carroll et al., 2009), via the 
lectin pathway activators, MBL and ficolins (Bartlomiejczyk et al., 2014; Hoppe et al., 1997; 
Luo et al., 2013) or the positive feedback loop of C3b deposition by the alternative pathway 
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(Schlesinger et al., 1990). Furthermore, M. tuberculosis forms a C3 convertase by recruiting 
C2a providing another mechanism of opsonisation (Schorey et al., 1997).  
During the establishment of infection, before the recruitment of systemic lectins such as MBL 
(Fidler et al., 2009), opsonisation via resident lectins such as C1q (in the absence of SP-A 
interactions) and ficolin-3 may trigger the complement cascade. Although complement 
activation has not been shown to lead to direct killing of mycobacteria, it has been implicated 
in bacterial control through the release of C5a anaphylatoxin in mice (Actor et al., 2001). 
Additionally, complement activation has been shown to be increased in tuberculosis patients 
(Senbagavalli et al., 2009).  
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Figure 1.6.1: The complement system. Adapted from Murphy, (2012), Copyright © 2012 by 
Garland Science, Taylor & Francis Group, LLC. Used by permission of W. W. Norton & 
Company, Inc.  All pathways converge on the generation of a C3 convertase and the 
deposition of C3b on the surface of a pathogen. This can be triggered by lectin pathway 
activators (complement activating collectins and ficolins), classical pathway activation 
through antibodies or the direct binding of C1q, or the spontaneous hydrolysis of C3 and 
generation of a fluid phase C3 convertase through the alternative pathway. The alternative 
pathway also amplifies C3b deposition by all pathways. Pathogenic mycobacteria also recruit 
C2a to their surface to form a C3 convertase and trigger C3b deposition (not shown) (Schorey 
et al., 1997). The effector functions of the complement pathway include the production of 
inflammatory modulators C3a and C5a, opsonisation and uptake of pathogens by phagocytes, 
and the formation of a membrane attack complex (a pore on the pathogen surface) which has 
been shown to be ineffective at killing Gram positive bacteria but may have other roles 
specific to certain pathogens still to be elucidated (Berends et al., 2013). 
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1.7 Part IV Phagocytosis 
PRRs expressed on the cell surface of phagocytes include complement receptors (CR), toll-
like receptors (TLRs), C-type lectin receptors such as dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN), mannose receptors (MR) and Mincle 
(Kleinnijenhuis et al., 2011; Lang, 2013). PRR-PAMP binding between pathogens and 
immune cells usually triggers cytokine/chemokine production and/or phagocytosis followed 
by phagosome-lysosome fusion and bacterial killing. This process is subverted by M. 
tuberculosis bacteria, which are able to exploit uptake mechanisms and inhibit phagosome 
maturation to turn immune cells into a benign replicative niche.  
It is thought the complement receptor CR3 can bind M. tuberculosis directly via its β-glucan 
lectin site interacting with M. tuberculosis capsular polysaccharides (Cywes et al., 1997). Or 
after deposition of complement proteins, which covalently bind to the surface of M. 
tuberculosis (Schlesinger et al., 1990). Complement receptor 3 (CR3), CR4 and to a lesser 
extent CR1 are capable of inducing complement-opsonised M. tuberculosis phagocytosis. It 
was shown using CR-specific antibodies and acid-fast staining that CR3 and CR1 are the 
primary CRs for M. tuberculosis uptake by monocyte-derived macrophages (Schlesinger et 
al., 1990) whereas CR4 was the primary CR in alveolar macrophages (Hirsch et al., 1994). 
Schlesinger et al. also used monoclonal antibodies (mAbs) against monocyte receptor 
antigens and showed that mAb against CR1 inhibited bacterial adherence by 40%. A 
combination of two mAbs against CR3, which targeted distinct epitopes, inhibited adherence 
by 81%. When these antibodies were used in combination with anti-CR1 it resulted in no 
greater inhibition. Schlesinger et al. used EDTA, which inhibits the classical and alternative 
complement pathways, and EGTA and MgCl2, which inhibits only the classical pathway, to 
show that C3b can be fixed to M. tuberculosis by the alternative pathway (Schlesinger et al., 
1990). Complement-opsonised uptake via CR3 prevents Ca
2+
 increase and inhibits 
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phagosome lysosome fusion (Malik et al., 2000). Notably C3 deficient mice have been shown 
to have comparable bacterial burdens, granuloma formation and survival patterns to wild type 
mice suggesting M. tuberculosis is able to enter host cells via other receptors to establish 
infection (Hu et al., 2000).   
TLR2 recognises mycobacterial components including Man-LAM, PIMs, LM and TDM 
(Bowdish et al., 2009; Pitarque et al., 2008) TLR4 recognises mycobacterial proteins such as 
heat shock protein 65 (Bulut et al., 2005). They form as heterodimers TLR2/TLR1, TLR2/6 
and homodimers TLR2/2 and TLR4/4 on the plasma membrane of phagocytes (Saraav et al., 
2014). While TLRs do not directly induce phagocytosis they are associated with the release 
of proinflammatory cytokines and chemokines as well as increased membrane ruffling and 
adhesion which can result in nonspecific phagocytosis (Underhill and Goodridge, 2012) 
Mannose receptors (MRs) play a role in phagocytosis of only virulent strains of M. 
tuberculosis and directly recognises mannose residues such as those present in Man-LAM 
(Schlesinger, 1993). MRs are highly expressed in mouse alveolar macrophages (Hussell and 
Bell, 2014). Uptake via MR due to direct binding to Man-LAM directs M. tuberculosis to a 
phagosomal compartment with limited fusion to lysosomes (Kang et al., 2005). Hence, the 
intracellular niche provided through uptake via both CRs and MRs provides a safe haven for 
M. tuberculosis to replicate and persist.  
Mincle and DC-SIGN have been shown to bind to mycobacterial TDM and Man-LAM. 
respectively (Geijtenbeek et al., 2002; Lang, 2013). DC-SIGN is expressed on both 
macrophages and dendritic cells (Tailleux et al., 2005). Uptake of M. tuberculosis via DC-
SIGN induces IL-10 expression and prevents dendritic cell maturation (Geijtenbeek et al., 
2002). Mincle deficient macrophages show impaired production of proinflammatory 
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cytokines after stimulation with M. bovis BCG and TDM (Behler et al., 2012; Schoenen et 
al., 2010).  
Once inside macrophages, M. tuberculosis prevents phagosome-lysosome fusion through the 
action of immunomodulatory lipids and lipoglycans (Mishra et al., 2011). PIMs interfere with 
phagosome maturation arrest by stimulating Rab5 GTPase to enhance fusion between 
phagosomes and early endosomes, and involves inducing the acquisition of endosomal 
SNARE protein syntaxin-4 and the transferrin receptor (Fratti et al., 2003; Vergne et al., 
2004a, 2004b). Through this process M. tuberculosis gains access to nutrients necessary for 
mycobacteria residing in phagosomal compartments (Kelley and Schorey, 2003; Vergne et 
al., 2004b). LM is recognised by TLR2 leading to the induction IL-12 and apoptosis, Man-
LAM does not induce this response (Dao et al., 2004). Man-LAM inhibits cytosolic Ca
2+ 
increase during phagocytosis by excluding EEA1 from the early endosome, as shown in 
experiment using Man-LAM-coated beads, although the exact mechanism is not known 
(Fratti et al., 2001; Mishra et al., 2011). LAM is known to accumulate in lipid rafts in human 
macrophages via its glycosylphosphatidylinositol anchor and this coincides with reduced 
phagosome maturation (Welin et al., 2008). 
A recent paper used mCherry labelled M. tuberculosis bacteria and time-lapse confocal 
microscopy to investigate the importance of mycobacterial aggregation on the cellular fate of 
the bacteria after phagocytosis. They found internalisation of large aggregates caused 
macrophage necrosis and M. tuberculosis replication, leading to a positive feedback loop of 
increasing macrophage cell death and increasing aggregate size (Mahamed et al., 2017). 
Aggregates, clumps or flocs in microbiology are interchangeable descriptions of a mass of 
bacteria that are often stuck together via a self-secreted matrix i.e. biofilms. Hence, if a single 
M. tuberculosis bacterium enters an alveolar macrophage, it prevents phagosome-lysosome 
fusion and is able to replicate and produce EPS. As the intracellular biofilm grows and 
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effectors of disease are secreted, a threshold is reached at which point the infected 
macrophage undergoes necrosis. The biofilm can then continue to grow extracellularly even 
more rapidly in the nutrient rich cellular debris until another phagocytosis event. 
The mechanism by which M. tuberculosis aggregates triggers necrosis of infected 
macrophages is an area currently being studied but is likely to involve active secretion of 
mycobacterial effectors via the ESX-1 secretion system. For example, ESAT-6 mediates 
escape from the phagosome into the cytosol (Houben et al., 2012) and can trigger necrosis 
(Welin et al., 2011).    
1.8 Part IV Granuloma formation 
Either via taxis of infected macrophages across the lung epithelium or direct infection of lung 
epithelial cells, M. tuberculosis enters the parenchyma where additional macrophages 
aggregate (Pai et al., 2016). Some macrophages gradually transform into lipid saturated foam 
cells, epithelioid cells or fuse into multinucleated giant cells. The concurrent release of 
cytokines and chemokines draws neutrophils, dendritic cells, natural killer (NK) cells as well 
as activated T and B cells after the onset of adaptive immunity (Ramakrishnan, 2012). These 
events culminate in the formation of a tuberculosis granuloma, a distinctive feature in 
tuberculosis disease (Figure 1.8.1). Tuberculosis granulomas are heterogeneous in nature and 
are not all associated with disease progression. Early granuloams are non-necrotizing and can 
heal through calcification or progress into necrotic granulomas associated with high bacilliary 
load in their central caseous necrosis. The immune cell granuloma becomes surrounded by a 
fibrotic rim of fibroblasts, collagen and interspersed immune cells (Lenaerts et al., 2015).
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Figure 1.8.1: The tuberculosis caseating granuloma. Adapted from Ramakrishnan, 2012 
(permission to reuse via Springer Nature Licence number 4274221181184). From the outside 
inwards; activated T and B cells accumulate around the peripheries of the granuloma after the 
onset on adaptive immunity 14 – 17 day after exposure (O’Garra et al., 2013). The bulk of the 
granuloma is comprised of epithelioid macrophages with interspersed NK cells, dendritic 
cells and neutrophils. Towards the inner-rim of the granuloma, some macrophages have 
transformed into multinucleated giant cells and foam cells. M. tuberculosis is prevalent in the 
central area of caseous necrosis and its periphery, where aggregates infect host cells (Irwin et 
al., 2015).  
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1.9 Part V Adaptive immunity and latency 
In order to initiate adaptive immunity to tuberculosis, M. tuberculosis infected dendritic cells 
and monocytes migrate from early forming granulomas to the pulmonary lymph nodes for T 
cell priming (Pai et al., 2016). M. tuberculosis protein and lipid antigens are loaded onto the 
surface of antigen presenting cells via MHC and CD1 expression respectively (Lopez-Marin, 
2012). Subsequently activated CD4
+ 
T cells travel back to the site of infection and secrete 
cytokine IFN-γ to mediate mycobacterial killing mechanisms in phagocytes such as the 
production of reactive oxygen and nitrogen species to control and contain the infection 
(O’Garra et al., 2013).  
However, the induction of a strong CD4
+
 T cell response that controls the infection (often 
indefinitely) yet fails to eradicate all the bacteria may be central to the pathogen’s success. A 
landmark study has shown M. tuberculosis T cell epitopes are hyperconserved (Comas et al., 
2010). T cells are mainly primed to epitopes on secreted proteins such as the 
immunodominant antigens CFP10 and Ag85B and hence T-cell responses to these antigens 
are dependent on their secretion (Woodworth et al., 2008). This enables M. tuberculosis to 
exert some control over CD4
+
 T cell responses through the controlled expression and 
secretion of these ‘immunological decoys’ (Baena and Porcelli, 2009; Rogerson et al., 2006). 
There is not an evolutionary pressure for M. tuberculosis to evade the activation of a T-cell 
response because secreted antigens induce T-cell responses that are incapable of completely 
eradicating M. tuberculosis (Baena and Porcelli, 2009). Potent T-cell activation may also 
benefit M. tuberculosis by contributing to the pathology required for M. tuberculosis 
transmission; via a chronic proinflammatory response which leads to tissue damage, possibly 
driven by the upregulation of matrix metalloproteinases, leading to cavity formation (Behr, 
2013; Comas et al., 2010; Elkington et al., 2011).     
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However in the vast majority of cases, the onset of adaptive immunity triggers a prolonged 
and often permanent period of latent disease where the infected individual is no longer 
infectious. 80-95% of latently infected individuals will never progress to post-primary 
tuberculosis and the remaining 5-20% of the infected population will develop active TB, most 
likely around 2 to 5 years after the initial infection (Baddeley et al., 2013). Despite the low 
likelihood of an individual progressing to the contagious phase of TB, the reservoir of latently 
infected individuals worldwide is colossal with an estimated third of the world’s population 
estimated to be latently infected with TB (Russell et al., 2010). Latent TB is defined by the 
immune response directed against M. tuberculosis rather than directly observing the presence 
of the bacteria. Therefore the latently infected population may include exposed individuals 
who have cleared the infection through an effective innate and/or adaptive immune response 
but remain tuberculin skin test positive (TST
+
) and IFN-γ release assay positive (IGRA+), 
because their adaptive immune response remains detectable (O’Garra et al., 2013). Further 
confounding the identification of latent TB is the fact that a false positive TST can sometimes 
occur in BCG vaccinated individuals, of which there are 3 billion (Andersen and Doherty, 
2005) and through exposure to environmental non-tuberculosis mycobacteria (Horsburgh, 
2004; Van Rhijn et al., 2009). Nevertheless, failed immune facilitated suppression of true 
latent M. tuberculosis infection leads to the reactivation of tuberculosis, also known as post-
primary tuberculosis (Hunter, 2011). 
1.10 Part VI Cavitation  
In immunocompetent individuals, the most prominent signature of post-primary tuberculosis 
is the development of a pulmonary cavities and this is seen in 40 – 87% of pulmonary TB 
cases (Saeed, 2012). There are two competing theories of how M. tuberculosis cavities arise, 
one is based on animal models and argues that cavities arise from the liquefaction of a 
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caseating granuloma (Dannenberg, 1994) and the other, based on human pathology states that 
cavities arise independent of granulomas due to a tuberculosis pneumonia (Hunter, 2016). 
Cavities form when necrotic lung fragments are coughed out. As cavities mature they are 
characterised by a layer of caseous necrotic material over a fibrotic layer. The surface of the 
cavities provide the perfect growth conditions for the extensive extracellular M. tuberculosis 
biofilm formation over there surface of the cavity (Figure 1.10.1) (Hunter, 2011). M. 
tuberculosis cavity biofilms produce more TDM compared to extrapulmonary sites and 
resemble in vitro pellicle cultures (Arora et al., 2016; Hunter, 2016; Robert L. Hunter et al., 
2006). Early studies from the 1940s to 1960 often described the extensive bacterial growth in 
open cavities, where ‘the soft necrotic layer and abundant oxygen supply provide an excellent 
culture medium for tubercle bacilli’ (Canetti, 1965). One historical report, prior even to the 
discovery of the bacillus itself, describe the lumen of tuberculosis cavities as coated in an 
expansive soft semi-transparent greyish-white ‘membrane’ which can detach into sputum 
(Laennec and Forbes, 1821). Robert Hunter and colleagues have repeatedly published 
evidence that M. tuberculosis residing in cavities resemble in vitro pellicle biofims (Arora et 
al., 2016; Hunter, 2016, 2011; Hunter et al., 2014; Robert L. Hunter et al., 2006). 
Despite catastrophic lung damage during cavity formation, infected immunocompetent 
individuals with mature cavities can show remarkable constitution, able to remain mobile, 
relatively active with a persistent cough and thereby capable of spreading the disease for 
decades unless treated (Hunter, 2016). Since the majority of tuberculosis transmission occurs 
via infected individuals with cavities, and these cavities are likely to be associated with 
pellicle biofilm formation, it is plausible that the majority of expectorated M. tuberculosis 
bacteria are shed from biofilms. Hence biofilm phenotype M. tuberculosis bacteria may 
directly compete with the innate immune system of a newly infected host to establish 
24 
 
infection. This theory is the cornerstone of this thesis. Prior to presenting an outline of the 
primary aims of this thesis, it is appropriate to review the current literature regarding M. 
tuberculosis biofilm formation.
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Figure 1.10.1: The tuberculosis cavity. Adapted from (Hunter, 2011) (Permission to reuse via 
Elsevier licence number 4274730590976). (A) A cavity from a largely asymptomatic 
tuberculosis patient who died of an unrelated illness. (B) 200x acid-fast stain with enormous 
numbers of M. tuberculosis bacteria at the cavity surface. 
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1.11 M. tuberculosis biofilm formation 
Biofilms are surface-associated microbial communities surrounded by an extracellular 
polymeric substance (EPS) matrix (Hall-Stoodley and Stoodley, 2009). The exact 
composition of EPS varies between bacterial species but is thought to be primarily 
polysaccharides (Donlan, 2002). The extracellular polymeric substance (EPS) secreted by 
mycobacteria to form the biofilm matrix has yet to be fully characterised. In other bacteria 
that form single-species biofilm, the principle substance in EPS is composed of 
exopolysaccharides; alginate in Pseudomaonas aeruginosa biofilms and colanic acid in 
Escherichia coli biofilms (Watnick and Kolter, 2000). Scrutiny of mycobacterial genomes 
suggest that mycobacteria lack the capability for exopolysaccharide production, but instead 
may be held together by free mycolic acids (Ojha et al., 2005; Sochorová et al., 2014; 
Zambrano and Kolter, 2005). On the contrary, exocellular polysaccharides glucan and 
arabinomanannan and mannan are present in crude exocellular extracts of M. tuberculosis 
pellicles (biofilms) which have only traces of lipids (Lemassu and Daffé, 1994; Ortalo-Magné 
et al., 1995). Therefore, it is feasible that these polysaccharides also contribute to the 
mycobacterial EPS in addition to free mycolic acids (Ojha et al., 2008), and TDM (Robert 
Lee Hunter et al., 2006), secreted proteins and other lipids. 
The classical definition of biofilms, whether mono or multispecies, includes surface 
attachment and a typical model of biofilm formation is shown in Figure 1.11.1, taken from 
Zoubos et al., (2012). Notably, while surface-attachment is often a key defining characteristic 
of microbial biofilms (Watnick and Kolter, 2000), host-pathogen in vivo studies show 
bacterial aggregates that appear to have grown uncoupled from attachment; such as mucoid-
phenotype Pseudomonas aeriginosa clusters in sputum (a mixture of airway mucus, immune 
system factors , bacteria and bacterial products) in the cystic fibrosis lung (Yang et al., 2008). 
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This raises the notion that aggregation may not always require surface attachment. Indeed, 
Staphylococcus aureus clusters in joint-fluid aspirates may have derived from surface-
attached biofilm shedding or grown as clusters in the fluid (Hall-Stoodley and Stoodley, 2009; 
Stoodley et al., 2008). Recently in comprehensive reviews of the role of biofilms in chronic 
infections, biofilms are defined as ‘a coherent cluster of bacterial cells embedded in a matrix, 
which is more tolerant of most antimicrobials and host defences compared with planktonic 
bacterial cells’(Bjarnsholt, 2013; Burmølle et al., 2010).  
In addition to pellicle-type biofilm formation, aggregates of M. tuberculosis in animal model 
infections have been visualised. Both the guinea pig and C3HeB/FeJ mouse models of 
tuberculosis show human-like pathology. Aggregates of extracellular M. tuberculosis have 
been observed using acid fast staining of guinea pig model (Hoff et al., 2011; Lenaerts et al., 
2007; Ryan et al., 2010). Also a more sensitive acid fast method using SYBR Gold nucleic 
acid stain has shown the existence of aggregates within foamy macrophages in the rim of 
caseous granulomas and in extracellular necrosis in the C3HeB/FeJ mouse infection model 
(Driver, 2014; Irwin et al., 2015). An in vitro macrophage infection model has suggested 
aggregates are more cytotoxic than multiple phagocytosis events of the same number of 
bacteria (Mahamed et al., 2017), suggesting aggregates are more than simply multiple bacteria 
in close proximity and are held together by an immunomodulatory EPS matrix. 
There remains reluctance in the field to define any M. tuberculosis aggregates as biofilms. 
This may be due a tendency to regard in vitro clumps that occur in detergent-free shaken 
cultures as disorganised masses of cells, whereas biofilms must be surface associated and 
highly organised. Recently M. tuberculosis has been shown to gradually accumulate 
distinctive extracellular material during progression from exponential growth phase to a non-
replicating persistent growth phase (NRP) with concurrent gradual depletion of Tween 80. 
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This material was visible by scanning electron microscopy (Bacon et al., 2014). It is argued in 
this thesis that all self-formed M. tuberculosis aggregates are biofilms. In defence of this 
assumption, here are two important points: Firstly, in vitro mycobacterial clumps grown in 
shaken cultures are not a mass of cells that can be dispersed by simple methods such as 
vortexing or pipetting. They require harsher methods to disperse such as the introduction of 
detergents into the medium (Ojha and Hatfull, 2012). This is due to the EPS that glues the 
bacteria together in the turbulent conditions of shaken cultures and is presumably a 
phenotypic adaptation to protect the mycobacterial cell wall from the shearing forces inside 
the flask. Secondly, in shaken cultures M. tuberculosis clumps are biofilms formed around the 
surface of pre-existing mycobacteria rather than the walls of the flask. There is no reason why 
a surface for biofilm establishment could not be other mycobacteria. After all, that is in 
essence how all biofilms continue to grow following establishment on any surface, building 
upon an existing framework of bacteria and EPS. The turbulent conditions inside a shaken 
flask are very different to the conditions present in static cultures during pellicle formation 
probably resulting in considerable differences in the amount of EPS secreted and its 
composition. Although the latter resembles in vivo cavity biofilms the former environment 
bears little relation to in vivo necrosis associated biofilms (Basaraba and Ojha, 2017), where 
EPS constituents may differ again. A biofilm is a biofilm regardless of whether it is 
intracellular e.g. an aggregate within a foamy macrophage (Irwin et al., 2015), or extracellular 
e.g. an aggregate in caseous necrosis (Lenaerts et al., 2007). 
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Figure 1.11.1: Biofilm formation. Adapted from (Zoubos et al., 2012) (Permission to reuse via Creative Commons Attribution License). 
Cartoon of the classic model of biofilm development. Stage 1: Planktonic bacteria attach to a surface. Stage 2: EPS production begins. 
Stage 3: The bacterial population becomes established and biofilm structure begins to develop. Stage 4: Growth continues until maturation 
of biofilm as a highly organised structure with oxygen/nutrient gradients and physical features such as air channels. Stage 5: Planktonic 
bacteria are released from the mature biofilm when environmental conditions become unfavourable. Note M. tuberculosis biofilms in 
cavities do not release flagellated bacteria. The biofilm can spread across the cavity surface via sliding motility and bacteria may be shed 
by the mechanical forces of human aspiration and expiration into the respiratory tract to transport the bacteria to a new host. In the case of 
in-vitro pellicle biofilms on the air-liquid interface, surface-association with settled liquid rather than solid-surface attachment allows for 
biofilm formation. 
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In vitro M. tuberculosis pellicle biofilms are surface associated, forming a confluent 
membrane across the air-liquid interface of the culture vessel with some growth up the sides 
and can easily be scraped off their associated surfaces. Pellicle biofilms grow in limited O2, 
high CO2 conditions and show retarded growth in low iron or low zinc medium (Ojha et al., 
2008). In the same paper Ojha et al., show pellicle formation is genetically distinct from 
planktonic growth, as it requires gene Rv1013 (polyketide synthase pks16). In addition, the 
genes Rv2454c and Rv2455c, which encode 2-oxoglutarate dehydrogenase enzymes, are 
required for mature biofilm formation. Triacylglycerides in the cell wall are reduced in M. 
tuberculosis pellicle biofilms, possibly being used as an intracellular carbon source. Pellicles 
have increased free mycolic acids compared to planktonic cultures. Synthesis of free mycolic 
acids has been shown to be due to cleavage of TDM in M. smegmatis by a specific serine 
esterase also present in M. tuberculosis (Ojha et al., 2010, 2008).  
A genetic screen revealed 12 genes that result in biofilm formation deficiency after 
transposon insertion including, pks1, a component of the pks15/1 gene required for the 
production of phenolic glycolipid in some strains (not H37Rv) (Pang et al., 2012). Pellicle 
formation (in the conditions tested) was shown to not be a universal trait among clinical 
isolates. From a sample of 15 clinical isolates, 3 strains formed mature pellicles, 9 strains 
partially formed pellicles and 3 strains failed to produce any pellicle. The pellicles were 
grown in Sauton’s medium-filled wells of microplates wrapped in parafilm and incubated at 
37
o
C for 5 weeks without shaking. Laboratory strain H37Rv formed the thickest pellicle, and 
importantly pellicle formation was seen in all four clades suggesting pellicle biofilm 
formation is not specific to any particular lineage (Pang et al., 2012).  
Pellicle formation can occur without cording, a specific form of organised growth in 
mycobacteria where the mycobacteria are aligned pole-to-pole in linear strands, as a cording 
mutant has been shown to still produce a pellicle with a similar morphology to wildtype M. 
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tuberculosis H37Rv (Sambandan et al., 2013). Through the production of mutants deficient in 
the production of either α, methoxy and keto or keto only mycolic acids, keto mycolic acids 
have been shown to be required for pellicle formation despite the greater accumulation of free 
α and methoxy mycolic acids present in pellicles compared to free keto mycolic acids 
(Sambandan et al., 2013). M. tuberculosis produces highly aggregative curli pili that are 
antigenic and bind to extracellular matrix protein laminin in vitro (Alteri, 2005; Alteri et al., 
2007). The mtp curli pili gene is not upregulated during biofilm formation, although mtp 
mutants show a 68.43% reduction in biofilm biomass suggesting curli pili contribute to cell-
cell contact and surface association during biofilm formation (Ramsugit et al., 2013). 
Furthermore putative MtrAB two component system accessory lipoprotein LpqB, which has a 
homologue in M. tuberculosis, has been shown to be required for mature biofilm formation in 
M. smegmatis, a non-pathogenic species (Nguyen et al., 2010).  
A recent study of pellicle formation in M. smegmatis used scanning electron microscopy and 
proteomics to investigate mycobacterial changes between the early and late stages of pellicle 
development. The authors found that the cell size of M. smegmatis significantly decreased (2 
fold in length and 25% in width) over time. Proteins expressed highly during pellicle 
formation include several proteins involved in cell-wall biosynthesis and modifications 
(Sochorová et al., 2014). GroEL1 showed highest expression during the transition from 
floating flocks to a compact pellicle (Sochorová et al., 2014). GroEL1, a chaperone protein 
thought to be involved in the early stages of TMM transport prior to free mycolate production 
via synthesis and cleavage of TDM (Ojha et al., 2010) has been shown to be required for 
mycobacterial biofilm formation and is involved in the regulation of the synthesis of mycolic 
acids (Ojha et al., 2005). Other proteins upregulated during pellicle formation include antigen 
85A a secreted mycolyl transferase involved in the addition of mycolic acids to 
arabinogalactan and TDM (Huygen, 2014) and two proteins involved in the synthesis of 
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inositol; inositol-3-phosphate synthase and methylmalonate-semialdehyde dehydrogenase 
(Sochorová et al., 2014). Inositol is a monosaccharide incorporated into lipoglycans, PIMs, 
LM and LAM (Mishra et al., 2011).  
Kerns et al., (2014 ) used proteomics and western blots to identify 9 M. tuberculosis H37Ra 
antigenic and pellicle-specific proteins. These proteins were consistently expressed since they 
were isolated from 3 week, 5 week and 7 week old pellicle cultures but not from control 
shaken cultures in the same medium. The western blots were incubated with 60-day old low-
dose M. tuberculosis H37Rv-infected guinea pig serum and probed with horseradish 
peroxidase-labelled anti-Guinea Pig IgG to identify antigenic proteins. Proteins were 
identified by matrix-assisted laser desorption ionization time-of-flight/time-of-flight 
(MALDI-TOF/TOF) mass spectrometry (Kerns et al., 2014). Some interesting pellicle 
specific proteins were identified in this study. The signal transducer FhaA is believed to 
repress peptidoglycan synthesis following activation by a peptidoglycan sensor (Gee et al., 
2012). This could be a response to nutrient starvation (Kerns et al., 2014). CeoB is involved 
in potassium uptake (Cholo et al., 2006) and has been shown to restore isoniazid resistance 
when complementing an E. coli oxyR mutant (Chen and Bishai, 1998). This may therefore 
help explain the phenotypic isoniazid resistance by M. tuberculosis biofilms, although 
overexpression of ceoBC gene pair in M. bovis BCG had no effect on isoniazid susceptibility 
(Chen and Bishai, 1998). Rv3519 has been suggested as a putative acetoacetate 
decarboxylase which could be used by M. tuberculosis to obtain acetone from acetoacetate 
(Kerns et al., 2014; May et al., 2013). M. tuberculosis could utilise acetone as a carbon source 
as seen in M. smegmatis (Lukins and Foster, 1963) and more intriguingly has been speculated 
to perhaps be a diffusible signalling model (Kerns et al., 2014). The case for a mycobacterial 
acetone-quorum sensing mechanism is made stronger by the discovery that MimR is an 
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acetone responsive transcriptional regulator in M. smegmatis (Furuya et al., 2011; Kotani et 
al., 2007). 
Bacon et al., (2014) has shown infection of guinea pigs with NRP phase M. tuberculosis 
H37Rv, which forms aggregate biofilms with distinct EPS, results in reduced pathology and 
delayed onset of disease. Two studies have linked mycobacterial biofilm formation with in 
vivo persistence using M. bovis (Chandra et al., 2010; Flores-Valdez et al., 2015). In the first 
study, a mutant for the cell wall and culture medium associated glutamate synthetase, 
encoded by the gene glnA-1 had reduced levels of intracellular glutamate and abolished 
extracellular levels. The mutant had a 50% reduction in biofilm formation and did not persist 
as long as the wild type in BALB/c mice (Chandra et al., 2010). Flores-Valdez and colleagues 
showed the importance of bis-(3′-5′)-cyclic-dimeric guanosine monophosphate (c-di-GMP) in 
regulating biofilm formation in mycobacteria for the first time. c-di-GMP has been shown to 
regulate between planktonic and biofilm phenotypes in many bacteria (Hengge, 2009). M. 
tuberculosis has two genes involved in the synthesis and regulation of c-di-GMP. Rv1354c 
encodes a protein with diguanylate cyclase and phosphodiesterase domains while Rv1357c 
encodes a protein with a phosphodiesterase domain only (Gupta et al., 2010) Flores-Valdez et 
al., deleted the phosphodiesterase gene Rv1357c from M. bovis BCG, required for the 
degradation of c-di-GMP. This enhanced pellicle biofilm formation, as did supplementation 
of growth medium with c-di-GMP. Notably the authors were unable to detect c-di-GMP 
levels in M. bovis BCG directly. The mutant also displayed resistance to in vitro nitrosative 
stress and persisted in infected BALB/c mice for longer compared to the wild type, measured 
by viable counts. Interestingly a different study where deletion of the same gene in M. 
tuberculosis H37Rv was performed showed that the mutant was less able to persist in 
C57BL/6 mice after 10 weeks (Hong et al., 2013). Notably no assessment of biofilm 
formation was performed and the mutant was not complemented in the mouse infection 
34 
 
experiment. It would be interesting to see what effect on biofilm formation deletion of 
Rv1357c has in H37Rv and whether the reduced pathogenicity is consistent with other animal 
models with more human-like pathology. Flores-Valdez and colleagues have suggested since 
M. tuberculosis actively replicates and increases its burden in the host unlike M. bovis BCG, 
c-di-GMP may have different roles in two strains. M. bovis BCGΔRv1357c is no more 
virulent than parental M. bovis BCG in nude mice and has been tested in BALB/c mice as a 
vaccine (Pedroza-Roldán et al., 2016). It was found to perform better than BCG after M. 
tuberculosis H37Rv challenge, with increased local IFNγ producing T cells, reduced tissue 
damage, and lower bacterial burden and even increased the threshold of corticosterone 
dependent immunosuppression required for disease progression of chronically infected mice. 
This study highlights how improved understanding of M. tuberculosis biofilm formation and 
its effect on host immune responses can be utilised to develop vaccines with greater efficacy 
than BCG (Pedroza-Roldán et al., 2016). Future studies could also identify novel pathogen or 
host targets for adjuvant therapies, which inhibit biofilm formation/EPS production with the 
aim of enhanced cell-mediated clearance and antibiotic activity. Such an approach could 
reduce the lengthy current treatment regimen for tuberculosis. 
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1.12 Thesis aims 
M. tuberculosis biofilm formation has only recently been acknowledged as a fundamental 
aspect of its growth and its importance in pathogenesis is still being researched. In this thesis 
in vitro pellicle M. tuberculosis biofilms are used due to their resemblance of in vivo M. 
tuberculosis biofilms in cavities (Arora et al., 2016; Hunter, 2016). Comparisons are made 
between these biofilms and planktonic cultures. Planktonic M. tuberculosis cultures refer to 
exponential phase shaken cultures, grown using the same medium as used for biofilm culture. 
Despite not being single-cell dispersed, these cultures are still referred to as planktonic 
similarly to another study (Kerns et al., 2014). 
Primary aims for this thesis are as follows: 
 Measure growth and viability of M. tuberculosis biofilms over time (2.3). 
 Define exponential phase planktonic M. tuberculosis (2.3). 
 Find evidence for M. tuberculosis pellicle biofilm EPS from growth data and 
microscopy (2.3 and 2.4). 
 Identify changes to cell wall and EPS carbohydrates/lipoglycans and lipids specific to 
M. tuberculosis pellicle biofilms (3.3 and 3.4). 
 Assess whether changes in carbohydrates/lipoglycans extracts and capsule extracts 
specific to M. tuberculosis pellicle biofilms alter innate human cytokine and 
chemokine responses in a whole blood stimulation assay and multiplex analysis (4.3 
and 4.6) 
 Optimise the dispersion of planktonic and biofilm phenotype M. tuberculosis cultures 
for flow cytometry analysis (5.3). 
 Compare live biofilm and planktonic cells induction of complement activation (5.4, 
5.5 and 5.6). 
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 Investigate if carbohydrate changes specific for M. tuberculosis pellicle biofilms 
affect human complement activation using ELISAs (5.7). 
The discussion sections of each chapter will be limited to technical evaluations of the 
methods applied with further discussion on key aspects of the results in the context of 
published literature on tuberculosis pathogenesis and the innate immune response presented 
in chapter 6.  
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2 OPTIMISATION OF BIOFILM AND PLANKTONIC M. 
TUBERCULOSIS CULTURE 
2.1 Introduction 
The classical definition of ‘planktonic’ phenotype is a transient, motile life stage to transport 
the bacterium to a favourable environment on which to attach and form a biofilm (Watnick 
and Kolter, 2000). There are multiple mechanisms of bacterial motility including swimming 
by use of flagellum, twitching and gliding (Madigan et al., 2010). Mycobacteria are 
nonflagellated and were thought to be nonmotile, although fast growing M. smegmatis and 
slow growing M. avium have been shown to exhibit sliding motility on solid surfaces 
(Martínez et al., 1999) and it is likely that M. tuberculosis shares this characteristic. Sliding 
motility is defined as surface translocation of cells over a substrate, often assisted by EPS to 
reduce friction, and caused by the outward force of a growing culture (Henrichsen, 1972). 
Since mycobacterial sliding is a passive process, moving a population of bacteria as a single 
unit, the planktonic classical definition is not appropriate. Rather, due to the bacteria’s 
reliance on growth, sliding motility could be regarded a mechanism for directional growth 
during biofilm expansion.  
Mycobacterial cell division is different to many bacteria as the division is asymmetrical 
(Kieser and Rubin, 2014). The suggested advantage of this form of growth is that the host 
environment is heterogeneous and can also be in a state of flux meaning differentially sized 
cells may have specific survival advantages dependent on their environment (Kieser and 
Rubin, 2014). Asymmetrical cell division is due to faster growth at the old pole relative to the 
new pole after cytokinesis (Santi et al., 2013). Furthermore, asymmetrical cell division 
coupled with sliding motility may provide a simple mechanism of directional growth towards 
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a favourable environment. Mycobacterial cording could be a manifestation of this process 
(Julián et al., 2010).  
 
The term planktonic M. tuberculosis has previously been used to describe in vitro cultures 
grown in shaking flasks with or without Tween-80 detergent (Kerns et al., 2014; Ojha et al., 
2008). Likewise, in this project the term ‘planktonic’ is defined as M. tuberculosis grown in 
shaking, vented flasks without Tween-80 and using the same medium as used for pellicle 
growth. Under these conditions, M. tuberculosis forms macroscopic clumps, which are 
harvested during exponential growth. In the presence of Tween-80 the bacteria are single-cell 
dispersed but the native capsule layer of each bacterium is shed into the medium. In the 
absence of Tween-80, the bacteria clump together and capsule shedding is less pronounced 
(Sani et al., 2010). The mycobacteria within clumps may have oxygen/nutrient gradients 
(Islam et al., 2012) and therefore a proportion of the population within the clump may not be 
exponentially growing. Effectively, mycobacterial clumps in shaking cultures are a type of 
biofilm in their own right.  The use of the term planktonic bacteria is therefore a little 
misleading. For clarity, the terms planktonic and biofilm in this thesis are used to differentiate 
between younger exponentially growing shaking cultures and older mature pellicles 
respectively. This has been adopted by Kerns et al., (2014) in their study of M. tuberculosis 
biofilms.  
2.2 Chapter 2 hypothesis  
M. tuberculosis pellicle biofilms produce EPS and show organised morphology, which is 
distinct from exponential phase shaken planktonic cultures grown in the same detergent-free 
medium. 
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2.3 M. tuberculosis planktonic and biofilm culture 
M. tuberculosis biofilms were cultured as described in methods section 7.1. Briefly, M. 
tuberculosis H37Rv was cultured in modified Sauton’s medium, grown on 24-well plates 
(which for containment reasons were placed in an airtight container) and incubated for 5 
weeks at 37
o
C. In each of the wells, a thick hydrated yellowish pellicle biofilm formed. A 
photograph of a typical M. tuberculosis biofilms in a 24-well plate and a close-up of one of 
the wells is shown in Figure 2.3.1. Notably this biofilm culture was incubated for 6 weeks 
before harvesting instead of the typical 5 week incubation period. The pellicles did not dry 
out during incubation since humidity was maintained in a sealed box.  
To assess the growth of M. tuberculosis biofilms, two independent cultures were used to 
inoculate a series 24-well plates individually sealed in boxes. Therefore, any one plate per 
time point contained two biological replicate M. tuberculosis cultures in x12 technical 
replicate wells each. This allowed sacrificial sampling without altering the aeration of other 
plates. To quantify the number of viable bacteria in a biofilm, the number of colony forming 
units (CFU) per gram of wet-weight biofilm was calculated at weekly intervals between the 
third and seventh week of culture (method 7.2). On day 0 the inoculum was calibrated to 0.05 
OD540 nm in PBS pH 7.4. Viable counts were performed following serial dilution in detergent-
containing PBS to remove clumps to ensure accuracy. A viable count of 1.94 x 10
6
 ± 2.23 x 
10
5
 CFU mL
-1
 was calculated. Prior to re-suspension in modified Sauton’s medium, the 
inoculum was pelleted and the wet-weight pellet was weighed to determine the number of 
viable bacteria per gram (CFU g
-1
). This was determined to be 4.92 x 10
8
 ± 2.83 x 10
8
 CFU g
-
1
. On day 21 and subsequent sampling days, one plastic container was opened and the liquid 
medium in each well of the 24-well plate was removed from underneath the biofilm. x6 
technical replicate wells of each independent culture were sampled and weighed before being 
dispersed using 1% Tween-80 to determine CFU g
-1
 (Figure 2.3.1c) and the 12 remaining 
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wells were used for a crystal violet assay in the same fashion (Figure 2.3.1d) to quantify 
biomass (method 7.3). Regression analysis between weeks 3 and 5 showed a statistically 
significant downward trend in CFU g
-1
 R
2
 = 0.9968 P= 0.0358. Since CFU g
-1
 essentially 
measures the density of bacteria within the biofilm, this result suggests that either there were 
an increasing proportion of dead or dormant bacteria between weeks 3 and 5 or an increasing 
proportion of biomass was attributable to EPS between weeks 3 and 5. The CFU g
-1
 between 
weeks 5 and 7 appeared to plateau, which would not be expected if cell death was occurring 
as a death phase would result in a continuing drop in CFU g
-1
. Likewise a plateau would not 
be expected if an ever increasing proportion of the population was entering a dormant and 
non-culturable phase due to exhaustion of one or more of the environmental factors required 
for growth. Therefore, the downward trend in CFU g
-1
 between weeks 3 and 5 is indicative of 
an increasing proportion of EPS. This is supported by the time-series crystal violet assay 
which showed statistically significant positive trend towards increasing biomass between 
weeks 3 and 6, R
2
 = 0.9634 P = 0.0185. Therefore, while the density viable bacteria decreases 
between weeks 3 and 5 and plateaus between weeks 5 - 7, the biomass of the biofilm 
increases between weeks 3 to 6. Together these data suggest that M. tuberculosis biofilms 
cultured by the method described above produce sufficient EPS between weeks 3 and 5 to 
lower the density of the bacterial population. 
The inoculum was derived from Tween-80 containing chemostat culture (Bacon and Hatch, 
2009), which harbours dispersed planktonic bacteria. This means most EPS is shed into the 
culture liquid. Prior to inoculation the culture was washed in PBS and pelleted. Therefore the 
viable count (CFU g
-1
) of the inoculum represents a crude estimation of the density of M. 
tuberculosis bacteria in the absence of EPS. It is then possible to estimate the percentage of 
the biofilm that is EPS at each time-point by dividing the viable counts of the biofilm (at T3 – 
7) by the viable count of planktonic bacteria (T0) (Figure 2.3.1e). 
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% EPS   = Viable count of biofilm (CFU g
-1
)   = (Cells + EPS) g
-1 
  Viable count of planktonic inoculum (CFU g
-1
)   Cells g
-1
 
 
These results suggest that during biofilm culture, significant pellicular EPS production does 
not occur until week 4 where it represents around 11% of the biofilm biomass. Between 
weeks 5 and 7 EPS represents consistently around 50% of the biofilm biomass.  
Planktonic control culture medium was identical to the biofilm medium. In the absence of 
detergents, shaken cultures are clumpy. In addition, rather than use a control the same age as 
mature 5-week pellicle biofilms, it was decided that comparing biofilm phenotype bacteria to 
exponential phase shaking cultures would provide a more useful control to determine the 
specific immunological effects of pellicle biofilms. This is because a comparison of biofilms 
to healthy, exponential phase shaken cultures in the same medium is more typical of M. 
tuberculosis cultures routinely used in biochemical and immunological studies. 
To identify the exponential phase of planktonic growth, viable counts of three biological 
replicate cultures were taken on day 0, 4, 10 and 14 (Figure 2.3.1f) (method 7.4). Each 
culture was inoculated at 0.05 OD540 nm, which equated to 1.69x10
6
 ± 5.52 x 10
5
 CFU mL
-1
. 
By day 4 this had risen slightly to 4.06x10
6
 ± 1.2x10
6
 CFU mL
-1
 indicating a lag phase. After 
10 days there was an increase in the number of viable bacteria consistent with exponential 
growth. The viable count reached 1.34x10
8
 ± 8.43x10
7
 CFU mL
-1
. The final viable count 
taken on day 14 was 9.53x10
7
 ± 5.69x10
7
 CFU mL
-1
. This was lower than expected but still 
may be consistent with stationary phase. For consistent reproducible planktonic controls, 
mid-exponential phase bacilli were used for comparison with mature 5 week M. tuberculosis 
pellicle biofilms. Therefore, it was decided that planktonic cultures would be harvested on 
day 7. The generation time of M. tuberculosis in modified Sauton’s medium during 
exponential phase was calculated to be approximately 28.7 hours.  
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Figure 2.3.1: Culture of biofilm and planktonic phenotype M. tuberculosis. (A) Photograph 
of M. tuberculosis biofilms cultured using a 24-well plate and modified Sauton’s medium 
over 6 weeks. (B) Close-up photograph of an M. tuberculosis pellicle biofilm. (C) Viable 
counts of wet-weighed pellet inocula (T0) and biofilms to determine the density of viable M. 
tuberculosis (CFU g
-1
) harvested at 0, 3, 4, 5, 6 and 7 weeks (x2 biological replicates, error 
bars = standard deviation). (D) Crystal violet assay of pelleted innocula (T0) and biofilms to 
quantify biomass of M. tuberculosis harvested at 0, 3, 4, 5, 6 and 7 weeks (x2 biological 
replicates, error bars = standard deviation). (E) Percentage of extracellular polymeric 
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substance (EPS) present in M. tuberculosis biofilms, calculated after dividing the mean 
density of biofilm biomass at weeks 3, 4, 5, 6 and 7 by the mean density of planktonic 
biomass (T0), to determine the proportion of biomass attributable to the bacteria only. (F) 
Planktonic growth curve showing mean total viable count over two weeks, sampled on days 
0, 4, 10 and 14 (x3 biological replicates, error bars = standard deviation)  
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2.4 Microscopy of M. tuberculosis biofilms 
To image the native state of M. tuberculosis pellicle biofilms (method 7.5), biofilms were 
cultured for 5 weeks with a sterilised plastic coverslip placed on the bottom of each well prior 
to the addition of the inoculum. At the point of harvest, the pellicles were gently separated 
from the edges of the wells using a sterile spatula and the medium was removed so that the 
intact pellicle rested on the plastic coverslip. These could then be removed using tweezers 
and fixed using formaldehyde for scanning electron microscopy (SEM). SEM was performed 
by Howard Tolley, PHE. 
SEM analysis showed M. tuberculosis pellicle biofilms contained areas of cording, where the 
majority of bacteria within the cord were oriented pole-to-pole and these cords showed 
variable thickness (Figure 2.4.1a, b and Figure 2.4.2) Sheets of confluent growth were also 
observed (Figure 2.4.3). Air-dried samples better preserved the EPS of the biofilm (Figure 
2.4.1a, Figure 2.4.2a, c, e, Figure 2.4.3a, c) while processing the samples through graduated 
solvents stripped away the EPS and revealed the bacteria within the biofilm in greater detail 
(Figure 2.4.2b, d, f, Figure 2.4.3b, d). Figure 2.4.2a and Figure 2.4.3b appear to show 
mycobacterial cords growing on top of a layer of confluent growth. Figure 2.4.3b, a sample 
stripped of EPS, showed a complex network of serpentine cords on top of the layer. It is 
possible that the confluent growth on the right of the image reveals an area where during 
sample preparation the pellicle had been folded over itself, revealing the confluent bacteria on 
the liquid interface. Figure 2.4.2a has the EPS preserved and shows an area where cording 
has formed a pile or stack. Surrounding this area, cords are completely shrouded by EPS. The 
crevices visible in the EPS may represent air channels or be artefacts of the dehydration 
process of fixation and air-drying.   
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To investigate the vagaries surrounding the distinction between capsule and EPS, fixed 
planktonic and biofilm samples were sent to Dr. Nicole N van der Wel, University of 
Amsterdam for capsule immuno gold EM labelling of the capsule using anti-PIM/LAM 
antibody. This antibody binds to α(1-2) mannosyl residues, present on the mannose caps of 
PIM, LM and LAM and their non-lipdated counterparts. SEM analysis performed by Zehui 
Zhang, a researcher at the University of Amsterdam revealed both planktonic clumps and 
biofilm clumps labelled with α(1-2) mannosyl residues (Figure 2.4.4). The clumps often 
contained few distinguishable individual bacteria and large areas of heavily labelled EPS. 
Interestingly biofilm phenotype showed what appeared to be two types of EPS which were 
both labelled (Figure 2.4.4b). This suggests that similar to the capsule, M. tuberculosis EPS 
also contains α(1-2) mannosyl residues. 
To investigate whether there was a difference in the extent of α(1-2) mannosyl residues 
present on planktonic and biofilm phenotypes, individual bacterium from fixed samples of 
both cultures were identified and the number of gold labels present on each bacterium was 
calculated and the measurements were normalised to the length of each bacterium (method 
7.6). Both planktonic and biofilm bacterium showed an electron transparent zone which was 
heavily labelled suggesting this was the mycobacterial capsule (Figure 2.4.1c, d). 
Interestingly, bacterium from biofilm cultures were on average significantly longer than 
bacterium from planktonic cultures (Figure 2.4.1e) (P<0.0001 Welch’s t-test n≥38). 
Bacterium from planktonic cultures measured 2.803 ± 0.720 µm (mean ± standard deviation) 
while bacterium from biofilm cultures measured 3.842 ± 0.874 µm. This could be because the 
mature biofilm bacteria have ceased dividing after elongation in response to nutrient and/or 
oxygen depletion, whereas the planktonic bacteria divide rapidly following elongation, during 
their exponential growth phase. There was no significant difference in the extent of α(1-2) 
mannosyl labelling between bacterium from planktonic and biofilm cultures.  
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Figure 2.4.1: Scanning electron microscopy and immuno gold labelling of M. tuberculosis 
biofilms. (A) Scanning electron micrograph (SEM) of formaldehyde-fixed and air-dried M. 
tuberculosis biofilm. (B) SEM of formaldehyde fixed and graduated solvent treated M. 
tuberculosis biofilm. Immuno gold anti-PIM/LAM labelled planktonic (C) and biofilm (D) 
M. tuberculosis. (E) Mean length of M. tuberculosis cells. (F) Quantification of immuno gold 
anti-PIM/LAM dots visible on each micrograph associated with a bacterium/length of 
bacterium. n of planktonic and biofilm samples ≥38. * P<0.05 Welch’s t-test. Error bars = 
standard deviation.
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Figure 2.4.2: Scanning electron micrographs of cording bacteria within M. tuberculosis 
biofilms. Samples prepared by air drying (left column) and graduated solvent dehydration 
(right column). (A) and (B) 50x magnification, (C) and (D) 500x magnification, (E) and (F) 
8000x magnification. 
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Figure 2.4.3: Scanning electron micrographs of surface spreading bacteria within M. 
tuberculosis biofilms. Samples prepared by air drying (left column) and graduated solvent 
dehydration (right column). (A) and (B) 50x magnification, (C) and (D) 4000x magnification 
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Figure 2.4.4: SEM image of immuno gold anti-PIM/LAM labelled M. tuberculosis 
aggregates. Representative images of fixed M. tuberculosis samples from planktonic (shaken 
flask) (A) and biofilm (pellicle) (B) cultures. Anti-PIM/LAM antibody binds to α(1-2) 
mannosyl residues.  
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2.5 Technical discussion 
To summarise the results presented in this chapter, M. tuberculosis pellicle biofilms produce 
EPS. Pellicular EPS, as distinct from EPS present in aggregates of shaken cultures, does not 
appear as a major constituent of microbial biomass in cultures until between weeks 3 and 4 of 
biofilm culture and EPS production does not increase indefinitely but plateaus around 50% 
from week 5 of culture. M. tuberculosis planktonic cultures (in identical detergent-free 
medium) also grow as aggregates and reach exponential phase growth between days 4 and 10 
of culture. Planktonic and biofilm M. tuberculosis aggregates label with α(1-2) mannosyl 
residues which appears to be present both in the capsule layer of each bacterium at similar 
levels and in EPS. Bacteria from M. tuberculosis biofilms appear to be on average longer 
than bacteria from exponentially growing cultures in shaken flasks. SEM analysis of native 
state M. tuberculosis pellicle biofilms show copious EPS, which can be removed by 
immersing samples in graduated solvents. M. tuberculosis pellicles show networks of 
intertwined cords as well as areas of confluent growth. 
M. tuberculosis strain H37Rv was used for all M. tuberculosis experiments described in this 
thesis. It has been shown to produce thicker biofilms than most clinical isolates (Pang et al., 
2012), which may be a phenotypic adaptation to laboratory culture methods. However, 
H37Rv is virulent and as previously mentioned, M. tuberculosis pellicle biofilm formation is 
not particular to any specific lineage (Pang et al., 2012) suggesting it is an ideal strain to 
investigate biofilm formation and innate immune responses. Sauton’s medium was modified 
with a 10-fold reduction in monopotassium phosphate, which has previously been shown to 
lead to faster pellicle formation (Lethbridge, 2012 pers. comm.). Therefore this culture 
medium was used to follow on from this previous work. The biofilm culture method also 
differed from a published protocol (Kulka et al., 2012) because there was limited gas 
exchange. The published protocol used microplates wrapped in parafilm to maintain humidity 
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and incubated at 37
o
C in 5% CO2 (Kulka et al., 2012). The biofilm cultures described in this 
thesis were in x12 plate batches, sealed within a 5.5L box for the generation of cell wall 
material and frozen biofilm bacteria stocks. In addition, individual biofilm culture plates in a 
550 mL sealed box were used to analyse M. tuberculosis biofilm growth over time.  
Biofilm culture in a sealed box abided the safety considerations for manipulating containment 
level 3 organisms, which require double containment at all times. Humidity was maintained 
since water could not escape the closed system. However, gas composition and pH may have 
changed over the course of culture. Consistent air composition could be provided in future 
experiments by using specially designed chambers fitted with double 0.2 µm filters, end-
capped with parafilm in a 5% CO2 incubator. This would prevent the release of aerosolised 
bacteria and water vapour, while also ventilating the cultures with a maintained supply of 5% 
CO2 supplemented atmospheric air, similar to the method used by Kulka but with double 
containment. The CO2 concentration of the human lung fluctuates between atmospheric 
levels during inhalation and around 5% during expiration (Krogh and Lindhard, 1914) and 
hence neither a closed system or consistent 5% CO2 supply are likely to replicate in vivo 
fluctuations in air composition within tuberculosis cavities. The effect of a limited oxygen 
supply on the biofilm cultures was not assessed and one can only infer that over the 5 week 
period the surrounding atmosphere of the biofilm cultures gradually altered as M. 
tuberculosis bacteria respired. There would be a gradual increase in CO2 and waste 
metabolised products and a decrease in O2. An increase in CO2 concentration may also lower 
the pH of the medium over time as it dissolves. Such changes may be detected by two 
component systems expressed by M. tuberculosis such as the DosRST system which 
responds to hypoxia and leads to downregulation of protein synthesis and upregulation of the 
Dos regulon to assist in redox homestasis to maintain energy levels through catabolism of 
nutrients and anabolism of cellular components in a low oxygen environment (Poole et al., 
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2012). Notably previous studies have shown pellicles with unlimited gas exchange mature 
after 5 weeks of culture (Kulka et al., 2012) and the cultures described in this thesis similarly 
mature after 5 weeks incubation, suggesting oxygen may not be fully depleted and the pH 
remains high enough for maximal biofilm growth within the well (Figure 2.3.1). The rate of 
oxygen depletion, CO2 increase and pH could be measured by including sensors in the closed 
system or for example with oxygen concentration; methylene blue could be used in one of the 
wells as a simple indicator of depletion. Additionally comparative crystal violet assays to 
measure growth of ventilated and sealed biofilm cultures would highlight the cumulative 
effects of any air composition and pH changes on M. tuberculosis biofilm formation.  
The spread plate method was used to quantify viable counts of planktonic and biofilm 
phenotype M. tuberculosis. Future work could include improvements in the approach to 
quantify bacterial numbers in the cultures studied since the cultures did not contain the 
commonly used detergent Tween-80 for mycobacterial dispersal, which allowed clumping to 
occur. The approach of sampling instantly after using a vortex on the vessel was used in an 
attempt to minimise sedimentation and randomly distribute the clumps throughout the 
medium. Serial dilutions in PBS-Tween-80 were also performed to disperse visible clumps 
for viable counts.  
Quantification of the number of viable bacteria in M. tuberculosis pellicle biofilms was 
performed by calculating the number of colony forming units per gram of wet-weight 
biofilm. Six technical replicates for each biological replicate were included to reduce the 
effect of weight variation between cell pastes. However, an improvement to the method 
would have been to measure dry weights of the biomass with the caveat that the sample dried 
and weighed would not be the same sample spread onto plates.  
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To quantify pellicle-specific EPS (Figure 2.3.1e), viable counts (CFU g
-1
) of biofilm samples 
were divided by the viable count (CFU g
-1
) of the planktonic inoculum. Estimates of the 
percentage of biomass that is EPS are commonly used in biofilm EPS extraction as they 
allow the estimation of EPS extraction efficiency (Nielsen and Jahn, 1999). 
The planktonic cultures used in this thesis comprised of aggregates and therefore did not 
harbour truly planktonic dispersed bacteria. Yet clumps are even seen in Tween-80 
containing chemostat cultures (James et al., 2000). This has implications for the comparisons 
made between planktonic and biofilm cultures. Firstly since the clumps contain 
oxygen/nutrient gradients it suggests there may be additional heterogeneity in the population 
with bacteria at the peripheries of the clump replicating more rapidly than those in the centre 
(Islam et al., 2012). Therefore it is possible not all the bacteria harvested on day 7 of culture 
were in an exponential phase growth state (Figure 2.3.1f) with structurally similar cell 
envelopes. Importantly, M. tuberculosis replication generates heterogeneity in part controlled 
through expression of the gene LamA during replication to produce daughter cells of different 
sizes and growth rates (Hesper Rego et al., 2017). This variation would be present regardless 
of aggregation. However, the additional heterogeneity due to aggregation may further 
increase variability when measuring innate immune responses.  
The incorporation of a detergent such as tyloxapol into the planktonic cultures, which cannot 
be hydrolysed by the bacteria, unlike Tween-80 (de Carvalho et al., 2010) may have provided 
some advantages since it would have dispersed the bacteria effectively. This would have 
allowed more accurate quantitation for growth curves and (as to be discussed in chapter 3) 
would likely enhance the low yield of planktonic cells for biomass because each bacterium 
would have optimal surface area for gas exchange and nutrient uptake. However, this 
approach was not taken because the defining of detergent-free shaken cultures as planktonic 
has been used previously (Kerns et al., 2014). Secondly, the addition of detergents induces a 
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shedding effect on the capsules of the bacteria, which is reduced in detergent-free shaken 
cultures (Sani et al., 2010). Therefore the use of detergents would likely exaggerate any 
disparate innate immune responses between planktonic and biofilm M. tuberculosis due to the 
shedding cell wall components of planktonic cells and these changes could not be attributed 
to pellicle biofilm formation but to the presence/absence of detergent. Notably, α(1-2) 
mannosyl immuno-gold EM capsule labelling of detergent free aggregates showed the 
capsule layer of M. tuberculosis to be barely distinguishable from biofilm EPS in aggregates 
from both planktonic and biofilm cultures (Figure 2.4.4). Therefore, it may be difficult to 
retain capsule but remove EPS and a planktonic state using detergents. 
Another possible approach to determining the effect of biofilm formation on innate immune 
responses to M. tuberculosis that future researchers could pursue, which would complement 
the approach taken here, would be to utilise biofilm-deficient mutants. A mutant M. 
tuberculosis strain in which biofilm formation was inhibited and dispersed planktonic growth 
was observed, compared to wild type (WT) and a complemented mutant strain, cultured in 
exactly the same conditions as WT M. tuberculosis biofilms, would provide an elegant study 
of biofilm formation. One possibility would be to modulate cyclic dimeric guanosine 
monophosphate (c-di-GMP) production, which in turn regulates biofilm formation. 
Modulation of this pathway has been shown to affect M. tuberculosis biofilm formation 
(Flores-Valdez et al., 2015). Deletion of the only known GGDEF domain (with diguanylate 
cyclase activity) in M. tuberculosis H37Rv gene Rv1354c does not affect aerobic planktonic 
growth in Middlebrook 7H9 medium (Hong et al., 2013) but may severely inhibit pellicle 
biofilm growth since it would cease c-di-GMP production (Hengge, 2009). Therefore, these 
mutants and complemented strains could be ideal for further study of biofilm formation.  
The SEM investigations performed here (2.4) using M. tuberculosis and other mycobacteria 
have utilised the contrast between air-drying fixed samples, which preserves EPS, and 
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dehydrates samples using a graded series of ethanol washes, which removes the EPS (Julián 
et al., 2010; Sambandan et al., 2013). The use of plastic coverslips in the bottom of M. 
tuberculosis biofilm cultures allowed removal of the fragile pellicles into formaldehyde for 
SEM with large section still intact. The use of formaldehyde to fix the samples was sufficient 
to preserve biofilms and was the only validated fixative for killing M. tuberculosis biofilms. 
The contrast between air drying samples and gradual dehydration using ethanol in preserving 
EPS of mycobacteria or removing it respectively has previously been shown in M. 
tuberculosis (Sambandan et al., 2013) and non-tuberculosis bacteria (Julián et al., 2010). 
Although their methods used secondary fixation with osmium vapour, this appeared to be 
unnecessary since SEM of formaldehyde only fixed biofilms still preserved M. tuberculosis 
EPS (Figure 2.4.1, Figure 2.4.2, Figure 2.4.3).  
Treatment of fixed biofilms through graded alcohols effectively removed EPS from the 
bacteria (Figure 2.4.1, Figure 2.4.2, Figure 2.4.3). Unfortunately the use of ethanol to 
extract EPS, leaving behind intact cells would be hampered due to the leakage of intracellular 
components as ethanol penetrates the cell membrane (Ingram, 1990). It would be interesting 
to use the air drying EPS preserving technique and EPS removal through graded alcohols on 
planktonic cultures to compare the morphology to pellicle biofilms. 
The biofilm samples sent for α(1,2) mannosyl immuno gold EM labelling were not preserved 
on coverslips but were instead broken-up into clumps use of a vortex and fixed. This released 
enough individual bacteria from both biofilm and planktonic cultures for visualising the 
capsule. However, it would be useful to use this technique on intact biofilms to identify the 
EPS constituents with more specific antibodies in addition to α(1,2) mannose caps. Targets 
could include other capsular components e.g. α-glucan (Sani et al., 2010), known biofilm 
EPS components such as free mycolate and TDM (Robert Lee Hunter et al., 2006) and 
identify whether virulence associated secreted proteins such as CFP10, ESAT-6 and PE/PPE 
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are associated with biofilm EPS. The quantification of gold labelling has been used before to 
discriminate between labelled and unlabelled bacteria (Sani et al., 2010). Since biofilm cells 
were on average longer than planktonic cells (Figure 2.4.1e), and M. tuberculosis width is 
uniform (Kieser and Rubin, 2014), it was possible to quantify the extent of labelling on both 
planktonic and biofilm cells. The accuracy of the quantification may be effected by dark 
regions on the micrographs and large labelled aggregates where counting could have been 
underestimated. The large sample size of individual bacterium (≥38) should cumulatively 
reduce the overall effect of errors in quantitation on each bacterium. 
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3 ANALYSIS OF THE OUTERMOST LIPIDS AND 
CARBOHYDRATES OF PLANKTONIC AND BIOFILM 
PHENOTYPE M. TUBERCULOSIS 
3.1 Introduction 
In chapter 2, it was shown that pellicle biofilms are distinct from planktonic bacteria in 
shaken flasks. Therefore, to determine the biochemical changes that occur, M. tuberculosis 
biomass from planktonic and biofilm cultures was heat-inactivated, evaporated to dryness and 
taken to the University of Birmingham where lipid and carbohydrate analyses was performed. 
M. tuberculosis biofilm lipids have been characterised previously (Ojha et al., 2008). Ojha 
compared mc
2
7000 strain planktonic cultures in Middlebrook 7H9 with 0.05% Tween 80 to 
mc
27000 strain cultured as pellicle biofilms in Sauton’s medium. They observed a reduction 
in triacylglycerol in biofilm M. tuberculosis lipid extracts and an increase in free mycolic 
acids, predominantly α and methoxy mycolates, with 10% keto-mycolates. The planktonic 
and biofilm models described in chapter 2, which use the same detergent-free medium, were 
used to try to replicate and expand on the findings of Ojha et al., (2008). M. tuberculosis lipid 
profiles have been annotated in detail (Besra, 1998; Dobson et al., 1985; Wheeler, 2009). 
Although the growth medium used in the more recent protocols is not stated, Dobson et al., 
used Sauton’s medium, but as to whether the biomass was derived from shaken or pellicle 
cultures is not specified.  
An established method for non-covalently attached cell wall carbohydrate/lipoglycan 
extraction was followed (Besra, 1998). This method removes lipid-anchored 
lipoarabinomannan (LAM), lipomannan (LM), phosphtidylinsitol mannans (PIMs), capsular 
α-glucan, arabinomannan (AM) and mannan (M) from the mAGP cell wall core. It also 
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removes any carbohydrates associated with secreted EPS. Comparison of planktonic and 
biofilm phenotype M. tuberculosis carbohydrates/lipoglycans has not been performed 
previously. Once differences in lipid and carbohydrate extracts have been identified, their 
ability to modulate innate immune responses can be assessed through multiplex and ELISA 
based techniques.  
3.2 Chapter 3 hypothesis 
1) Pellicle biofilm phenotype M. tuberculosis has a lipid profile distinct from 
exponential phase planktonic M. tuberculosis, cultured in shaken flasks with identical 
medium. 
2) Pellicle biofilm phenotype M. tuberculosis has a carbohydrate profile distinct from 
exponential phase planktonic M. tuberculosis, cultured in shaken flasks with identical 
medium. 
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3.3 Analysis of polar and apolar lipids 
To determine whether there was differential expression of lipids in planktonic and biofilm 
cultures grown using identical medium, three independent biological replicates of both M. 
tuberculosis planktonic and biofilm phenotypes were cultured according to methods section 
7.1 and were harvested according to methods section 7.7. Polar and apolar lipids were 
extracted by the method described in section 7.8 and analysed by two direction thin layer 
chromatography (2D-TLC) described in section 7.9 using the solvent systems shown in 
Table 3.3-1.  
Solvent system Direction 1 solvent Direction 2 solvent 
A (apolar) Petroleum ether/ethyl acetate 
98:2 x3 times 
Petroleum ether/acetone 98:2 x1 time 
B (apolar) Petroleum ether/acetone 92:8 
x3 times 
Toluene/acetone 95:5 x1 time 
C (apolar and 
polar) 
Chloroform/methanol 96:4 x1 
time 
Toluene/acetone 80:20 x1 time 
D (apolar and 
polar) 
Chloroform/methanol/water 
250:75:4 x1 time 
Chloroform/acetone/methanol/water 
100:120:5:6 x1 time 
E (polar) Chloroform/methanol/water 
60:30:6 x1 time 
Chloroform/acetic acid/methanol/water 
40:25:3:6 
 
Table 3.3-1: The solvent systems used for analysis of polar and apolar lipids of M. 
tuberculosis by 2D-TLC. 
Densitometry analysis of the scanned raw images of TLC plates was performed as described 
in section 7.10 to quantify changes in lipids between planktonic and biofilm phenotype M. 
tuberculosis. 
Inspection of equally loaded triplicate biological replicate planktonic and biofilm apolar 2D 
TLCs, developed using system A (Figure 3.3.1) revealed a lipid smear in each biofilm 
replicate, which is likely to be triacylglycerols (TAG). This smear was not present in each 
planktonic replicate but a faint spot could be seen in the vicinity. Since TAG did not appear 
as a uniform spot it was not possible to perform densitometry. Phthiocerol dimycocerosates 
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(PDIMs) and menaquinone (MK) were also identifiable. Densitometry analysis (Figure 
3.3.8) showed the biofilm PDIMs spots had a relative density of 63% ± 11% (mean ± 
standard deviation) compared to planktonic spots 36% ± 11%. Densitometry analysis also 
showed the biofilm MK spots had a relative density of 81% ± 6% compared to planktonic 
spots 19% ± 6%. An unidentifiable spot was also present in both planktonic and biofilm lipid 
extracts. This spot labelled ?1 was prominent enough for densitometry analysis and the 
biofilm replicates had a relative density of 71%  ± 9% compared to planktonic replicates 29% 
± 9%. T-tests corrected for multiple comparisons by false discovery rate (Q=5%) showed a 
significant difference in MK and ?1 lipid spot density but not PDIM spot density between 
planktonic and biofilm lipid extracts (P<0.05). 
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Figure 3.3.1: Apolar lipid analysis of planktonic and biofilm phenotype M. tuberculosis 
(Solvent system A ). 2D-TLC plates of apolar fractions from three replicate (independently 
inoculated cultures) of planktonic (left column) and biofilm (right column) phenotype M. 
tuberculosis stained with molybdophosphoric acid (MPA). Phthiocerol dimycocerosates 
PDIMs, Menaquinone (MK), Triacylglycerol (TAG), Unidentified lipid (?1). 
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System B identified trehalose mycolipenates (TMPs) and free fatty acids (FFA). 
Densitometry analysis (Figure 3.3.8) showed biofilm FFA spots had a relative density of 
58% ± 5% compared to planktonic replicates 42% ± 5%. The relative density of biofilm 
phenotype TMPs was 45% ± 8% compared to planktonic spots 55% ± 8%. 2/3 biofilm 
replicates showed an unidentified spot in the top left corner of the TLC, which was not 
present on the planktonic TLCs and the remaining biofilm replicate TLC (?2) (Figure 3.3.2). 
Also adjacent to the free fatty acid spot, present in both planktonic and biofilm apolar lipid 
extracts, is another unidentified spot (?3). The biofilm ?3 spots had a relative density of 48% ±  
19% compared to the planktonic spots 52% ±  19%. T-tests corrected for multiple 
comparisons by false discovery rate (Q=5%) showed a significant difference in FFA lipid 
spot density but not TMPs and ?3 spot density between planktonic and biofilm lipid extracts 
(P<0.05).
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Figure 3.3.2: Lipid analysis of planktonic and biofilm phenotype M. tuberculosis (Solvent 
System B).  2D-TLC plates of apolar fractions from three replicate (independently inoculated 
cultures) of planktonic (left column) and biofilm (right column) phenotype M. tuberculosis 
stained with molybdophosphoric acid (MPA). Free fatty acid (FFA), Trehalose mycolipenates 
(TMPs), Unidentified lipid (?2), Unidentified lipid (?3). 
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System C identified an increase in free mycolic acids (FMA) in the biofilm non-polar lipid 
extract replicates relative to the planktonic replicates (Figure 3.3.3). Densitometry analysis 
(Figure 3.3.8) showed the relative density of biofilm FMA to be 61% ± 4% compared to 
planktonic spots 39% ± 4%. The FMA spot may in fact be two overlapping spots in the M. 
tuberculosis replicates. Additionally two unidentified lipid spots ?4 and ?5 were present in the 
top right corner of most replicates. Another unidentified lipid spot ?6 was present on 2/3 
biofilm replicates. These spots were too faint for accurate densitometry analysis. T-tests 
corrected for multiple comparisons by false discovery rate (Q=5%) showed a significant 
difference in FMA lipid spot density between planktonic and biofilm lipid extracts (P<0.05).
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Figure 3.3.3: Lipid analysis of planktonic and biofilm phenotype M. tuberculosis (Solvent 
system C). 2D-TLC plates of apolar fractions from three replicate (independently inoculated 
cultures) of planktonic (left column) and biofilm (right column) phenotype M. tuberculosis 
stained with molybdophosphoric acid (MPA). Free mycolic acid (FMA), Unidentified lipid 
(?4), Unidentified lipid (?5), Unidentified lipid (?6). 
 
66 
 
Inspection of apolar 2D TLCs developed using system D did not show prominent lipid spots 
in some of the replicates (Figure 3.3.4). Sulfolipid-1 (SL-I) and trehalose dimycolate (TDM) 
appeared consistently in the biofilm replicates and in 2/3 planktonic replicates. Trehalose 
monomycolate (TMM) did not consistently show up in either planktonic or biofilm replicates. 
All spots from the non-polar extracts were too faint for densitometry analysis.  
The separation of polar lipids into an aqueous phase and apolar lipids into an organic phase 
using a separatory funnel does not result in complete separation of both apolar and polar 
lipids but rather an equilibrium, meaning apolar lipids may be detectable in the polar fraction. 
TDM and TMM and SL-I were also present in the polar fraction of the M. tuberculosis lipid 
extracts and were present in both planktonic and biofilm phenotypes (Figure 3.3.5). 
Unfortunately, one planktonic and biofilm replicate polar lipid extract was contaminated due 
to a technical error and could not be used. Only the SL-I spot was prominent enough in the 
polar lipid fractions for densitometry analysis. The biofilm SL-I spots had a relative density 
of 67% ± 3% compared to the planktonic replicates 33% ± 3%. T-tests corrected for multiple 
comparisons by false discovery rate (Q=5%) showed a significant difference in SL-I lipid 
spot density between planktonic and biofilm lipid extracts (P<0.05). 
To confirm that these spots were glycolipids, TLC plates were stained with α-napthol (Figure 
3.3.6). Inspection of polar lipid TLCs developed using system D and stained with α-napthol 
showed TMM, TDM and SL-I spots, confirming them to be glycolipids. TDM and SL-I were 
too faint to visualise on one of the planktonic replicates. 
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Figure 3.3.4: Apolar lipid analysis of planktonic and biofilm phenotype M. tuberculosis 
(Solvent System D). 2D-TLC plates of apolar fractions from three replicate (independently 
inoculated cultures) of planktonic (left column) and biofilm (right column) phenotype M. 
tuberculosis stained with molybdophosphoric acid (MPA). Trehalose monomycolate (TMM), 
Trehalose dimicolate (TDM), Sulfolipid I (SL-I). 
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Figure 3.3.5: Polar lipid analysis of planktonic and biofilm phenotype M. tuberculosis 
(Solvent System D). 2D-TLC plates of polar fractions from two replicate (independently 
inoculated cultures) of planktonic (left column) and biofilm (right column) phenotype M. 
tuberculosis stained with molybdophosphoric acid (MPA). Sulfolipid-I (SL-I), Trehalose 
monomycolate (TMM), Trehalose dimicolate (TDM).  
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Figure 3.3.6: Polar glycolipid analysis of planktonic and biofilm phenotype M. tuberculosis 
(Solvent system D). 2D-TLC plates of polar fractions from two replicate (independently 
inoculated cultures) of planktonic (left column) and biofilm (right column) phenotype M. 
tuberculosis stained with α-napthol. Sulfolipid-I (SL-I), Trehalose monomycolate (TMM), 
Trehalose dimicolate (TDM). 
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System E was developed after spraying with α-napthol to stain mycobacterial glycolipids and 
identified phosphatidylinositol mannosides (PIMs) with no major changes between 
planktonic and biofilm phenotype M. tuberculosis (Figure 3.3.7). Only the Monoacyl 
phospho-myo-inositol-dimannoside (Ac1PIM2) spot was prominent enough for densitometry 
analysis. The analysis (Figure 3.3.8) revealed biofilm Ac1PIM2 spots had a relative density of 
45% ± 11% compared to the planktonic replicates 55% ± 11%. Figure 3.3.7 also shows 
additional spots (?7) and (?8) present in the top right corner of both planktonic and biofilm 
polar lipid extract TLCs which are an unidentified glycolipids. T-tests corrected for multiple 
comparisons by false discovery rate (Q=5%) showed no significant difference in Ac1PIM2 
lipid spot density between planktonic and biofilm lipid extracts (P<0.05).
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Figure 3.3.7: Polar glycolipid analysis of planktonic and biofilm phenotype M. tuberculosis 
(Solvent system E). 2D-TLC plates of polar fractions from two replicate (independently 
inoculated cultures) of planktonic (left column) and biofilm (right column) phenotype M. 
tuberculosis stained with α-napthol. Monoacyl phospho-myo-inositol- hexamannoside 
(Ac1PIM6), Diacyl phospho-myo-inositol- hexamannoside (Ac2PIM6), intermediate PIMs 
(Ac1PIMx), Monoacyl phospho-myo-inositol- dimannoside (Ac1PIM2), Diacyl phospho-myo-
inositol- dimannoside (Ac2PIM2), Unidentified glycolipid (?7), Unidentified glycolipid (?8)  
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Figure 3.3.8: Densitometry of lipid spots. Relative density (%) of planktonic and biofilm M. 
tuberculosis lipid spot size from equally loaded TLC plates. Relative percentage was 
calculated from integrated density measurements on scanned raw data images, processed 
using ImageJ software (Schindelin et al., 2012), method 7.10. Phthiocerol dimycocerosates 
(PDIMs), Menaquinone (MK), Unidentified lipid from solvent system A (?1), Free fatty acid 
(FFA), Trehalose mycolipenates (TMPs), Free mycolic acid (FMA), Sulfolipid-I (SL-I), 
Monoacyl phospho-myo-inositol-hexamannoside (Ac1PIM2). Graph shows mean of x3 
biological replicates. SL-1 and Ac1PIM2 data is mean of x2 biological replicates. Error bars 
show standard deviation. Significant differences calculated by t-tests corrected for multiple 
comparisons by false discovery rate (Q= 5%).
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To determine if biofilm formation alters the inner leaflet outer membrane mycolic acid 
profiles of M. tuberculosis, MAMES and FAMES analysis was performed. Mycolyl-
arabinogalactan-peptidoglycan (mAGP) extracts from planktonic and biofilm samples were 
purified and processed as described in methods sections 7.11 and 7.12 to create methyl ester 
derivatives. The samples were spotted on a single direction TLC plate and the TLC plate was 
developed and sprayed with MPA. α-mycolates, methoxy-mycolates and keto-mycolates 
were present in both biofilm and planktonic samples (Figure 3.3.9). Fatty acids were also 
present in the samples. There appeared to be an additional fatty acid spot in the biofilm 
sample which was not seen in the planktonic sample. A biological replicate of the MAMES 
analysis using independently grown planktonic and biofilm cultures is also shown (Figure 
3.3.10). Analysis of the replicate samples showed a similar profile of mycolic acids. 
However, fatty acids were not seen in the planktonic sample. In addition, the three fatty acid 
spots in the biofilm sample appeared to show that the relative proportions of each fatty acid 
were altered compared to the MAMES and FAMES analysis shown in Figure 3.3.9.   
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Figure 3.3.9: Analysis of mycolic acid methyl esters (MAMES) and fattty acid methyl esters 
(FAMES). Derived M. tuberculosis mycolyl-arabinogalactan-peptidoglycan extracts planktonic 
(left lane) and biofilm (right lane). MAMES: α-mycolates, Methoxy-mycolates and keto-
mycolates 
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Figure 3.3.10: Analysis of replicate mycolic acid methyl esters (MAMES) and fatty acid 
methyl esters (FAMES). Derived M. tuberculosis mycolyl-arabinogalactan-peptidoglycan 
extracts planktonic (left lane) and biofilm (right lane). MAMES: α-mycolates, Methoxy-
mycolates and keto-mycolates. Biological replicate repeat of analysis shown in Figure 3.3.9. 
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3.4 Analysis of outermost carbohydrates of the M. tuberculosis cell wall  
To identify whether any changes to the outermost lipoglycans and carbohydrates occur when 
M. tuberculosis adopts a biofilm phenotype, non-covalently bound cell wall components from 
the cell wall core were extracted. Three separate extractions were performed using 
independently grown planktonic and biofilm M. tuberculosis cultures. The samples were heat 
inactivated and dried as described in methods section 7.7. Heat-inactivated planktonic and 
biofilm dried biomass samples were heated under ethanol reflux and phenol-treated to 
remove contaminating proteins and obtain the outermost non-covalently bound cell wall 
carbohydrate/lipoglycan fraction (method 7.13). Non-covalently bound lipoglycans and 
carbohydrates were visualised using ProQ Emerald 300 carbohydrate (and glycoprotein) stain 
according to the method described in section 7.14. Figure 3.4.1 shows the results of the third 
extraction where 150 µg of pooled-planktonic and three independent biofilm phenotype M. 
tuberculosis carbohydrate samples along with M. smegmatis LAM standard was loaded onto 
a gel and visualised greyscale as a coloured spectrum, which approximates the quantity of 
carbohydrate in each band. Planktonic biomass was pooled due to low a yield of dried 
biomass. The ≈120 kDa α-glucan band was not clearly detected in any sample run on the gel. 
There may be a faint band in the planktonic sample but this bleeds into the background so 
could be an artefact. LAM and LM were detected in both planktonic and biofilm samples at 
similar quantities.  
Figure 3.4.2 shows the results from carbohydrate extractions 1 and 2. Extraction 1 revealed 
the presence of α-glucan (visible in the biofilm sample) and PIMs in addition to LAM and 
LM. Extraction 2 did not reveal α-glucan and PIMs. Furthermore, the LAM to LM ratio in 
extraction 1 showed that the biofilm extract had a greater proportion of LAM to LM. 
Contrary to this, extraction 2 showed the reverse; with a greater proportion of LM to LAM. In 
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extraction 3 (Figure 3.4.1) the ratio of LM to LAM was roughly equal between planktonic 
and biofilm phenotype. 
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Figure 3.4.1: Analysis of planktonic control and triplicate biofilm M. tuberculosis 
carbohydrates of the cell wall. Non-covalently bound carbohydrate extracts from planktonic 
(pooled x3 biological replicates) and biofilm phenotype (x3 biological replicates) M. 
tuberculosis stained with Pro-Q Emerald 300, which binds to periodate-oxidized 
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carbohydrate groups. The image was taken using a Molecular Imager with Image-Lab 
software Gel Doc XRT (Bio-Rad, USA). Greyscale image (Top) and Spectrum image 
(Bottom) The spectrum highlights the intensity of staining with red indicating intense staining 
and blue unstained. 
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Figure 3.4.2: Carbohydrate/lipoglycan gels (extractions 1 and 2). Biological replicate 
planktonic (PK) and biofilm (BF) cultures M. tuberculosis stained with Pro Q Emerald 300 
stain and viewed using Molecular Imager® Gel Doc™ XR System with Image Lab™ 
Software. Top panel - greyscale gel image. Bottom panel - spectrum gel image indicating 
band intensities. 
81 
 
To determine the relative proportions of the constituent sugars in M. tuberculosis planktonic 
and biofilm phenotype carbohydrate extracts and mAGP extracts, samples were hydrolysed 
and converted into alditol-acetate derivatives for gas chromatography analysis. Gas 
chromatography was performed by staff at the University of Birmingham. The relative 
proportions of arabinose, mannose and glucose from two independent total sugar analyses of 
planktonic carbohydrate extracts were 17.83±8.65 % (mean ± standard deviation), 
33.75±0.39 % and 48.43±8.26 % respectively. The relative proportions of arabinose, 
mannose and glucose from two independent total sugar analyses of biofilm carbohydrate 
extracts were 34.89±0.65 %, 50.33±6.99 % and 14.78±6.34 % respectively. 
These results indicated outermost carbohydrates were altered in M. tuberculosis biofilms 
compared to planktonic culture. To gain a clearer understanding of these constituent sugar 
changes that occur in M. tuberculosis biofilms compared to planktonic culture, sugar:sugar 
ratios were determined. The proportion of glucose, relative to both arabinose and mannose, 
was reduced in the biofilm phenotype compared to planktonic phenotype, while the 
proportion of arabinose relative to mannose was unchanged (Figure 3.4.3a). The relative 
proportions of sugars in cell wall arabinogalactan appeared unchanged due to phenotype 
(Figure 3.4.3b).  These results suggest that there is a phenotype-specific reduction in glucose 
in the M. tuberculosis biofilm carbohydrate extract. Since glucose is the constituent sugar of 
capsular α-glucan, this suggests that the prevalence of α-glucan relative to other outermost 
carbohydrates may diminish during the formation of mycobacterial biofilms under the 
conditions described in this study.
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Figure 3.4.3: Sugar analysis of M. tuberculosis planktonic and biofilm phenotype 
carbohydrate and mAGP cell wall extracts. (A) Mean constituent sugar:sugar ratios of 
planktonic and biofilm phenotype M. tuberculosis carbohydrate extracts. (B) Mean 
constituent sugar:sugar ratios of planktonic and biofilm phenotype mAGP cell wall extracts. 
Error bars show standard deviation of x2 biological replicates. 
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3.5 Technical discussion 
The results presented in this chapter suggest modification to the outermost lipids and 
carbohydrates of M. tuberculosis when it adopts a pellicle biofilm phenotype. To summarise 
the key findings, Solvent system A showed that M. tuberculosis biofilms have increased MK 
and an unidentified lipid (?1) relative to planktonic samples. Solvent system B showed 
biofilm M. tuberculosis bacteria had increased FFA. System C revealed the biofilm 
phenotype had increased free mycolates in agreement with the findings of Ojha et al., (2008) 
who showed free mycolates were part of the mycobacterial biofilm EPS and were increased 
compared to the planktonic phenotype. System D showed biofilm lipid extracts had increased 
SL-I and solvent system E revealed no consistent changes in mycobacterial PIMs between 
planktonic and biofilm phenotypes. Sugar analysis of carbohydrate extracts revealed a 
reduction in glucose in the biofilm phenotype, which is most likely to be the constituent sugar 
of the exopolysaccharide α-glucan. 
The culture of M. tuberculosis biofilms produced ample biomass for biochemical analyses. 
However, the culture of exponential phase planktonic M. tuberculosis in flasks produced a 
low yield of biomass. The yield could have been increased by setting up more flasks or by 
further optimising the planktonic control to increase the yield. Preliminary optimisation for 
planktonic growth showed that vented flasks produced a higher yield than sealed flasks and 
standard Sauton’s medium, with ten-fold higher KH2PO4, produced a higher yield than 
modified Sauton’s medium (data not shown). This suggests oxygen and KH2PO4 availability 
are important limiting factors for planktonic growth, as has been previously described in the 
literature: Gradual depletion of oxygen triggers nonreplicating persistence (Wayne and 
Hayes, 1996) and both potassium and phosphate depletion trigger M. tuberculosis to enter a 
non-replicative persistent growth state (Rifat et al., 2009; Salina et al., 2014). Furthermore, 
phosphate depletion causes elongation of M. tuberculosis bacterium over 28 days (Rifat et al., 
84 
 
2009) similar to what was seen in 35 day pellicle biofilm M. tuberculosis (Figure 2.4.1). 
While the use of vented flasks was subsequently implemented, the use of modified Sauton’s 
medium was continued for consistency, as it had been used previously for biofilm growth 
(Lethbridge 2013 pers. comm.). However, pellicles have been shown to grow sufficiently in 5 
weeks with Sauton’s medium (Kulka et al., 2012) and the benefit of a higher planktonic yield 
may have out-weighed any cost in reduced biofilm biomass for cell wall extractions and 
analyses.  
Preliminary data showed that the addition of 0.05% Tween-80 to planktonic Sauton’s cultures 
increased the yield of biomass (data not shown). The addition of detergent inhibits biofilm 
formation (Ojha and Hatfull, 2012) and therefore an ideal planktonic control would not use 
any detergent, and especially not Tween 80 because it can be used as a carbon source by M. 
tuberculosis (Bacon et al., 2014). However the detergent tyloxapol cannot be hydrolysed (de 
Carvalho et al., 2010) and therefore needn’t be added to biofilm cultures to keep medium 
nutrient levels equivalent. If the addition of Tween-80 increases planktonic yield due to its 
detergent effects of greater dispersion of the bacteria and hence surface area for nutrient 
uptake and gas exchange, and not due to the hydrolysable nature of Tween-80, then one could 
consider the use of 0.05% tyloxapol in planktonic cultures to increase yield. However, it is 
not possible to separate M. tuberculosis lipids from the detergent in culture filtrates (Wheeler, 
2009) and importantly, the addition of a detergent would cause shedding of lipids and 
carbohydrates into the medium (Sani et al., 2010). Therefore, it would be preferable to 
compare lipid and carbohydrate extracts from wildtype (WT) M. tuberculosis and a biofilm-
deficient mutant, which grows amply as a dispersed culture under the same conditions that 
the WT grows as a biofilm, rather than utilise detergents. 
The accuracy of quantitation of lipids could have been improved by incorporating 
14
C 
labelled glycerol into the medium of the M. tuberculosis cultures, which would then be 
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incorporated into synthesised lipids. After polar and non-polar lipid extraction and TLC 
analyses, the quantity of label in each lipid spot could be measured using a PhosphorImager 
(Wheeler, 2009).  
Separation of lipids in the biological replicate samples alongside one another in the same 
solvent system eliminated variations that might have been caused from making up the solvent 
system multiple times. There was an additional unannotated spot in the top-right corner of 
solvent system A TLCs that was not analysed by densitometry because it could not be 
separated from the solvent front and therefore it could have contained a mixture of lipids. 
Solvent system D TLC plates (Figure 3.3.5, Figure 3.3.6 and Figure 3.3.4) showed faint 
spots in all replicates. Extraction from more initial biomass or loading more lipids onto the 
TLC plate to produce bolder spots could have made them amenable to densitometry analysis, 
however care must be taken not to overload the plates which can result in poor separation. 
The quantity of lipid in the culture filtrates of the biofilm and planktonic cultures was not 
assessed. The turbulence created in shaken flasks may have caused the shedding of free lipids 
into the medium in planktonic cultures to a greater extent than in biofilm cultures. This could 
account for the presence of higher quantities of PDIMs, MK, unidentified lipid-?1, FFA, 
FMA and SL-I seen in the biofilm extracts. Analyses of culture filtrates from both growth 
conditions would be required to ascertain if there was an upregulation in the synthesis of 
these lipids by M. tuberculosis during pellicle biofilm formation or whether these lipids are 
partially shed into the medium of the planktonic cultures because of shearing through 
shaking. Notably, shaken cultures without detergent still shed capsular polysaccharides, but 
to a lesser extent, suggesting that shearing effects do have an impact (Sani et al., 2010).  
Gel analysis of non-covalently bound carbohydrates and lipoglycans showed disparate 
proportions of LM to LAM between planktonic and biofilm samples with initial extractions 
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(Figure 3.4.1, Figure 3.4.2). However, gel analyses of the third extraction (Figure 3.4.1), 
which was prepared from three biological replicates of M. tuberculosis biofilms and a pooled 
planktonic biological replicates (run in parallel) showed no differences between planktonic 
and biofilm LAM and LM in their relative quantities. The utilisation of additional replicates 
in this gel suggests it is likely to be more reliable than the single extractions 1 and 2 (Figure 
3.4.2). As the culture method for M. tuberculosis was consistent for each extraction, it is 
possible that the efficiency of the extraction process was dependent on the reagents and 
equipment used on the day and/or human error. 
Despite the variation in the results of the gel electrophoresis, there was a consistent decrease 
in the quantity of glucose relative to arabinose and mannose with extracts 1 and 2 from the 
total sugar analysis (Figure 3.4.3). Unfortunately, samples from the third extraction were 
contaminated during the derivatization process to prepare samples for gas chromatography 
(data not shown), since the gel of extraction 3 showed no contaminants (Figure 3.4.1). α-
glucan could only be visualised on the gel in the biofilm extract of extraction 1 (Figure 
3.4.2). This biofilm gel lane appeared to be more heavily loaded with carbohydrate extract 
compared to the planktonic lane in extraction 1 which could have been human error. This 
could account for the α-glucan band visible in the biofilm but not planktonic extract, despite 
total sugar analysis suggesting glucose prevalence was reduced on biofilm phenotype M. 
tuberculosis. It is possible that levels of α-glucan were below the limit of detection in most 
cases. The ProQ Emerald labelling kit can detect ≥0.5 ng of periodate-oxidized carbohydrate 
groups per band. This suggests there was less than 0.5 ng α-glucan extracted in the M. 
tuberculosis samples, with the exception of the biofilm sample from extraction 1 (Figure 
3.4.2).  
A third replication of the total sugar analysis to support the finding of reduced glucose 
constituent sugar in the carbohydrate extracts could have made the data amenable to 
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statistical analyses. However, there is good consistency in the findings from the replicate 
samples used. Further work could include linkage analysis through per-O methylation and 
GC/MS analysis of the carbohydrate extracts (Alderwick et al., 2005). This would allow 
confirmation that the glucose is derived from α-glucan, if α(1,4) glucopyranosyl and α(1,6) 
linked glucopyranosyl residues were identified (Angala et al., 2014). Alternatively, if β(1,4) 
linked glucopyranosyl units were identified, it would be indicative of cellulose, as has been 
found in surface attached M. tuberculosis biofilms (Trivedi et al., 2016). Until these analyses 
have been performed, the reduction in glucose constituent sugars from the results presented in 
this thesis could be due to a reduced prevalence of α-glucan, cellulose, or both. However, 
previous linkage analysis of M. tuberculosis H37Rv cultured in Sauton’s medium as pellicle 
biofilms has only identified α-glucan (Ortalo-Magné et al., 1995) leading to the reasoning the 
glucose identified in the extracts here is also derived from α-glucan.  
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4 OPTIMISATION AND ANALYSIS OF DIFFERENENTIAL 
CYTOKINE/CHEMOKINE RELEASE IN WHOLE BLOOD 
STIMULATED WITH PLANKTONIC AND BIOFILM 
PHENOTYPE M. TUBERCULOSIS EXTRACTS 
4.1 Introduction (Part 1) 
Chapter 3 identified a novel change in M. tuberculosis carbohydrate extracts through total 
sugar analysis. M. tuberculosis biofilms possess reduced glucopyranose constituents 
compared to exponentially growing planktonic cultures in their outermost carbohydrates. 
Glucose is the constituent sugar of α-glucan, a capsular polysaccharide that represents a key 
component of the host-pathogen interface (Schwebach et al., 2002).  
α-glucan has been shown to modulate the immune response in tuberculosis as it is required 
for virulence and affects phagocytosis. A genetic study used an M. tuberculosis strain 
deficient in two genes required for α-glucan synthesis. One gene, glgC, encodes an ADP-
glucose pyrophosphorylase enzyme and the other, treS, encodes a trehalose synthase enzyme. 
The M. tuberculosis H37Rv ∆glgC ∆treS mutant was deficient in α-glucan and this resulted 
in reduced bacterial load in a BALB/c mouse infection model (Koliwer-Brandl et al., 2016). 
Complement receptor 3 (CR3), one of the many PRRs involved in the uptake of M. 
tuberculosis, binds to α-glucan without prior opsonisation (Cywes et al., 1997). Uptake via 
this receptor downregulates cell mediated immunity due to limited IL-12 secretion (Marth 
and Kelsall, 1997). However Stokes et al., (2004) used sonication to alter the exposed 
carbohydrate groups on M. tuberculosis capsules and showed increased binding to 
macrophages and snowdrop lectin (GNA) compared to control (not sonicated) bacteria. GNA 
specifically binds to mannopyranose units with preferential binding to terminal α(1-3) 
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mannose units but also to mannooligosaccharides with α(1-6) linkages (Shibuya et al., 1988). 
α(1-3) mannopyranose units have not been described in M. tuberculosis capsular 
polysaccharides however mannopyranose α(1-6) linkages are the backbone of capsular 
arabinomannans and mannans (Angala et al., 2014). This suggests α-glucan has 
antiphagocytic properties by covering capsular mannans and arabinomannans, which induce 
rapid phagocytosis when recognised by PRRs such as mannose receptors.  
This raises the intriguing possibility that in vivo planktonic M. tuberculosis i.e. individual 
bacterium, non-replicating in areas of necrosis (Irwin et al., 2015), could be rich in α-glucan 
to limit phagocytosis and evade immune responses. While actively replicating M. 
tuberculosis, as a biofilm aggregate of increasing size, could downregulate capsular α-glucan 
synthesis; exposing arabinomannans to impair phagosome-lysosome fusion to promote serial 
phagocytosis-necrosis cycles, to drive M. tuberculosis pathogenesis (Mahamed et al., 2017).  
To investigate whether the altered carbohydrate profile of biofilm phenotype M. tuberculosis 
affects the host innate immune response, a whole blood stimulation assay was optimised and 
developed to measure cytokine and chemokine secretion induced by the carbohydrate 
extracts. Cytokine secretion such as TNFα has been shown to be increased by M. tuberculosis 
LAM in numerous studies (Källenius et al., 2015) and changes to its structure, such as 
truncation or its arabinomannan domain, have been shown to increase proinflammatory 
responses through TLR2 activation (Birch et al., 2010).  
Innate immunity can be sufficient to clear M. tuberculosis infection. Evidence for this is 
shown in studies where heavily exposed individuals fail to show signs of infection (Houk et 
al., 1968; Israel et al., 1941; Morrison et al., 2008). Cytokines and chemokines are essential 
for regulating innate killing mechanisms effective against M. tuberculosis (Khan et al., 2016). 
For example the release of reactive nitrogen intermediates (RNIs) which effectively control 
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M. tuberculosis growth, can be initiated by IFN-γ (Flesch and Kaufmann, 1991; Khan et al., 
2016) secreted by natural killer (NK), NK T and γδ T cells in the early stages of infection 
(Feng et al., 2006; Ladel et al., 1995; Sada-Ovalle et al., 2008). Also activation of the NLRP3 
inflammasome in THP-1 macrophages can be triggered by purified Man-LAM resulting in a 
nine-fold induction of caspase-1 activation, which cleaves pro-IL-1β into its activated form 
(Mishra et al., 2010). IL-1β initiates the maturation and clearance of M, tuberculosis 
containing phagosomes (Master et al., 2008) and has been shown to effectively control M. 
tuberculosis infection using knockout mice (Sugawara et al., 2001).  
The reason for choosing a whole blood stimulation to measure innate cytokine responses 
instead of alternatives such as a cell line, peripheral blood mononuclear cells (PBMCs) or 
bronchoalveolar lavage fluid are as follows: Firstly immortal macrophage cell lines such as 
THP-1 cells in 2D-monolayers have undergone cancer-like mutations meaning they may not 
be representative of in vivo phagocytes in their cytokine and chemokine responses. Secondly 
primary cell lines, such as human alveolar macrophages, or PBMCs, while overcoming this 
issue, lack fundamental soluble factors present in serum and BAL fluid which may interact 
with M. tuberculosis carbohydrates, such as complement proteins (Ferguson et al., 2004). 
BAL fluid contains many of the primary cells that M. tuberculosis first encounters during 
infection while the cells present in whole blood must be recruited to the site of infection. This 
is because tuberculosis is rarely a disseminated disease in immunocompetent individuals but 
is instead isolated in the lung and lymph nodes. Furthermore, BAL fluid also contains sPRRs 
not present in whole blood that modulate cytokine secretion. For example, SP-A recognises 
M. tuberculosis LAM (Sidobre et al., 2000) triggering TNFα (Weikert et al., 2000) and IL-6 
(Gold et al., 2004) production by macrophages. 
Why then choose whole blood over BAL fluid? Primarily because the bronchoalveolar lavage 
procedure is invasive and requires hospitalisation, with limited yields, whereas whole blood 
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can be readily taken from donors by trained phlebotomists at PHE Porton. Although whole 
blood does not contain surfactant proteins, it does contains other important soluble factors not 
present in cell lines such as complement proteins which may be important in recognising M. 
tuberculosis PAMPs and triggering cytokine production and phagocyte recruitment through 
the release of anaphylatoxins C3a and C5a (Merle et al., 2015). Furthermore there is cross-
talk between the complement system and inflammasome activation (Triantafilou et al., 2015). 
Complement proteins are present in both whole blood and the lung (Watford et al., 2000). 
Finally it may be unethical to expect donors to provide BAL fluid for early-stage methods 
development. In the absence of a fully optimised assay measuring specific cytokines and 
chemokines of interest secreted after stimulation of BAL fluid with planktonic and biofilm M. 
tuberculosis extracts with quantifiable potency, whole blood stimulation seems the most 
appropriate approach. 
Whole blood has successfully been used to measure cytokine responses to M. tuberculosis 
culture filtrates (van Crevel et al., 1999). This study found that stimulation with 100 µg 
culture filtrate led to a dose dependent increase in TNFα in whole blood from three donors 
which peaked after 4 hours incubation. Furthemore, IFNγ responses were reported in whole 
blood from three tuberculin-skin-test positive individuals stimulated with 100 µg culture 
filtrate, peaking at 24 hours incubation.  
M. tuberculosis culture filtrates will likely contain capsular components but also 
immunomodulatory proteins and lipids. The carbohydrate samples extracted for experimental 
use as described in this chapter are free of these proteins but contained lipids moieties in 
molecules such as LAM and PIMs and might therefore be more comparable to stimulation 
assays using purified M. tuberculosis LAM. There have been extensive stimulation studies 
assessing cytokine and chemokine responses to M. tuberculosis LAM which have differed 
wildly in their outcome, providing consistently conflicting results (Källenius et al., 2015). 
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The closest study to M. tuberculosis carbohydrate stimulation in whole blood is a study using 
primary human monocytes and M. tuberculosis ManLAM at 10 µg mL
-1
 (Dahl et al., 1996). 
This study used ELISAs measuring TNFα, IL-1, IL-6, IL-10 and TGF secretion and the 
results suggested that ManLAM at this concentration was a poor inducer of all these 
cytokines bar TGF-β compared to LPS. Cytokine production by blood monocytes may be 
further enhanced by complement activation in whole blood and the release of complement 
anaphylatoxins, which have been shown to regulate cytokines and chemokines such as IL-12 
and CCL2 (Actor et al., 2001) 
To measure cytokine and chemokine induction in whole blood by M. tuberculosis planktonic 
and carbohydrate extracts, a Luminex Magpix multiplexing unit and a ProcartaPlex Th1/Th2 
panel were used, which can assesses a broad range of secreted cytokines and chemokines 
with sensitivity in the picogram mL
-1
 range.  
The 20-plex panel of cytokine and chemokine analytes can be divided into three groups: 
Proinflammatory cytokines, anti-inflammatory cytokines and chemokines. The pro-
inflammatory cytokines tested are IFN-γ, IL-12p70, IL-1β, IL-2, IL-6, TNF-α, GM-CSF, and 
IL-18. The anti-inflammatory cytokines tested are IL-4, IL-5, and IL-13 and the chemokines 
are CCL11 (Eotaxin), CXCL1 (GRO-α), CXCL8 (IL-8), CXCL10 (IP-10), CCL2 (MCP-1), 
CCL3 (MIP-1α), CCL4 (MIP-1β), CXCL12a (SDF-1α) and CCL5 (RANTES).  
The reason for choosing these twenty analytes in a Th1/Th2 panel, despite not focussing on 
adaptive immunity was because these chemokines and cytokines may also be secreted after 
innate activation by PRRs and TLRs recognising mycobacterial carbohydrate and lipid 
PAMPS (see sections1.6 and 1.7). Especially since pellicle biofilm phenotype M. 
tuberculosis resemble M. tuberculosis found in sputum (Arora et al., 2016). Therefore pellicle 
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biofilm derived carbohydrate extracts may be a significant component of the host-pathogen 
interaction in newly infected individuals. 
Results for each of the three donors were kept separate. Individual donor results allowed the 
variation in cytokine/chemokine response in each donor to be visualised in addition to the 
difference in response between planktonic and biofilm carbohydrate stimulants. This is 
important since the donors may different genetic and acquired immunological backgrounds 
that could influence responses. No donors had previously had tuberculosis and all donors had 
received the BCG vaccine earlier in their lives.  
Analysis was performed as described in methods section (7.16). Briefly, carbohydrate 
extracts from biofilm and planktonic cultures dissolved in RPMI medium were added to 
undiluted whole blood to give final concentrations of 10 µg mL
-1 
in triplicate and 25 µg mL
-1
 
in duplicate (Table 4.1-1). For a positive control, yeast cell wall extract zymosan was used at 
a final concentration of 10 µg mL
-1
. Zymosan mostly comprises of α-D-mannans and β-D-
glucans known to induce the production of inflammatory cytokine both in vivo and in vitro 
(Ohno, 2012). Negative controls were included comprising of unstimulated whole blood and 
whole blood stimulated with RPMI medium only. After 24 hours incubation, whole blood 
was pelleted and the plasma was filtered before being stored at -80
o
C until required. The 
samples were then incorporated into a 20-plex eBioscience Procartaplex Human Th1/Th2 & 
Chemokine Panel 1 kit and run on a Luminex Magpix according to manufacturer’s 
instructions. 
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 Standards Donor1 Donor2 Donor3  
1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
Std1 Std1 Unstim PK2 BF3 Unstim PK2 BF3 Unstim PK2 BF3 BF1(25) 
B 
 
Std2 Std2 Unstim PK2 BF3 Unstim PK2 BF3 Unstim PK2 BF3 BF1(25) 
C 
 
Std3 Std3 Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) BF1(25) 
D 
 
Std4 Std4 Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) BF1(25) 
E 
 
Std5 Std5 Zy BF1 PK2(25) Zy BF1 PK2(25) Zy BF1 PK2(25) BF1(25) 
F 
 
Std6 Std6 Zy BF1 PK2(25) Zy BF1 PK2(25) Zy BF1 PK2(25) BF1(25) 
G 
 
Std7 Std7 PK1 BF2 BF1(25) PK1 BF2 BF1(25) PK1 BF2 BF1(25)  
H 
 
Std8 Std8 PK1 BF2 BF1(25) PK1 BF2 BF1(25) PK1 BF2 BF1(25)  
Table 4.1-1: Whole blood carbohydrate stimulation plate layout. Std, standards; Unstim, unstimulated plasma; Unstim RPMI, plasma stimulated 
with RPMI 2mM L-glutamine only; Zy, zymosam 10 µg mL
-1
; PK1-PK3, planktonic M. tuberculosis carbohydrate extracts 10 µg mL
-1
; BF1-
BF3 biofilm M. tuberculosis carbohydrate extracts 10 µg mL
-1
; (25) 25 µg mL
-1
. 
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4.2 Chapter 4 hypothesis I 
The reduction in the constituent sugar glucose in the outermost carbohydrate extract of 
biofilm phenotype M. tuberculosis causes altered innate cytokine and chemokine secretion in 
whole blood compared to planktonic carbohydrate extracts.  
4.3 Analysis of whole blood stimulated with carbohydrate/lipoglycan fractions from 
planktonic and biofilm phenotype M. tuberculosis 
 
The upper limits and lower limits of quantitation for the 5-parameter logistic standard curves 
were determined using the recommended default bias of 30% (acceptable percentage 
variation form the ideal standard curve.) setting provided by Procartaplex Analyst software. 
Total cytokine secretion by all stimulants, including the negative control RPMI response and 
positive control zymosan response was calculated from the standard curves.  
Fold-change was calculated using the following formula: 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = (
Response in stimulated whole blood
Response in unstimulated RPMI whole blood
) − 1 
Multiple t-tests corrected for multiple comparisons by false discovery rate (Q=5%) 
determined there was no significant difference in any of the secreted cytokines/chemokines 
(pg mL
-1
) induced by M. tuberculosis planktonic and biofilm carbohydrate extracts 
(stimulants) at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations, normalised to the RPMI only 
negative control.  
Without correcting for multiple comparisons, more results were significant (P<0.05) a 25 µg 
mL
-1 
compared to 10 µg mL
-1
. The lowest uncorrected P values for stimulations at 25 µg mL
-
1 
are collated in Table 4.3-1. 
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Planktonic vs Biofilm carbohydrate 
extracts 
P Value Significant after correction 
for multiple comparisons 
Donor 2 CCL4 0.021183 No 
Donor 1 CCL2 0.022914 No 
Donor 2 CXCL8 0.032551 No 
Donor 2 CCL5 0.032892 No 
Donor 1 CXCL1 0.035933 No 
Donor 1 IL-6 0.045357 No 
Table 4.3-1: P values of multiple planktonic vs biofilm carbohydrate t-tests. The lowest P 
values from multiple t-tests of Planktonic vs Biofilm carbohydrate stimulations at 25 µg mL
-1 
where P<0.05. The P value shown is uncorrected for multiple comparisons using false 
discovery rate (Q=5%). 
 
All results for the cytokines and chemokines are described below. Standard curves are shown 
in appendix section 9.1. Additionally, the corresponding figures for the cytokines and 
chemokines for which there was no consistent response above the lower limit of quantitation 
after incubation with any of the stimulants (IL-12p70, IL-4, IL-5, GM-CSF and IL-13) are 
shown in the appendix section 9.2 .  
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The CCL4 (MIP-1β) standard curve is shown in Figure 9.1.4b. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted CCL4 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.1a,b). 
Zymosan induced an ≈ 2 – 5-fold increase in CCL4 production dependent on donor. There 
was no discernible difference in CCL4 secretion induced by either planktonic and biofilm 
derived carbohydrates at both 10 µg mL
-1
 and 25 µg mL
-1 with each extract inducing an ≈ 0 – 
1 fold change in both planktonic and biofilm phenotype carbohydrate extracts (Figure 
4.3.1c,d). Planktonic M. tuberculosis carbohydrate extracts induced on average higher CCL4 
secretion than biofilm carbohydrate extracts in donor 1 and 2 at 25 µg mL
-1
 stimulant 
concentration however this was not seen in donor 3
98 
 
 
Figure 4.3.1: CCL4 (MIP-1β) response in whole blood stimulated with carbohydrate extracts 
from planktonic and biofilm phenotype M. tuberculosis. Total secreted CCL4 (A) and fold 
change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood 
after 24h stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
). Total secreted CCL4 (B) and fold change (D) in whole blood after 
24h stimulation with x2 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), Positive control 
Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents the lower limit of 
quantitation. Each donor blood stimulation is presented separately by vertical dotted lines. 
Error bars = standard deviation.
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The CCL2 (MCP-1) standard curve is shown in Figure 9.1.3e. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted CCL2 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.2a,b). 
Zymosan induced a <1-fold change in CCL2 production dependent on donor. While 
planktonic and biofilm derived carbohydrates induced ≈0 – 1 fold change in CCL2 secretion 
(Figure 4.3.2). Biofilm M. tuberculosis carbohydrate extracts induced on average higher 
CCL2 secretion than planktonic carbohydrate extracts in donor 1 at 25 µg mL
-1
 stimulant 
concentration however this was reversed in the other donors.
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Figure 4.3.2: CCL2 (MCP-1) response in whole blood stimulated with carbohydrate extracts 
from planktonic and biofilm phenotype. Total secreted CCL2 (A) and fold change ((stimulant 
response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h stimulation 
with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts (10 µg mL
-1
) 
and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 µg mL
-1
). 
Total secreted CCL2 (B) and fold change (D) in whole blood after 24h stimulation with x2 
biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) and x2 
biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). Negative 
control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). The 
horizontal dotted line on each graph represents the lower limit of quantitation. Each donor 
blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation.
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The CXCL8 (IL-8) standard curve is shown in Figure 9.1.3c. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted CXCL8 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.3a,b). 
Zymosan induced an ≈ 0 – 1-fold increase in CXCL8 production dependent on donor. While 
planktonic and biofilm derived carbohydrates induced between 0 – 2 fold increase with the 
highest levels observed in donor 1 and <1-fold changes in donors 2 and 3. Planktonic M. 
tuberculosis carbohydrate extracts induced on average higher CXCL8 secretion than biofilm 
carbohydrate extracts in donors 1 and 2 at 25 µg mL
-1
 stimulant concentration however this 
was not seen in donor 3.
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Figure 4.3.3: CXCL8 (IL-8) response in whole blood stimulated with carbohydrate extracts 
from planktonic and biofilm phenotype M. tuberculosis. Total secreted CXCL8 (A) and fold 
change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood 
after 24h stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
). Total secreted CXCL8 (B) and fold change (D) in whole blood after 
24h stimulation with x2 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), Positive control 
Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents the lower limit of 
quantitation. Each donor blood stimulation is presented separately by vertical dotted lines. 
Error bars = standard deviation.
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The CCL5 (RANTES) standard curve is shown in Figure 9.1.4e. A t-test corrected for 
multiple comparisons by false discovery rate (Q=5%) determined there was no significant 
difference in the total secreted CCL5 (pg mL
-1
) induced by M. tuberculosis planktonic and 
biofilm carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.4a,b). All stimulants including Zymosan induced a <1-fold change in CCL5 in each 
donor (Figure 4.3.4c,d). Planktonic M. tuberculosis carbohydrate extracts induced on 
average higher CCL5 secretion than biofilm carbohydrate extracts in donor 2 at 25 µg mL
-1
 
stimulant concentration however this was not seen in donors 1 and 3.
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Figure 4.3.4: CCL5 (RANTES) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CCL5 (A) 
and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CCL5 (B) and fold change (D) in whole 
blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation.
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The CXCL1 (GRO-α) standard curve is shown in Figure 9.1.3b. A t-test corrected for 
multiple comparisons by false discovery rate (Q=5%) determined there was no significant 
difference in the total secreted CXCL1 (pg mL
-1
) induced by M. tuberculosis planktonic and 
biofilm carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.5a,b). However, in donor 1 and donor 2 planktonic M. tuberculosis carbohydrates at 25 
µg mL
-1
 induced ≈ 1 – 2-fold increase in CXCL1 secretion compared to unstimulated 
controls while biofilm derived carbohydrates induced < 1-fold change. In donor 3 the 
planktonic and biofilm carbohydrates were close to or below the LLOQ. The increase in 
CXCL1 secretion was not observed at 10 µg mL
-1. Zymosan induced an ≈ 3 – 7-fold increase 
in CXCL1 secretion (Figure 4.3.5c,d). Planktonic M. tuberculosis carbohydrate extracts 
induced on average higher CXCL1 secretion than biofilm carbohydrate extracts in donors 1 
and 2 at 25 µg mL
-1
 stimulant concentration however this was not seen in donor 3.
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Figure 4.3.5: CXCL1 (GRO-α) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CXCL1 (A) 
and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CXCL1 (B) and fold change (D) in 
whole blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation.
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
0
1 0 0
2 0 0
3 0 0
S tim u la n t
p
g
 m
L
-1
D o n o r 1
D o n o r 2
D o n o r 3
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
0
1 0 0
2 0 0
3 0 0
S tim u la n t
p
g
 m
L
-1
D o n o r 1
D o n o r 2
D o n o r 3
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
- 2
0
2
4
6
8
S tim u la n t
F
o
ld
 c
h
a
n
g
e
D o n o r 1
D o n o r 2
D o n o r 3
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
- 2
0
2
4
6
8
S tim u la n t
F
o
ld
 c
h
a
n
g
e
D o n o r 1
D o n o r 2
D o n o r 3
A B
C D
107 
 
The IL-6 standard curve is shown in Figure 9.1.2b. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted IL-6 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.6a,b). 
Zymosan induced an IL-6 response between ≈ 45 – 69-fold above control levels in each 
donor. M. tuberculosis planktonic carbohydrates induced a ≈ 0 – 3-fold increase at 10 µg mL-
1
 and a 0 – 24-fold increase in secreted IL-6, with the highest secretion observed in donor 
1(Figure 4.3.6c,d). M. tuberculosis biofilm carbohydrates induced a <1-fold increase in 
secreted IL-6 at 10 µg mL
-1
 and a 0 – 3-fold increase at 25 µg mL-1 with the highest secretion 
observed in donor 1. The higher IL-6 production induced by stimulation of whole blood with 
planktonic carbohydrate extracts compared to biofilm carbohydrate extracts in donor 1 was 
not observed in the other two donors. Planktonic M. tuberculosis carbohydrate extracts 
induced on average higher IL-6 secretion than biofilm carbohydrate extracts in donor 1 at 25 
µg mL
-1
 stimulant concentration however this was not seen in donors 2 and 3.
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Figure 4.3.6: IL-6 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-6 (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted IL-6 (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The IFN-γ standard curve is shown in Figure 9.1.1a. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted IFN-γ (pg mL-1) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts (stimulants) at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.7a,b) Zymosan induced an IFN-γ response between ≈ 1 to 6-fold above control levels in 
each donor. M. tuberculosis carbohydrates induced a negligible < 1-fold change in secreted 
IFN-γ irrespective of the concentration used (Figure 4.3.7c,d). 
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Figure 4.3.7: IFN-γ response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IFN-γ (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted IFN-γ (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The IL-1β standard curve is shown in Figure 9.1.1c. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted IL-1β (pg mL-1) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.8a,b). 
Zymosan induced an IL-1β response between ≈ 200 – 400-fold above control levels in each 
donor. M. tuberculosis planktonic carbohydrates induced a variable ≈ 0 – 12-fold increase at 
10 µg mL
-1
 and a 0 – 91-fold increase in secreted IL-1β, with the highest secretion observed 
in donor 1(Figure 4.3.8c,d). M. tuberculosis biofilm carbohydrates induced a 0 – 1-fold 
increase in secreted IL-1β at 10 µg mL-1 and a 0 – 17-fold increase at 25 µg mL-1 with the 
highest secretion observed in donor 1. 
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Figure 4.3.8: IL-1β response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-1β (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted IL-1β (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The IL-2 standard curve is shown in Figure 9.1.1d. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted IL-2 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.9a,b). 
All samples, including zymosan induced an IL-2 response between >1-fold above control 
levels in each donor (Figure 4.3.9c,d).  
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Figure 4.3.9: IL-2 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-2 (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted IL-2 (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The TNFα standard curve is shown in Figure 9.1.2c. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted TNFα (pg mL-1) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.10a,b). 
Zymosan induced a TNFα response between ≈ 66 – 76-fold above control levels in each 
donor. M. tuberculosis planktonic carbohydrates induced a ≈ 0 – 2-fold increase at 10 µg mL-
1
 and a 0 – 14-fold increase at 25 µg mL-1 in secreted TNFα, with the highest secretion 
observed in donor 1(Figure 4.3.10c,d). M. tuberculosis biofilm carbohydrates induced a <1-
fold increase in secreted IL-6 at 10 µg mL
-1
 and a 0 – 11-fold increase at 25 µg mL-1 with the 
highest secretion observed in donor 1. 
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Figure 4.3.10: TNFα response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted TNFα (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted TNFα (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The IL-18 standard curve is shown in Figure 9.1.2e. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted IL-18 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.11a,b). 
Zymosan induced an IL-18 response between ≈ 0 – 1-fold above control levels in each donor. 
All M. tuberculosis carbohydrate samples induce <1-fold change in IL-18 secretion (Figure 
4.3.11c,d). 
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Figure 4.3.11: IL-18 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-18  (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole blood after 24h 
stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate extracts (10 
µg mL
-1
). Total secreted IL-18 (B) and fold change (D) in whole blood after 24h stimulation 
with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) 
and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). 
Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). 
The horizontal dotted line on each graph represents the lower limit of quantitation. Each 
donor blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation. 
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The CCL11 (Eotaxin) standard curve is shown in Figure 9.1.3a. A t-test corrected for 
multiple comparisons by false discovery rate (Q=5%) determined there was no significant 
difference in the total secreted CCL11 (pg mL
-1
) induced by M. tuberculosis planktonic and 
biofilm carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.12a,b). All blood stimulants induced a <1-fold change in CCL11 secretion. (Figure 
4.3.12c,d). 
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Figure 4.3.12: CCL11 (Eotaxin) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CCL11 (A) 
and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CCL11 (B) and fold change (D) in 
whole blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation.
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The CXCL10 (IP-10) standard curve is shown in Figure 9.1.3d. A t-test corrected for 
multiple comparisons by false discovery rate (Q=5%) determined there was no significant 
difference in the total secreted CXCL10 (pg mL
-1
) induced by M. tuberculosis planktonic and 
biofilm carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.13a,b). Zymosan induced an ≈ 0 – 2-fold increase in CXCL10 production dependent on 
donor. While planktonic and biofilm derived carbohydrates induced between 0 – 2 fold 
increase with the highest level observed in donor 1 after stimulation with one of the biofilm 
extracts (Figure 4.3.13c,d). Due to the large amount of variation, there was no discernible 
difference in CXCL10 levels secreted after stimulation with either M. tuberculosis planktonic 
or biofilm carbohydrate.
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Figure 4.3.13: CXCL10 (IP-10) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CXCL10 (A) 
and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CXCL10 (B) and fold change (D) in 
whole blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation.
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
0
2 0
4 0
6 0
8 0
1 0 0
S tim u la n t
p
g
 m
L
-1
D o n o r 1
D o n o r 2
D o n o r 3
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
U
n
s
ti
m
 R
P
M
I
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
0
5 0
1 0 0
1 5 0
2 0 0
S tim u la n t
p
g
 m
L
-1
D o n o r 1
D o n o r 2
D o n o r 3
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
 
B
io
fi
lm
 
- 0 .5
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
S tim u la n t
F
o
ld
 c
h
a
n
g
e
D o n o r 1
D o n o r 2
D o n o r 3
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
Z
y
m
o
s
a
n
P
la
n
k
to
n
ic
B
io
fi
lm
- 1
0
1
2
3
4
S tim u la n t
F
o
ld
 c
h
a
n
g
e
D o n o r 1
D o n o r 2
D o n o r 3
A B
C D
123 
 
The CCL3 (MIP-1α) standard curve is shown in Figure 9.1.4a. A t-test corrected for multiple 
comparisons by false discovery rate (Q=5%) determined there was no significant difference 
in the total secreted CCL3 (pg mL
-1
) induced by M. tuberculosis planktonic and biofilm 
carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 4.3.14a,b). 
Zymosan induced an ≈ 6 – 7-fold increase in CCL3 production dependent on donor. There 
was no discernible difference in CCL3 secretion induced by either planktonic and biofilm 
derived carbohydrates at 10 µg mL
-1
 with each extract inducing an ≈ 0 – 1 fold change 
(Figure 4.3.14c). This was also the case at the higher carbohydrate concentration (25 µg mL
-
1) apart from in donor 1 where planktonic carbohydrate extracts induced an ≈ 3 – 4-fold 
increase in secreted CCL3 while biofilm derived carbohydrates induced an ≈ 0 – 2-fold 
increase (Figure 4.3.14d). This difference was not replicated in donors 2 and 3. 
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Figure 4.3.14: CCL3 (MIP-1α) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CCL3 (A) 
and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CCL3 (B) and fold change (D) in whole 
blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation.
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The CXCL12α (SDF-1α) standard curve is shown in Figure 9.1.4c. A t-test corrected for 
multiple comparisons by false discovery rate (Q=5%) determined there was no significant 
difference in the total secreted CXCL12α (pg mL-1) induced by M. tuberculosis planktonic 
and biofilm carbohydrate extracts at both 10 µg mL
-1
 and 25 µg mL
-1
 concentrations (Figure 
4.3.15a,b). All stimulants including Zymosan induced a <1-fold change in CXCL12α in each 
donor (Figure 4.3.15c,d).
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Figure 4.3.15: CXCL12α (SDF-1α) response in whole blood stimulated with carbohydrate 
extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted CXCL12α 
(A) and fold change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (C) in 
whole blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted CXCL12α (B) and fold change (D) in 
whole blood after 24h stimulation with x2 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (25 µg mL
-1
). Negative control RPMI response (Unstim RPMI), 
Positive control Zymosan (10 µg mL
-1
). The horizontal dotted line on each graph represents 
the lower limit of quantitation. Each donor blood stimulation is presented separately by 
vertical dotted lines. Error bars = standard deviation. 
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The IL-12p70 standard curve is shown in Figure 9.1.1b. The 5-parameter logistic regression 
did not fit well with the observed values at the lower end of the curve resulting in a higher 
LLOQ. IL-12p70 secreted in blood stimulated with M. tuberculosis carbohydrate samples and 
was below the LLOQ (Figure 9.2.1). In addition detectable IL-12p70 induced by zymosan 
was only above the LLOQ in 1 donor.  
The IL-4 standard curve is shown in Figure 9.1.1e. In donors 1 and 2 the quantity of secreted 
IL-4 was below the limit of detection and all stimulants including zymosan induced IL-4 
levels <1-fold above control levels in donor 3 (Figure 9.2.2).  
The IL-5 standard curve is shown in Figure 9.1.2a. Similarly to IL-4, IL-5 production was 
only above the LLOQ after 24h stimulation with Zymosan in donors 1 and 3 while other 
stimulants and unstimulated controls were below (donors 1 and 2) or clustered around the 
LLOQ in donor 3 (Figure 9.2.3). 
The GM-CSF standard curve is shown in Figure 9.1.2d. In donors 1 and 2 the quantity of 
secreted GM-CSF was below the limit of detection for all stimulants. This was also the case 
for donor 3 apart from zymosan which induced detectable levels of GM-CSF (Figure 9.2.4). 
The IL-13 standard curve is shown in Figure 9.1.4d. In donors 1 and 2 the unstimulated 
control and planktonic and biofilm stimulants were below the LLOQ. This was also the case 
for one of the planktonic replicates in donor 3 (Figure 9.2.5).
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4.4 Introduction (Part 2) 
The EPS of M. tuberculosis biofilms constitutes proteins and lipids in addition to 
carbohydrates. These may modulate innate immune responses. M. tuberculosis pellicle 
biofilms can be mechanically shaken with glass-beads and filtered to remove the outermost 
material, referred to as capsule extracts (Ortalo-Magné et al., 1995). This method was 
performed on planktonic and biofilm phenotype M. tuberculosis cultures to obtain the 
outermost material of both phenotypes. Rather than a broad 20-plex panel, a 4-plex panel 
measuring IFN-γ, IL-6, CCL-2, and MMP-1 (Matrix metalloproteinase-1) was used. 
IFN-γ is essential for M. tuberculosis control (O’Garra et al., 2013). Therefore an M. 
tuberculosis phenotype which induced reduced innate IFN-γ secretion in uninfected hosts 
may be better adapted for establishing infection. IL-6 was chosen in the panel because it has 
been shown to inhibit IFN-γ secretion in macrophages (Nagabhushanam et al., 2003) and 
therefore induction of high levels may be beneficial to M. tuberculosis. A phenotype which 
was better able to induce high IL-6 secretion may be better able to establish infection in naïve 
hosts. CCL2 levels have been shown to correlate with disease severity (Hasan et al., 2009). It 
has been hypothesised that CCL2 promotes a non-protective response to TB involving 
inhibition of IL-12 (Flores-Villanueva et al., 2005) (required for induction of a protective 
IFN-γ response) and recruitment of permissive phagocyte providing M. tuberculosis 
replicative niche (Cambier et al., 2013). Thus an M. tuberculosis phenotype that could induce 
higher CCL2 may be more transmissible. MMP-1 the primary collagenolytic MMP in TB 
most likely to be responsible for triggering cavitation, which is essential for M. tuberculosis 
transmission (Elkington et al., 2011). Since pellicle biofilms are associated with M. 
tuberculosis cavities (Hunter, 2016), they may contribute to their formation. Therefore, 
biofilm capsule may also be more potent inducers of MMP-1 than planktonic capsule. 
129 
 
In this experiment, two donors for whole blood instead of three and whole blood was 
stimulated at a single, higher concentration of 200 µg mL
-1
. This allowed space for extra 
capsule biological replicates and positive controls. A higher concentration of capsule 
compared to carbohydrate extract was possible because capsule could be harvested in much 
higher quantities in a shorter time-span than the carbohydrate extracts. Thus x6 biological 
replicates of both planktonic and biofilm phenotype M. tuberculosis capsule extracts derived 
from independent cultures, in addition to extra positive controls 12-O-Tetradecanoylphorbol-
13-acetate (PMA)/Ionomycin and tuberculin purified protein derivative (PPD) protein were 
included in the experiment Table 4.4-1.  
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 Standards Donor 1 PIP027 Donor 2 PIP004 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
Std1 Std1 Unstim PPD PK4 BF2 BF6 Unstim PPD PK4 BF2 BF6 
B 
 
Std2 Std2 Unstim PPD PK4 BF2 BF6 Unstim PPD PK4 BF2 BF6 
C 
 
Std3 Std3 Unstim 
RPMI 
PK1 PK5 BF3  Unstim 
RPMI 
PK1 PK5 BF3  
D 
 
Std4 Std4 Unstim 
RPMI 
PK1 PK5 BF3  Unstim 
RPMI 
PK1 PK5 BF3  
E 
 
Std5 Std5 Zy PK2 PK6 BF4  Zy PK2 PK6 BF4  
F 
 
Std6 Std6 Zy PK2 PK6 BF4  Zy PK2 PK6 BF4  
G 
 
Std7 Std7 PMA PK3 BF1 BF5  PMA PK3 BF1 BF5  
H 
 
Std8 Std8 PMA PK3 BF1 BF5  PMA PK3 BF1 BF5  
Table 4.4-1: Whole blood capsule stimulation plate layout. Std, standards; Unstim, unstimulated plasma; Unstim RPMI, plasma stimulated with 
RPMI 2mM L-glutamine only; Zy, zymosam 50 µg mL
-1
; PMA, 12-O-Tetradecanoylphorbol-13-acetate 4.8 µg mL
-1
 combined with Ionomycin 
95 µg mL
-1
; PK1-PK6, planktonic M. tuberculosis capsule extracts 200 µg mL
-1
; BF1-BF6 biofilm M. tuberculosis carbohydrate extracts 200 µg 
mL
-1
; 
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4.5 Chapter 4 hypothesis II 
Capsule extracts (defined as the M. tuberculosis outermost material, which included EPS and 
was extracted using agitation with glass beads and filtration) of biofilm phenotype M. 
tuberculosis alter innate cytokine (IFN-γ and IL-6), chemokine (CCL2) and MMP-1 protease 
secretion in whole blood compared to capsule extracts from exponential phase shaken flask 
planktonic phenotype M. tuberculosis cultured in identical medium. 
 
4.6 Whole blood stimulation with outermost material extracts from planktonic and 
biofilm phenotype M. tuberculosis. 
Capsule extractions from x6 biological replicate M. tuberculosis planktonic and biofilm 
cultures were performed as described in methods section 7.17 and the whole blood 
stimulation was performed as described in methods section 7.18. Briefly, whole blood from 
two healthy donors was stimulated for 24 hours with RPMI 2mM L-glutamine only, 
zymosam (50 µg mL
-1
), PMA/ionomycin (4.8 µg mL
-1
/95 µg mL
-1
); purified protein 
derivative (PPD) (200 µg mL
-1
)
 
x6 biological replicate planktonic M. tuberculosis capsule 
extracts or x6 biological replicate biofilm M. tuberculosis capsule extracts (200 µg mL
-1
). 
The standard curve for IFN-γ is given shown in Figure 9.3.1a Unstimulated RPMI only 
controls were below the LLOQ and therefore it was not possible to calculate fold-change in 
IFN-γ secretion of the stimulants to unstimulated controls level. Instead, since unstimulated 
controls = ≤ LLOQ, the fold-change to LLOQ (10.8 pg mL-1) was calculated. There was no 
significant difference in the amount of IFN-γ secretion induced by planktonic M. tuberculosis 
capsule extracts compared to biofilm M. tuberculosis extracts (t-test corrected for multiple 
comparisons by false discovery rate (Q=5%). Figure 4.6.1a and Figure 4.6.1c show the 
amount of secreted IFN-γ secreted by each stimulant tested (a), and with PMA/ionomicin 
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excluded (c). Unlike the previous whole blood stimulation with carbohydrate extracts, 
Zymosan induced a <1 fold IFN-γ response. PMA/ionomycin induced a 325-fold and 119-
fold increase in IFN-γ secretion in donors 1 and 2 respectively. PPD induced a <1-fold and 4-
fold increase in IFN-γ secretion in donors 1 and 2. Planktonic M. tuberculosis capsule 
extracts induced a 0 – 20-fold increase with the highest levels in donor 2. Biofilm M. 
tuberculosis capsule extracts induced a 0 – 21 fold increase in IFN-γ secretion with the 
highest levels also in donor 2. Figure 4.6.1b and Figure 4.6.1d show fold change induced by 
all stimulants (b) and with PMA/Ionomycin excluded (d). 
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Figure 4.6.1: IFN-γ response in whole blood stimulated with capsule extracts from 
planktonic and biofilm phenotype M. tuberculosis. IFN-γ response in whole blood stimulated 
with capsule extracts from planktonic and biofilm phenotype M. tuberculosis. Total secreted 
IFN-γ (A) and fold change ((stimulant response (pg mL-1) / RPMI response (pg mL-1) -1) (B) 
in whole blood after 24h stimulation with medium only (Unstim RPMI), Zymosan (50 µg 
mL
-1
), PMA/Ionomycin (4.8 µg mL
-1
/95 µg mL
-1
), PPD (200 µg mL
-1
), x6 biological 
replicate planktonic M. tuberculosis capsule extracts (200 µg mL
-1
) and x6 biological 
replicate biofilm M. tuberculosis carbohydrate extracts (200 µg mL
-1
). Total secreted IFN-γ 
(C) and fold change (D) with PMA/Ionomycin excluded. The horizontal dotted line on each 
graph represents the lower limit of quantitation. Each donor blood stimulation is presented 
separately by vertical dotted lines. Error bars are standard deviation. 
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The standard curve for IL-6 is shown in Figure 9.3.1b. There was no significant difference in 
the amount of IL-6 secretion induced by planktonic M. tuberculosis capsule extracts 
compared to biofilm M. tuberculosis extracts (t-test corrected for multiple comparisons by 
false discovery rate (Q=5%). Figure 4.6.2a shows the amount of IL-6 secreted by each 
stimulant tested. Zymosan induced a 3-fold and 12-fold IL-6 response in donors 1 and 2 
respectively. PMA/ionomycin induced a 133-fold and 143-fold increase in IL-6 secretion in 
donors 1 and 2 respectively. PPD induced a 7-fold and 4-fold increase in IL-6 secretion in 
donors 1 and 2. Planktonic M. tuberculosis capsule extracts induced a 9 – 90-fold increase 
with the highest levels in donor 2. Biofilm M. tuberculosis capsule extracts induced a 10 – 
165-fold increase in IL-6 secretion with the highest levels also in donor 2. Figure 4.6.2b 
shows fold change induced by all stimulants. 
135 
 
 
Figure 4.6.2: IL-6 response in whole blood stimulated with capsule extracts from planktonic 
and biofilm phenotype M. tuberculosis. Total secreted IL-6 (A) and fold change ((stimulant 
response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (B) in whole blood after 24h stimulation 
with medium only (Unstim RPMI), Zymosan (50 µg mL
-1
), PMA/Ionomycin (4.8 µg mL
-1
/95 
µg mL
-1
), PPD (200 µg mL
-1
), x6 biological replicate planktonic M. tuberculosis capsule 
extracts (200 µg mL
-1
) and x6 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (200 µg mL
-1
). The horizontal dotted line on each graph represents the lower limit of 
quantitation. Each donor blood stimulation is presented separately by vertical dotted lines. 
Error bars are standard deviation. 
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The standard curve for CCL2 (MCP-1) is shown in Figure 9.3.1c. There was no significant 
difference in the amount of CCL2 secretion induced by planktonic M. tuberculosis capsule 
extracts compared to biofilm M. tuberculosis extracts (t-test corrected for multiple 
comparisons by false discovery rate (Q=5%). Figure 4.6.3a shows the amount of CCl2 
secreted by each stimulant tested. Zymosan induced a <1-fold CCL2 response in donors 1 
and 2. Likewise PMA/ionomycin induced a <1-fold increase in CCL2 secretion in donors 1 
and 2. PPD induced a <1-fold and 1-fold increase in CCL2 secretion in donors 1 and 2 
respectively. Planktonic M. tuberculosis capsule extracts induced a 0 – 3-fold increase in 
CCL2 with the highest levels in donor 2. Biofilm M. tuberculosis capsule extracts induced a 0 
– 1-fold increase in CCL2 secretion with the highest levels also in donor 2. Figure 4.6.3b 
shows fold change induced by all stimulants.
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Figure 4.6.3: CCL2 (MCP-1) response in whole blood stimulated with capsule extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted CCL2 (A) and fold change 
((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (B) in whole blood after 24h 
stimulation with medium only (Unstim RPMI), Zymosan (50 µg mL
-1
), PMA/Ionomycin (4.8 
µg mL
-1
/95 µg mL
-1
), PPD (200 µg mL
-1
), x6 biological replicate planktonic M. tuberculosis 
capsule extracts (200 µg mL
-1
) and x6 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (200 µg mL
-1
). The horizontal dotted line on each graph represents the 
lower limit of quantitation. Each donor blood stimulation is presented separately by vertical 
dotted lines. Error bars are standard deviation. 
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The standard curve for MMP-1 is shown in Figure 9.3.1d. There was no significant 
difference in the amount of MMP-1 secretion induced by planktonic M. tuberculosis capsule 
extracts compared to biofilm M. tuberculosis extracts (t-test corrected for multiple 
comparisons by false discovery rate (Q=5%). Figure 4.6.4a and Figure 4.6.4c show the 
amount of secreted IFN-γ secreted by each stimulant tested (a), and with PMA/ionomycin 
excluded (c). Zymosan induced a <1 fold MMP-1 response in both donors. PMA/ionomycin 
induced a 3-fold and 7-fold increase in MMP-1 secretion in donors 1 and 2 respectively. PPD 
induced a <1-fold increase in MMP-1 secretion in donors 1 and 2. Both planktonic and 
biofilm M. tuberculosis capsule extracts induced a <1-fold increase in both donors. Figure 
4.6.4b and Figure 4.6.4d show fold change induced by all stimulants (b) and with 
PMA/ionomycin excluded (d).
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Figure 4.6.4: MMP-1 response in whole blood stimulated with capsule extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted MMP-1 (A) and fold 
change ((stimulant response (pg mL
-1
) / RPMI response (pg mL
-1
) -1) (B) in whole blood 
after 24h stimulation with medium only (Unstim RPMI), Zymosan (50 µg mL
-1
), 
PMA/Ionomycin (4.8 µg mL
-1
/95 µg mL
-1
), PPD (200 µg mL
-1
), x6 biological replicate 
planktonic M. tuberculosis capsule extracts (200 µg mL
-1
) and x6 biological replicate biofilm 
M. tuberculosis carbohydrate extracts (200 µg mL
-1
). Total secreted MMP-1 (C) and fold 
change (D) with PMA/Ionomycin excluded. The horizontal dotted line on each graph 
represents the lower limit of quantitation. Each donor blood stimulation is presented 
separately by vertical dotted lines. Error bars are standard deviation. 
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4.7 Technical discussion 
To summarise the results presented in this chapter, there were no significant differences in 
cytokine and chemokine responses to planktonic and biofilm phenotype M. tuberculosis 
carbohydrate/lipoglycan extracts. Generally, the higher carbohydrate concentration was the 
greater the cytokine/chemokine responses. The cytokines that showed the most consistent 
high expression above control levels when stimulated with the highest concentration of 
carbohydrate extract (25 µg mL
-1
) were IL-1β, TNFα and IL-6 yet none of these cytokines 
showed a >1-fold change across all replicates and donors. 25 µg mL
-1 
planktonic M. 
tuberculosis carbohydrate extract induced the highest response measured in the experiment, 
which was IL-1β (92-fold) yet this magnitude of response was not consistently seen between 
biological replicates or donors. Capsule extracts were used to stimulate whole blood at a 
higher concentration than the carbohydrate extracts (200 µg mL
-1
) but no significant 
differences were found in the amount of secreted IFN-γ, IL-6, CCL2 and MMP-1 between 
planktonic and biofilm phenotypes. Only IL-6 secretion was induced by M. tuberculosis 
capsule extracts consistently in both donors at >1-fold above control levels, with the highest 
response (254-fold) induced by biofilm capsule in whole blood from donor 2. 
Despite the evidence presented in chapter 3 of an altered carbohydrate profile of biofilm 
phenotype M. tuberculosis compared to planktonic M. tuberculosis, the results of the whole 
blood stimulation using carbohydrate extracts described in section 4.3 showed no evidence 
that these different phenotypes alter the innate immune response in whole blood. Analyses of 
20 different cytokines and chemokines in three different healthy BCG vaccinated donor blood 
samples were measured. The variation between donors was more apparent than any variation 
in innate response due to M tuberculosis phenotype. This could be due potential confounding 
factors such as the length of time between BCG vaccination and the whole blood stimulation, 
recent exposure to environmental mycobacteria or polymorphisms in genes responsible 
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expression of baseline levels of cytokines/chemokines. M. tuberculosis carbohydrates 
behaved markedly similar in all analytes tested, with no significant differences between 
planktonic and biofilm phenotypes after correcting for multiple comparisons with a 5% false 
discovery rate. In several cytokines: IL-12p70, IL-4, IL-5, GM-CSF and IL-13 the response 
generated was below the LLOQ in most donors. This could be because M. tuberculosis 
carbohydrate extract do not trigger secretion of these cytokines or because the concentration 
of carbohydrate extract was sub-optimal to maximise the response. In many cases the amount 
of secreted cytokine/chemokine was greater at the higher concentration (25 µg mL
-1
) than the 
lower concentration (10 µg mL
-1
). If the response generated is linear in relation to stimulant 
concentration then stimulating whole blood with carbohydrate extracts at higher 
concentrations may permit greater discrimination between phenotype. 
The whole blood stimulations could be optimised by harvesting a larger sample size of 
biological replicate carbohydrate extracts and stimulating whole blood with a broader range 
of concentrations. The gel analyses of lipoglycan extractions showed variation in the 
proportions of LAM and LM (Figure 3.4.1 and Figure 3.4.2) which could have a larger 
impact on immunomodulation than the changes in α-glucan which couldn’t be detected on the 
gel, given the immunomodulatory properties of these lipoglycans (Mishra et al., 2011).  
The whole blood stimulation was based on an established protocol (Thurm and Halsey, 
2005). For multiplex analysis, harvested plasma was filtered before running the assay since 
past experience revealed that unfiltered plasma blocked the instrument. This approach has 
been recommended in a paper published on immunoassay prerequisites for optimised 
multiplex analysis for clinical trials (de Jager et al., 2009). Given the sub-optimal response of 
some cytokines measured, further work is required to identify a positive control for the 
carbohydrate experiment. A good candidate would be PMA/ionomycin, which produced 
strong responses in all conditions tested with capsule extracts (see section 4.6). Multiple 
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optimisation experiments could be set-up to determine incubation period and titres of 
carbohydrate extract required for a measurable response. To perform this further work using 
multiplex kits would be prohibitively expensive however, kits for single cytokines or 
chemokines are available commercially and this approach could be coupled with use of a cell 
line instead of whole blood, such as THP-1 monocytes for preliminary work. However, 
optimal concentrations and incubation times for one cytokine/chemokine may be sub-optimal 
for another, and the response generated by a cell line may vary considerably from the 
response with whole blood. Additionally performing multiple optimisation experiments 
would require regular donation of blood and therefore if whole blood was used, experiments 
would need to test many conditions in a single experiment to reduce the number of donations 
required.  
The results of the whole blood stimulation assays showed significant variation in cytokine 
response between donors and highlights the importance of measuring cytokine responses 
from multiple donors. Commercial pooled human whole blood is available for purchase and 
would be a useful alternative to testing separate donors, especially if the pool was large. It 
would also permit a greater proportion of tests to be dedicated to comparing planktonic and 
biofilm extract biological replicates and/or additional concentrations of carbohydrate samples 
instead of different donors. Finally, the results may be more reproducible if stimulations were 
performed on large pools of healthy donors available from a specified supplier. 
Following optimisation with an immortal cell line or pooled whole blood, a primary cell line 
such as human lung alveolar macrophages or brochoalveolar lavage may better recapitulate 
the in vivo environment to which biofilm phenotype M. tuberculosis may encounter after 
expectoration from tuberculosis cavities and would therefore be the logical choice for 
optimised ex vivo stimulations in future. 
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Notably the Zymosan control was used to stimulate whole blood at different concentrations in 
the carbohydrate whole blood stimulation (10 µg mL
-1
) and capsule whole blood stimulations 
(50 µg mL
-1
). Yet paradoxically, larger responses were seen in IFN-γ, and IL-6 at the lower 
concentration in the whole blood stimulation with carbohydrate extracts. With hindsight, the 
zymosan concentration should have been kept consistent in both experiments after an initial 
preliminary experiment to determine the optimal concentration for maximum cytokine 
responses. Preliminary work showed 50 µg mL
-1
 to be optimal (data not shown) and despite 
how the results are presented in this chapter, the capsule experiment was performed first. This 
was because the capsule samples were much faster/easier to obtain in larger yields and 
therefore not as precious. However, for the subsequent carbohydrate whole blood stimulation, 
the decision was then made to keep the zymosan control at the same concentration as the 
carbohydrate samples. This allowed for relative comparison of the M. tuberculosis 
carbohydrates to a known proinflammatory stimulant (zymosan) at the same concentration. 
There was insufficient carbohydrate sample to stimulate with 50 µg mL
-1
. Yet this does not 
explain why responses were higher for zymosan at the lower concentration. One possibility is 
that the difference is due to the different blood donors used in the respective experiments and 
could be addressed by using pooled whole blood. Replicate data with zymosan at a range of 
concentrations using pooled whole blood would determine the relationship between 
concentration and response and validate the results for zymosan in both experiments.  
The PPD positive control for the capsule stimulation experiment was kept at the same 
concentration as the capsule extracts and induced broadly similar magnitude responses in 
IFN-γ, CCL2 and MMP-1 compared to the capsule extracts. Yet it did not induce a large IL-6 
response unlike the capsule extracts suggesting it does not share the mycobacterial 
component responsible for triggering IL-6 secretion Figure 4.6.2. Potential candidates for the 
IL-6 inducing component are evaluated in the general discussion (1). 
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In chapter 3 changes in the quantities of lipids PDIMs, MK, FFA, FMA and SL-I were found 
in addition to the changes in carbohydrate extracts. Therefore it would have been a good idea 
to perform whole blood stimulations with the non-polar and polar planktonic and biofilm M. 
tuberculosis extracts.  One issue with these extracts is their solubility in RPMI medium. This 
could be addressed by performing serial dilutions in the solvent used for TLC analysis e.g. 
dichloromethane for non-polar lipids. Care should be taken to ensure the vessel is compatible 
with the solvent. The solvent could then be evaporated-off leaving known quantities of lipid 
seeded on the bottom of tubes to which pooled whole blood could be added. There would not 
be a risk of blocking the MAGPIX instrument since after stimulation the plasma would be 
filtered.  
The whole blood stimulation of planktonic and biofilm M. tuberculosis capsule extracts 
utilised a larger number of biological replicates since the extraction method was simply 
double filtration of bead-treated biomass. There is a possibility that bead treatment ruptured 
the cell walls of M. tuberculosis bacteria leading to the leakage of intracellular material. 
Notably this has been shown to not be the case with glass bead treated M. tuberculosis cells 
(Ortalo-Magné et al., 1995). To confirm this is not the case with the capsule samples, a 
commercial glucose-6-phosphate dehydrogenase G6HDH detection assay could be used. The 
assay would need to compare capsule extracts to lysed M. tuberculosis, since G6PDH is an 
intracellular enzyme often used to confirm the absence of intracellular material from EPS 
extractions (Nielsen and Jahn, 1999). Some capsule material may also have been retained on 
the Minisart cellulose acetate filters during extraction. Since both planktonic and biofilms 
capsule extracts undergo the same treatment this should not significantly skew the results, 
however a range of filters could be compared by carbohydrate/lipoglycan gel analysis, total 
sugar analysis and lipid analysis to determine the filter that retains the least capsular material. 
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Notably cellulose acetate filters are described by suppliers as the most appropriate filters for 
biological aqueous solutions (Corning, 2011).  
Despite the larger sample size and simplified extraction method of capsule extraction, there 
was a large amount variation in the sample responses within each donor. This is most clearly 
seen when measuring IL-6 secretion after stimulation with capsule extracts, which produced 
the largest response compared to other analytes (Figure 4.6.2). The source of this variation 
may be due to the intrinsic heterogeneity of biofilms (Stewart and Franklin, 2008). It is 
important to bear in mind that even the planktonic cultures clumps may have oxygen/nutrient 
gradients (Islam et al., 2012). In addition, mycobacteria replicate asymmetrically to produce 
heterogeneous populations (Kieser and Rubin, 2014). The constituents of the outermost 
capsular material and EPS surrounding each bacterium may vary dependent on the position of 
the bacteria within the biofilm. Hence, minor variations in biofilm morphology between 
replicates could result in differential expression of immunomodulatory macromolecules. 
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5 ANALYSIS OF COMPLEMENT ACTIVATION BY 
PLANKTONIC AND BIOFILM PHENOTYPE M. 
TUBERCULOSIS 
5.1 Introduction 
In chapter 2 M. tuberculosis biofilm EPS was identified by measuring the density of the 
bacterial population (CFU g
-1
) over time and by direct visualisation using SEM. Furthermore, 
immuno-gold EM labelling identified this outermost material to contain α(1,2) 
mannopyranose residues, although there was no significant difference in labelling between 
planktonic and biofilm phenotype samples. Chapter 3 extended the biochemical analyses and 
a reduction in the constituent sugar glucose in the non-covalently bound carbohydrate 
fraction of pellicle biofilm phenotype M. tuberculosis was identified. This indicated that the 
prevalence of exopolysaccharide α-glucan was reduced in pellicle biofilm phenotype M. 
tuberculosis compared to planktonic phenotype M. tuberculosis. Chapter 4 investigated 
whether the carbohydrate changes affected the innate immune response by stimulating whole 
blood with the extracts for 24 hours and measuring cytokine/chemokine responses. The 
experiment did not reveal significant difference in cytokine/chemokine response. However, 
changes to M. tuberculosis carbohydrates may directly influence human complement 
activation via the lectin pathway and the binding of C1q. The complement system is 
essentially an innate immune surveillance system involved in pathogen defence, modulation 
of inflammation and homeostasis (Merle et al., 2015). Activation of this signalling cascade 
affects tuberculosis pathogenesis, as will be discussed below, and may be modulated by M. 
tuberculosis biofilm formation, as shown with other bacteria such as Streptococcus 
pneumoniae (Domenech et al., 2013).  
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Complement activation by M. tuberculosis can be triggered by the alternative pathway, 
classical pathway, lectin pathway and C2 pathway (Bartlomiejczyk et al., 2014; Ferguson et 
al., 2004; Schlesinger et al., 1990; Schorey et al., 1997). In the lung, the alternative pathway 
is not significantly activated due to low levels of factor B (Watford et al., 2000).  
Previous studies have suggested C3b/iC3b deposition onto M. tuberculosis is one of a number 
of mechanisms utilised by the pathogen to gain access to its intracellular niche. Complement 
opsonisation with nonimmune serum enhances adherence to monocytes predominantly via 
complement receptor 3 (CR3) (Schlesinger et al., 1990). Furthermore entry via complement 
receptors of viable complement-opsonised M. tuberculosis does not lead to Ca
2+
 signalling 
associated with phagosome-lysosome fusion (Malik et al., 2000).  
A study measuring levels of complement component C3d (the end product from the cleavage 
of C3) anaphylatoxins C3a, C4a and C5a, and C5b-9 in circulating immune complexes 
showed these components were all significantly higher in untreated tuberculosis patients 
compared to treated and heathy controls. Furthermore immune complexes showed decreased 
solubilisation, which prevents complement activation, in TB patients, suggesting excessive 
complement activation in TB patients (Senbagavalli et al., 2009).  
Downstream components of the complement system may be involved in modulation of 
tuberculosis pathogenesis. While C5b-9 assembly onto the M. tuberculosis cell surface may 
not result in direct lytic activity, as observed with some gram negative bacteria, a study 
utilising congenic C5 sufficient and C5 deficient mouse strains showed decreased IL-12p40 
transcription in lung tissue of C5-deficient mice. Additionally, C5-deficiency enhanced 
bacterial growth in the lung and was required for granulomatous inflammation (Actor et al., 
2001). Subsequent studies which utilised C5 and C5aR deficient mice also showed that C5 
mediated events were essential for generation of a granulomatous response against 
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mycobacterial trehalose dimycolate (TDM) (Borders et al., 2005; Welsh et al., 2008). During 
M. tuberculosis infection C5a also affects IFNγ production in T cells, since C5-deficient T 
cells produce less IFNγ (Mashruwala et al., 2011). The extent of C5/C5aR induced IFNγ 
production may be M. tuberculosis strain dependent since M strain but not H37Rv has been 
shown to induce higher IFNγ production in healthy donors and TB patients when C5aR is 
blocked (Sabio y García et al., 2017). C7-deficient mice infected with M. tuberculosis 
showed decreased lung immunopathology with reduced macrophages and smaller 
granulomas (Welsh et al., 2012).. 
Biofilm phenotype M. tuberculosis may induce altered levels of complement activation due 
to the changes in its outermost carbohydrates, specifically reduced α-glucan prevalence. 
These changes may directly impact the binding of lectin pathway activators such as MBL, 
which binds to glucose residues (Weis et al., 1992). MBL but not ficolin-3 has been shown to 
bind to M. tuberculosis LAM (Bartlomiejczyk et al., 2014; Świerzko et al., 2016). 
Interestingly both lectin pathway activators can bind to recombinant antigen 85 protein 
complex; proteins without posttranslational modification or acetylation (Świerzko et al., 
2016). Antigen 85 is a secreted complex of mycolyl transferases involved in the addition of 
mycolic acids to arabinogalactan and TDM (Huygen, 2014).  
Biofilm formation of the Gram-positive bacteria Streptococcus pneumoniae has been shown 
to reduce C3b/iC3b deposition and C1q binding (Domenech et al., 2013). Biofilm formation 
has also been shown to modulate complement deposition on Staphylococcus epidermidis and 
Mycoplasma pulmonis (Kristian et al., 2008; Simmons and Dybvig, 2007). Although the cell 
wall and EPS of mycobacteria varies considerably from these species, the reduced constituent 
glucose in M. tuberculosis biofilm carbohydrate extracts compared to planktonic extracts 
(section 3.4) may modulate the extent of C3b/iC3b and C5b-9 deposition via altered binding 
of complement activators. Furthermore the M. tuberculosis cell surface contains a unique but 
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currently unidentified C2a binding protein which together with C2a forms a functioning C3 
convertase (Schorey et al., 1997). It is possible that the expression of this protein is affected 
by M. tuberculosis biofilm formation.  
 
Prior to measuring C3b/iC3b and C5b-9 deposition on planktonic and biofilm phenotype M. 
tuberculosis cells, the disaggregation of clumpy ‘planktonic’ and biofilm M. tuberculosis 
samples was optimised in order to measure complement deposition directly on live M. 
tuberculosis planktonic and biofilm phenotypes, by flow cytometry. With the use of live, 
dispersed planktonic and biofilm phenotype M. tuberculosis bacteria, the relative 
contributions of each known complement activation pathway in this deposition; the classical 
pathway, the alternative pathway, the lectin pathway and the C2a pathway was investigated. 
Finally, enzyme linked immunosorbent assays (ELISAs) were developed to interrogate 
whether complement deposition is altered on M. tuberculosis biofilm carbohydrate extracts 
compared to planktonic carbohydrate extracts. C3b/iC3b deposition, C5b-9 deposition and 
MBL deposition were measured. 
5.2 Chapter 5 hypotheses 
1) Live biofilm phenotype M. tuberculosis cells show altered complement deposition 
(C3b/iC3b and C5b-9) compared to planktonic phenotype. 
2) The relative contribution of the known complement activation pathways that trigger 
C3b/iC3b and C5b-9 deposition are altered in biofilm phenotype M. tuberculosis 
compared to planktonic phenotype. 
3) C3b/iC3b and C5b-9 deposition is altered on biofilm M. tuberculosis carbohydrate 
extracts compared to planktonic extracts 
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4) MBL deposition is altered on biofilm M. tuberculosis carbohydrate extracts compared 
to planktonic extracts. 
 
5.3 Optimisation of planktonic and biofilm phenotype M. tuberculosis samples for 
flow cytometry 
 
To gain an understanding of how M. tuberculosis phenotype effects complement activation, 
complement deposition onto live M. tuberculosis cells was measured using flow cytometry. 
In order to use flow cytometry to study mycobacteria, let alone biofilms, the cells must be 
efficiently dispersed. This was achieved by following a method previously described in 
several papers using agitation with glass beads without damaging the bacterial cells (N’Diaye 
et al., 1998; Ortalo-Magné et al., 1995; Villeneuve et al., 2003). To investigate the effect of 
agitation with glass beads on mycobacteria, a viable count using fast-growing M. smegamtis 
biofilms before and after agitation with glass beads was performed. In addition, glass-bead 
treated and untreated M. tuberculosis samples were sent to the University of Amsterdam for 
immune-gold EM mannosyl labelling to determine the extent of shedding of the outermost 
carbohydrates.  
Pre and post bead treatment viable counts were performed as described in the method 
(sections 7.23). Briefly, x3 biological replicate M. smegmatis pellicle biofilm cultures were 
set up in separate plates. After 7 days incubation the biofilms were scraped into pre-weighed 
falcon tubes. Prior to glass bead treatment M. smegmatis samples were suspended in 10 mL 
PBS and plated. The serial dilutions were performed in PBS 1% Tween 80 to disperse clumps 
before spreading. Glass beads were added at ≈x5 the volume of the pellet. This step was 
skipped for control untreated cultures. Samples were vortexed with glass beads for 30 
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seconds and resuspended in 10 mL PBS and plated. Viable counts (CFU g
-1
) were performed 
on pre and post treatment and control plates after 7 days incubation Figure 5.3.1a. Welch’s t-
test showed there was no significant difference in viable count after glass bead agitation or 
compared to control untreated cultures. This shows that agitation with glass beads does not 
appear to effect mycobacterial viability. 
To assess to what extent agitation with glass beads shed outermost carbohydrates, M. 
tuberculosis planktonic cultures which had been dispersed using glass beads as described in 
methods section 7.22 or untreated controls, were resuspended in PBS 4%-formaldehyde and 
sent to Dr. Nicole N van der Wel, University of Amsterdam. Analysis of immuno gold 
labelling was performed as described in section 7.6 using anti-PIM/LAM antibody which 
binds to α(1-2) mannosyl residues, the mannose caps of PIM, LM and LAM and their non-
lipdated counterparts. A sample of ≥38 glass bead treated and untreated individual bacterium 
were imaged. Figure 5.3.1b shows a representative bead-treated M. tuberculosis bacterium. 
The length and number of gold particles and each bacterium was calculated using Image J 
software (Schindelin et al., 2012). Welch’s t-test confirmed there was a significant 60% 
reduction in the extent of α(1-2) mannosyl residues present on the mycobacterial cell surface 
after glass bead treatment Figure 5.3.1c. However, this meant that 40% of the outermost 
material remained associated with the dispersed bacteria. 
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Figure 5.3.1: The effect of glass bead dispersion on viability and capsule shedding. (A) 
Viable counts of M. smegmatis biofilms before and after glass bead treatment x3biological 
replicates Error bars = standard deviation. (B) Representative M. tuberculosis planktonic 
bacterium immuno gold labelled with anti PIM/LAM antibody. (C) Quantification of immuno 
gold anti-PIM/LAM dots visible on each micrograph associated with a bacterium/length of 
bacterium. Number of samples ≥38 Error bars = standard deviation.
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x4 biological replicate planktonic and biofilm M. tuberculosis cultures were set up, harvested 
and dispersed using glass beads followed by low-speed centrifugation and frozen in PBS 
aliquots at -80
o
C until required for flow cytometry experiments. The gating strategy for flow 
cytometry experiments is shown in Figure 5.3.2. Mycobacteria and positive controls 
zymosan and S. agalactiae were identified using a forward scatter / side scatter gating 
strategy constantly applied for all flow cytometry experiments Figure 5.3.2a. After labelling 
with the appropriate fluorescent antibodies, events with fluorescence intensities higher than 
the negative control samples (bacteria + conjugate without complement) were deemed 
positive (Figure 5.3.2b). The magnitude of deposition was determined by multiplying the 
median fluorescence intensity (MFI) by % positive cells to calculate the integrated median 
fluorescence intensity iMFI (Darrah et al., 2007). 
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Figure 5.3.2: Gating strategy for flow cytometry experiments. (A) Forward scatter and side 
scatter gates for M. tuberculosis (top left) and controls S. agalactiae (top right) and Zymosan 
(bottom left). (B) Example negative control sample M. tuberculosis with conjugate only 
(Mouse anti-human MBL and Goat anti-mouse FITC secondary antibody) (left panel) M. 
tuberculosis + recombinant MBL + conjugate (right panel).
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For flow cytometry experiments, the x4 biological replicates of planktonic and biofilm 
phenotype dispersed bacteria were thawed and their concentrations were equalised to an 
absorbance of 0.09 OD540 nm M. tuberculosis, equivalent to 2 x 10
5
 CFU mL
-1
.  
5.4 Analysis of C3b/iC3b and C5b-9 deposition on planktonic and biofilm phenotype 
M. tuberculosis with additional positive controls.  
The magnitude of C3b/iC3b and C5b-9 deposition on the surface of live planktonic and 
biofilm phenotype was assessed to determine the relative contribution of each of the major 
complement activation pathways; lectin, classical and alternative. The assay method was 
performed as described in section 7.24. Briefly M. tuberculosis x4 planktonic and x4 biofilm 
bead-treated biological replicate M. tuberculosis samples, S. agalactiae and Zymosan were 
incubated with complement under the following conditions: IgG-depleted complement was 
either pre-incubated with anti-C1q mAb or PBS control to interrogate the role of the classical 
pathway. Also, samples were incubated with either 2% or 10% complement concentrations as 
all three pathways are active at 10% complement concentration but the alternative pathway is 
inhibited at 2% complement concentration (Ferguson et al., 2004; Nilsson and Nilsson, 1984) 
(Table 5.4-1).  
Reference Complement pre-
incubation 
Complement 
concentration 
Outcome 
i 1/5 anti-C1q mAb  2% Classical and alternative pathway 
inhibited 
ii 1/5 anti-C1q mAb 10% Classical pathway inhibited 
 
iii 1/5 PBS 2% Alternative pathway inhibited 
 
iv 1/5 PBS 10% All pathways active 
 
Table 5.4-1: Experimental conditions for C3b/iC3b and C5b-9 deposition assay. 
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Following incubation, samples were labelled with rabbit anti-human C3c FITC pAb and 
mouse anti-human C5b-9 Alexafluor 647 mAb. Samples were fixed in 4% formaldehyde and 
run on a flow cytometer to 10 000 events per sample using the gating strategy shown in 
Figure 5.3.2. Net iMFI above negative control levels was calculated under all test conditions 
(Figure 5.4.1).  
 
In the absence of classical pathway blocking (Table 5.4-1iii and iv) C3b/iC3b deposition was 
highest in zymosan followed by planktonic M. tuberculosis, biofilm M. tuberculosis, 
planktonic M. smegmatis and planktonic S. agalactiae. This was the case at both 2% and 10% 
complement concentrations. Inhibition of the alternative pathway (2%) partially reduced 
C3b/iC3b deposition onto each sample Figure 5.4.1a.  
 
Blocking the classical pathway completely abolished C3b/iC3b deposition in S. agalactiae 
even when the alternative pathway was active at 10% concentration, suggesting deposition 
was entirely dependent on the classical pathway. M. smegmatis showed minimal C3b/iC3b 
deposition at 10% complement concentration after blocking the classical pathway and no 
deposition at 2% complement concentration suggesting roles for the classical pathway and a 
minor role for the alternative pathway. C3b/iC3b deposition was still present on Zymosan 
even when the alternative and classical pathways were inhibited suggesting the lectin 
pathway was also involved in deposition. Similarly, C3b/iC3b deposition was still present on 
M. tuberculosis phenotypes after inhibition of the classical and alternative pathways 
suggesting the lectin and/or C2 pathway contribute to C3b/iC3b deposition on M. 
tuberculosis Figure 5.4.1a.  
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In the absence of classical pathway blocking but when the alternative pathway was active 
(Table 5.4-1iv) C5b-9 deposition was highest in zymosan. This deposition was greatly 
reduced in comparison to the other samples when the alternative pathway was inhibited. M. 
tuberculosis phenotypes showed only partial inhibition of C5b-9 deposition when the 
alternative pathway was inhibited and all other pathways were active. M. smegmatis followed 
by S. agalactiae showed less C5b-9 deposition than M. tuberculosis phenotypes when all 
three pathways were active. C5b-9 was diminished further in M. smegmatis and S. agalactiae 
when the alternative pathway was inhibited Figure 5.4.1b.  
 
Blocking the classical pathway completely abolished C5b-9 deposition in S. agalactiae even 
when the alternative pathway was active at 10% concentration suggesting deposition was 
entirely dependent on the classical pathway. M. smegmatis showed minimal C5b-9 deposition 
at 10% complement concentration after blocking the classical pathway and no deposition at 
2% complement concentration suggesting roles for the classical pathway and a minor role for 
the alternative pathway. Despite the predominant role of the alternative pathway in the 
deposition of C5b-9 on Zymosan, C5b-9 deposition was still present on Zymosan even when 
the alternative and classical pathways were inhibited suggesting the lectin pathway is also 
partially involved in deposition. C5b-9 deposition was still present on M. tuberculosis 
phenotypes after inhibition of the classical and alternative pathways suggesting the lectin 
and/or C2 pathway contribute to C5b-9 deposition on M. tuberculosis Figure 5.4.1b.  
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Figure 5.4.1: Complement deposition on planktonic and biofilm phenotype M. tuberculosis 
relative to planktonic M. smegmatis and planktonic S. agalactiae and Zymosan. (A) Net mean 
C3b/iC3b deposition (integrated median fluorescence intensity - iMFI) of samples after pre-
incubation of complement with mAb anti-C1q (shaded bars) or pre-incubation with PBS 
(clear bars) and labelling with anti-C3c FITC pAb. (B) Net mean C5b-9 deposition (iMFI) 
onto samples after pre-incubation of complement with mAb anti-C1q (shaded bars) or pre-
incubation with PBS (clear bars) labelled with anti-C5b-9 Alexafluor 647. Error bars show 
standard deviation of x4 biological replicates.
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A t-test corrected for multiple comparisons by false discovery rate (Q=5%)showed that 
C3b/iC3b (Figure 5.4.2a) and C5b-9 (Figure 5.4.2b) deposition were significantly reduced 
on biofilm phenotype M. tuberculosis compared to planktonic phenotype M. tuberculosis at 
both 2% concentration when the alternative pathway is inhibited and 10% concentration 
when all three major pathways are active. C3b/iC3b showed on average 14% less deposition 
in biofilm phenotype M. tuberculosis compared to planktonic phenotype at both 2% and 10% 
complement concentrations. C5b-9 showed on average 27% less deposition at 2% 
complement concentration and 6% less deposition at 10% complement concentration. There 
remained a significant difference in C3b/iC3b deposition when the classical pathway was 
inhibited and when both the classical and alternative pathways were inhibited (Figure 
5.4.2c). Furthermore, in the absence of the classical and alternative pathways the effect size 
was much larger. C3b/iC3b deposition after C1q blocking showed on average 60% less 
deposition in biofilm phenotype M. tuberculosis compared to planktonic phenotype M. 
tuberculosis at 2% complement concentration and 16% at 10% complement concentration. 
Likewise there remained a significant difference in C5b-9 deposition after C1q blocking with 
a much larger effect size with the classical and alternative pathways inhibited together Figure 
5.4.2d. At 2% complement concentration after C1q blocking, biofilm phenotype M. 
tuberculosis showed 60% less C5b-9 deposition compared to planktonic phenotype M. 
tuberculosis. At 10% complement concentration with C1q blocking, biofilm phenotype 
showed 26% less deposition compared planktonic phenotype Figure 5.4.2c.  
 
The percentage of C3b/iC3b deposition and C5b-9 deposition that was classical pathway 
dependent (C1q-dependent) was calculated by determining the percentage change in 
deposition before and after C1q blocking. C3b/iC3b deposition onto biofilm phenotype M. 
tuberculosis was significantly more dependent on the classical pathway (67%) compared to 
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planktonic M. tuberculosis (30%) in the absence of alternative pathway activity (2% 
complement). This difference was abolished when the alternative pathway was active (10% 
complement concentration) where 12% of C3b/iC3b deposition was classical pathway 
dependent on planktonic M. tuberculosis compared to 14% classical pathway dependence on 
biofilm M. tuberculosis (Figure 5.4.2e). C5b-9 deposition onto biofilm phenotype M. 
tuberculosis was significantly more dependent on the classical pathway (78%) compared to 
planktonic M. tuberculosis (60%) in the absence of alternative pathway activity (2% 
complement concentration) although the effect size was smaller than seen with C3b/iC3b 
deposition. Furthermore, unlike with C3b/iC3b deposition there was also a significant 
difference when the alternative pathway was active (10% complement concentration) where 
biofilm phenotype M. tuberculosis showed 33% classical pathway dependence compared to 
18% classical pathway dependence on C5b-9 deposition onto planktonic M. tuberculosis 
(Figure 5.4.2f).  
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Figure 5.4.2: Complement activation by planktonic and biofilm phenotype M. tuberculosis. 
(A) Net mean C3b/iC3b deposition (iMFI) of samples after pre-incubation of complement 
with PBS and labelling with anti-C3c FITC pAb. (B) Net mean C5b-9 deposition (iMFI) onto 
samples after pre-incubation of complement with PBS, labelled with anti-C5b-9 Alexafluor 
647. (C) Net mean C3b/iC3b deposition (iMFI) of samples after pre-incubation of 
complement with anti-C1q and labelling with anti-C3c FITC pAb. (D) Net mean C5b-9 
deposition (iMFI) of samples after pre-incubation of complement with anti-C1q and labelling 
with anti-C3c FITC pAb. (E) Net mean % C1q-dependent C3b/iC3b deposition onto 
planktonic and biofilm phenotype M. tuberculosis. (F) Net mean % C1q-dependent C5b-9 
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deposition onto planktonic and biofilm phenotype M. tuberculosis. Error bars = standard 
deviation of ≥3 biological replicates. * = P<0.05 corrected t-tests by false discovery rate 
Q=5%. 
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5.5 Analysis of complement activator binding to planktonic and biofilm phenotype M. 
tuberculosis 
The direct binding onto planktonic and biofilm phenotype M. tuberculosis of two lectin 
pathway activators, mannose binding lectin (MBL) and ficolin-3 in addition to classical 
pathway activator C1q were investigated using flow cytometry using the methods described 
in section 7.25. 
As with the C3b/iC3B and C5b-9 experiment, for each complement activator a final 
concentration of 0.09 OD540 nm x4 M. tuberculosis planktonic biological replicates, x4 M. 
tuberculosis biofilm biological replicates, M. smegmatis, S. agalactiae and Zymosan were 
added to respective wells. In separate experiments, purified human C1q, recombinant human 
MBL and recombinant human ficolin-3 were each incubated directly with live M. 
tuberculosis, labelled with primary and fluorescent secondary antibodies. Mycobacteria were 
identified in 10 000 events using a forward scatter side scatter gating strategy constantly 
applied for all flow cytometry experiments (Figure 5.3.2). The net magnitude of deposition 
was determined by multiplying the median fluorescence intensity (MFI) by % positive cells 
to calculate the integrated median fluorescence intensity iMFI (Darrah et al., 2007) and 
subtracting the negative controls (sample + complement activator + conjugate).  
MBL deposition was highest on M. tuberculosis planktonic samples, followed by zymosan 
and M. tuberculosis biofilm samples, with no deposition seen on M. smegmatis or S. 
agalactiae (Figure 5.5.1a). This result was consistent with the observation from the 
C3b/iC3b and C5b-9 deposition assay that complement deposition onto M. smegamatis and S. 
agalactiae was dependent on the classical pathway. C1q deposition was highest on M. 
tuberculosis planktonic samples, followed by M. tuberculosis biofilm samples followed by 
M. smegmatis and Zymosan (Figure 5.5.1b). Interestingly despite the C3b/iC3b and C5b-9 
deposition assay showing classical pathway dependent complement deposition on S. 
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agalactiae (Figure 5.4.1), Figure 5.5.1b suggests this does not appear to be dependent on 
direct C1q binding and therefore presumably C3b/iC3b and C5b-9 deposition is dependent on 
C1q via interaction with anti-S. agalactiae natural antibodies in the pooled IgG-depleted 
complement source. Ficolin-3 deposition was highest in planktonic M. tuberculosis followed 
by M. smegmatis, biofilm M. tuberculosis Zymosan and S. agalactiae Figure 5.5.1c.  
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Figure 5.5.1: Complement activator binding to planktonic and biofilm phenotype M. 
tuberculosis relative to planktonic M. smegmatis and planktonic S. agalactiae and Zymosan. 
(A) Net mean binding of MBL to samples (iMFI) after incubation with recombinant MBL 
and labelling with anti-MBL primary and anti mouse IgG (H+L) F(ab')₂ Fragment FITC. (B) 
Net mean binding of C1q to samples (iMFI) after incubation with purified C1q and labelling 
with anti-C1q primary and anti-mouse IgG (H+L) F(ab')₂ Fragment FITC. (C) Net mean 
binding of ficolin-3 to samples (iMFI) after incubation with recombinant ficolin-3 and 
labelling with anti-ficonin-3 primary and anti-mouse IgG (H+L) F(ab')₂ Fragment FITC. Error 
bars = standard deviation of ≥3 biological replicates. 
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Welch’s t-tests revealed MBL deposition was significantly reduced on biofilm phenotype M. 
tuberculosis compared to planktonic phenotype (P<0.05), showing a 59% knockdown in 
binding (Figure 5.5.2a). Similarly, direct binding of C1q was also significantly reduced in 
the biofilm phenotype and the effect size was slightly smaller showing a 42% knockdown 
(P<0.05) (Figure 5.5.2b). Notably despite the C3b/iC3b and C5b-9 deposition assay 
suggesting deposition onto biofilm phenotype M. tuberculosis was more dependent on the 
classical pathway, the total direct binding of C1q to biofilm phenotype compared to 
planktonic phenotype was reduced. Ficolin-3 was incubated with planktonic or biofilm 
phenotype M. tuberculosis and was reduced on the biofilm phenotype but this was not a 
statistically significant difference (Figure 5.5.2c).  
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Figure 5.5.2: Binding of complement activators to planktonic and biofilm phenotype M. 
tuberculosis. (A) Net mean binding of MBL to samples (iMFI) after incubation with 
recombinant MBL and labelling with anti-MBL primary and anti-mouse IgG (H+L) F(ab')₂ 
Fragment FITC. (B) Net mean binding of C1q to samples (iMFI) after incubation with 
purified C1q and labelling with anti-C1q primary and anti-mouse IgG (H+L) F(ab')₂ 
Fragment FITC. (C) Net mean binding of ficolin-3 to samples (iMFI) after incubation with 
recombinant ficolin-3 and labelling with anti-ficonin-3 primary and anti-mouse IgG (H+L) 
F(ab')₂ Fragment FITC. Error bars = standard deviation ≥3 biological replicates. * = P<0.05 
Welch’s t-test. 
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5.6 Investigation of the C2-pathway of complement deposition onto planktonic and 
biofilm phenotype M. tuberculosis. 
The C3b/iC3b and C5b-9 deposition assay inhibited both the classical and alternative 
pathways of complement deposition. With most bacterial species, this would leave any 
remaining deposition attributable to the lectin pathway. However, M. tuberculosis has a little-
studied fourth pathway of complement activation that relies on the capture of C2a after its 
cleavage from component C2 by an unidentified surface expressed protein to form a 
functioning C3 convertase. This pathway is unique to pathogenic mycobacteria (Schorey et 
al., 1997). C2 can be cleaved by MBL-associated serine protease 2 (MASP-2) which forms 
part of the complex of complement activating collectins and ficolins of the lectin pathway. It 
can also be cleaved by C1s which associates with C1q after it binds either directly or via 
antibodies to the bacterial surface (Murphy, 2012). Therefore when both the classical and 
alternative pathway were inhibited in C3b/iC3b and C5b-9 deposition experiment, the C2a 
pathway may have acted via MASP-2 to amplify lectin pathway complement deposition 
through C2a capture to create additional functioning C3 covertases. To investigate the C2a 
pathway of complement deposition, an experiment was planned to demonstrate C2 pathway 
activity by M. tuberculosis planktonic and biofilm phenotypes in the absence of the lectin, 
classical and alternative pathway activity. 
To demonstrate C2a binding to M. tuberculosis an experiment was performed as described in 
methods sections 7.26. Briefly, live planktonic and biofilm M. tuberculosis, in addition to 
negative controls M. smegmatis, S. agalactiae and zymosan was incubated with purified 
human C2 with or without pre-incubation with activated purified human C1s enzyme, which 
cleaves C2 into C2a and C2b. The samples were then washed and labelled with Rabbit anti-
human C2a FITC pAb and fixed with formaldehyde before measuring FITC fluorescence on 
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bacteria by flow cytometry. FITC channel iMFI values would be indicative of C2a binding in 
the absence of other complement components. The plate layout is shown in Table 5.6-1.
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 1 2 3 4 5 6 7 8 9 10 11 12 
A PKA 
 
PKB 
 
PKC 
 
PKD 
 
BFA 
 
BFB 
 
BFC 
 
BFD 
 
Smeg 
 
GBS 
 
Zy 
 
Zy 
 
B PKAcon 
 
PKB con 
 
PKC con 
 
PKD con 
 
BFAcon 
 
BFB con 
 
BFC con 
 
BFD con 
 
Smeg con 
 
GBS con 
 
Zy con 
 
Zy con 
 
C PKA con 
 
PKB con 
 
PKC con 
 
PKD con 
 
BFA con 
 
BFB con 
 
BFC con 
 
BFD con 
 
Smeg con 
 
GBS con 
 
Zy con 
 
Zy con 
 
D PKA C2 
 
PKB C2 
 
PKC C2 
 
PKD C2 
 
BFA C2 
 
BFB C2 
 
BFC C2 
 
BFD C2 
 
Smeg C2 
 
GBS C2 
 
Zy C2 
 
Zy C2 
 
E PKA C2 
 
PKB C2 
 
PKCC2 
 
PKD C2 
 
BFA C2 
 
BFB C2 
 
BFCC2 
 
BFD C2 
 
Smeg C2 
 
GBS C2 
 
Zy C2 
 
Zy C2 
 
F PKA 
C2a/b 
PKB 
C2a/b 
PKC 
C2a/b 
PKD 
C2a/b 
BFA 
C2a/b 
BFB 
C2a/b 
BFC 
C2a/b 
BFD 
C2a/b 
Smeg 
C2a/b 
GBS 
C2a/b 
Zy C2a/b Zy C2a/b 
G PKA 
C2a/b 
PKB 
C2a/b 
PKC 
C2a/b 
PKD 
C2a/b 
BFA 
C2a/b 
BFB 
C2a/b 
BFC 
C2a/b 
BFD 
C2a/b 
Smeg 
C2a/b 
GBSC2a/b Zy C2a/b Zy C2a/b 
H PKA 
 
PKB 
 
PKC 
 
PKD 
 
PKA 
 
BFB 
 
BFC 
 
BFD 
 
Smeg 
 
GBS 
 
Zy 
 
Zy 
 
Table 5.6-1: Plate layout of the C2 pathway experiment. C2 wells contain PBS-C2, C2a/b wells contain C2 cleaved by enzyme activated C1s 
into components C2a and C2. PKA – PKD, x4 biological replicate planktonic M. tuberculosis samples; BFA – BFD, x4 biological replicate 
biofilm M. tuberculosis samples; Smeg, M. smegmatis; GBS, S agalactiae; Zy, Zymosan.  
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The experiment did not show specific C2a binding to M. tuberculosis, as shown in Figure 
5.6.1d. Histograms showed no shift in fluorescence between M. tuberculosis sample 
incubated with conjugate only, conjugate + uncleaved C2 and conjugate in the presence of 
C2a. Figure 5.6.1c,d and e. However, there was a shift in fluorescence that was seen between 
‘mycobacteria only’ negative controls and ‘mycobacteria + rabbit-anti-human C2a pAb 
conjugate’ negative controls (Figure 5.6.1b and c). Since the shift was also seen with M. 
smegmatis it was not specific to pathogenic mycobacteria. Additional negative controls S. 
agalactiae and Zymosan did not show C2a binding (Figure 5.6.1d). Furthermore, S. 
agalactiae did not show a shift in fluorescence after incubation with Rabbit-anti-human C2a 
pAb conjugate while Zymosan showed a marginal shift (Figure 5.6.1b and c). These results 
suggest that mycobacteria may harbour epitopes on their surface with affinity to anti-human 
C2a pAb.  
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Figure 5.6.1: Assessment of C2-pathway deposition onto planktonic and biofilm phenotype M. tuberculosis with additional controls. Columns 
from left to right are representative fluorescence histograms from samples as indicated in the top row. Samples were incubated without rabbit 
anti-human C2a FITC pAb (a), with rabbit anti-human C2a FITC pAb only (b), with rabbit anti-human C2a FITC pAb and C2 (c) and with 
rabbit anti-human C2a FITC pAb and pre-incubated C2/C1s (d).  
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The extent of direct binding of Rabbit anti-human C2a pAb to bacteria and zymosan is shown 
in Figure 5.6.2a. M. tuberculosis planktonic samples showed the greatest magnitude of 
binding followed by M. tuberculosis biofilm samples and M. smegmatis planktonic samples 
which showed a similar magnitude of binding. There was minimal binding of rabbit anti- 
human C2a pAb to zymosan and S. agalactiae. A Welch’s corrected t-test (for unequal 
variances) showed there was no statistically significant difference in the magnitude of 
binding between planktonic and biofilm phenotypes (P>0.05). This was likely to be due the 
large variation in the magnitude of fluorescence in the planktonic samples between biological 
replicates. 
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Figure 5.6.2: Direct binding of Rabbit anti-human C2a polyclonal antibody to bacteria and 
zymosan. (A) Binding anti human-C2a pAb to x4 biological replicate M. tuberculosis 
planktonic and biofilm phenotype samples, M. smegmatis planktonic, S. agalactiae 
planktonic and zymosan samples. (B) Binding anti human-C2a pAb to x4 biological replicate 
M. tuberculosis planktonic and biofilm phenotype samples only. iMFI-background, iMFI of 
samples incubated with antibody minus iMFI of control samples incubated without antibody. 
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5.7 Optimisation and analysis of complement deposition on to M. tuberculosis 
carbohydrate extracts 
To investigate the extent of complement pathway activation by planktonic and biofilm 
phenotype M. tuberculosis carbohydrates extracts, A method by Bahia El Idrissi et al., (2015) 
was modified to include a standard curve. Carbohydrate extractions and C3b/iC3b, C5b-9 and 
MBL ELISAs were performed as described in methods sections 7.13, 7.19, 7.20 and 7.21 
respectively. 
To investigate C3b/iC3b deposition onto planktonic and biofilm M. tuberculosis carbohydrate 
extracts, Briefly 2.5 µg of x3 biological replicate planktonic and biofilm carbohydrate extract 
was coated onto wells and incubated with 2% and 10% IgG-depleted human complement. In 
addition to the x3 biological replicate planktonic and biofilm samples, known concentrations 
of purified human C3 were labelled with pAb anti-C3c HRP and incubated. Plates were 
developed by the addition of TMB substrate and quenched after 10 minutes. The absorbance 
was read and a 5-parameter logistic standard curve was generated with the absorbance 
readings of known quantities of human purified C3 (Figure 5.7.1a). Due to the large 
difference in C3 quantity at 2% and 10% complement concentrations, a second standard 
curve of higher C3 concentrations was required to quantify C3 deposition after incubation of 
carbohydrate extracts with 10% complement, shown in Figure 5.7.1b.  The net amount 
(sample + complement + conjugate pg mL
-1
 minus sample + conjugate only negative controls 
pg mL
-1
) of C3b/iC3b deposition on x3 biological replicate planktonic and biofilm phenotype 
M. tuberculosis carbohydrate samples was calculated by interpolating absorbance values into 
the standard curve Figure 5.7.2a.  Welch’s t-test revealed C3b/iC3b deposition was 
significantly reduced on biofilm phenotype M. tuberculosis carbohydrate extracts compared 
to planktonic carbohydrate extracts at physiologically relevant 2% complement concentration 
(Figure 5.7.2a) but not at 10% complement concentration (Figure 5.7.2b).  
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To investigate C5b-9 deposition onto planktonic and biofilm M. tuberculosis, carbohydrate 
extracts plates were prepared in the same manner as with the C3 ELISA and incubated with 
2% and 10% complement. Carbohydrate extracts and known concentrations of purified 
human C5b-9 were then labelled with mouse anti-human C5b-9 followed by goat anti mouse-
HRP secondary antibody and incubated. Plates were developed by the addition of TMB 
substrate and quenched after 10 minutes. The absorbance was read and a 5-parameter logistic 
standard curve was generated with the absorbance readings of known quantities of human 
purified C5b-9 Figure 5.7.1c. The net amount of C5b-9 deposition on x3 biological replicate 
planktonic and biofilm phenotype M. tuberculosis carbohydrate samples was calculated by 
interpolating absorbance values into the standard curve Figure 5.7.2b.  C5b-9 deposition was 
on average higher on planktonic M. tuberculosis carbohydrate extracts, however Welch’s t-
test showed no significant difference in C5b-9 deposition on planktonic and biofilm 
phenotype M. tuberculosis carbohydrate extracts at both 2% complement concentration 
(Figure 5.7.2c) and 10% complement concentration (Figure 5.7.2d). 
To investigate MBL deposition onto planktonic and biofilm M. tuberculosis carbohydrate 
extracts plates were prepared in the same manner as with the C3 ELISA and incubated with 
10 mg mL
-1
 recombinant MBL. Carbohydrate extracts and known concentrations of 
recombinant human MBL were then labelled with mouse anti-human MBL followed by goat 
anti mouse-HRP secondary antibody and incubated and the standard curve was generated 
with absorbance readings of known quantities of recombinant human MBL (Figure 5.7.1d). 
The net amount of MBL deposition on x3 biological replicate planktonic and biofilm 
phenotype M. tuberculosis carbohydrate samples was calculated by interpolating absorbance 
values into the standard curve Figure 5.7.2e. MBL deposition onto planktonic carbohydrate 
extracts was on average higher than on biofilm carbohydrates. However, Welch’s t-test 
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showed no significant difference in C5b-9 deposition on planktonic and biofilm phenotype 
M. tuberculosis carbohydrate extracts (Figure 5.7.2e)
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Figure 5.7.1: Standard curves for quantification of C3b, C5b-9 and MBL deposition on 
carbohydrate extracts. (A) 7 point ¼ standard curve of well-bound C3 starting at 600 ng 
purified C3. (B) 7 point ¼ standard curve of well-bound C3 starting at 15 000 ng purified C3. 
(C) 7 ¼ point standard curve of well-bound C5b-9 starting at 1080 ng purified C5b-9. (D) 7 
point ¼ standard curve of well-bound MBL starting at 1000 ng recombinant MBL. 
Horizontal dotted-lines indicate ULOQ, Error bars = standard deviation of two replicate 
curves.  
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Figure 5.7.2: ELISAs measuring complement deposition on planktonic and biofilm 
phenotype M. tuberculosis carbohydrate extracts. (A) C3b/iC3b deposition on planktonic and 
biofilm carbohydrate extracts incubated with 2% complement. (B) C3b/iC3b deposition on 
planktonic and biofilm carbohydrate extracts incubated with 10% complement. (C) C5b-9 
deposition on planktonic and biofilm carbohydrate extracts incubated with 2% complement. 
(D) C5b-9 deposition on planktonic and biofilm carbohydrate extracts incubated with 10% 
complement. (E) MBL deposition on planktonic and biofilm carbohydrate extracts incubated 
with 10 mg mL
-1
 MBL. Error bars = standard deviation of 3 biological replicates. * = P<0.05 
Welch’s t-test. 
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5.8 Technical discussion 
To summarise the final results chapter, M. tuberculosis biofilm carbohydrate extracts showed 
significantly reduced C3b/iC3b deposition compared to planktonic carbohydrate extracts 
when the alternative pathway was inhibited at 2% complement concentration. This effect was 
not seen with C5b-9 deposition or MBL binding. Analysis of whole live cell deposition on M. 
tuberculosis planktonic and biofilm phenotypes showed reduced C3b/iC3b deposition and 
C5b-9 deposition on biofilm phenotype cells and greater importance of the classical pathway 
in triggering this deposition. Biofilm phenotype M. tuberculosis also showed reduced direct 
C1q binding and MBL binding compared to planktonic phenotype M. tuberculosis. 
For flow cytometry experiments it was decided that dispersion of planktonic and biofilm 
cultures followed by low-speed centrifugation was the best way to prepare M. tuberculosis 
cultures. Clumping has been shown to cause issues with flow cytometry assay involving 
mycobacteria (Hartmann et al., 2001; Lowe et al., 2013). Methods such as dispersal using a 
vortex alone fail to declump mycobacteria and therefore vortexing samples followed by low 
speed centrifugation or filtration would be unfeasible due to the large amount of sample loss. 
As the yields from planktonic cultures were very low, it was not possible to obtain enough 
dispersed cells without prior mechanical disaggregation of mycobacterial clumps with glass 
beads. Dispersal using detergents has been shown to alter innate immune responses (Sani et 
al., 2010) and therefore would not be appropriate for these experiments. Dispersal using glass 
beads reduced the extent of capsular polysaccharides on the surface of the bacterium (Figure 
5.3.1), the effect was partial as α(1-2) mannosyl residues on the surface of glass bead treated 
bacteria could still be labelled. Furthermore, the viability of mycobacteria had been shown to 
be not significantly reduced after dispersion with glass beads (P>0.05).  
An ideal measurement of innate complement deposition on M. tuberculosis would need to 
recapture the aerosolised expectorated cells that cause transmission. These are a 
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heterogeneous population including aerobically growing bacteria and persisters with lipid 
bodies, as seen in sputum samples (Garton et al., 2008). The aerosolisation of bacteria shed 
from in vivo pellicle biofilms would disperse the bacteria as they are forced upwards and 
outwards from lung cavities into the air since typical infectious droplet sizes are less than 5 
µm in diameter (Fennelly and Jones-López, 2015). As EPS and capsule material are likely to 
be associated with bacteria in these aerosols, studying dispersed M. tuberculosis biofilms may 
have more in vivo relevance than deposition onto whole intact biofilms when studying innate 
immunity and the establishment of infection. 
Absorbance was used to equalise the planktonic and biofilm samples instead of viable counts 
to compare deposition on equal amounts of biomass. Pellicle biofilm cultures consisted of 
significant amounts of EPS that was not present in planktonic cultures (Figure 2.3.1). In 
addition, mature 5 week pellicle biofilm cultures may harbour increased viable but non-
culturable bacteria that may activate complement. Therefore, adjustment for viability may 
overcorrect the available surface area for complement interactions in biofilm cells compared 
to planktonic cells. Thus absorbance was used to keep the available surface area in the 
samples for complement deposition equal.  
Previous studies suggest lowering the complement concentration to ≈2% (1/50 dilution) 
inhibits the alternative pathway to a far greater extent than the classical pathway due to low 
availability of factor D, which cleaves factor B (Ferguson et al., 2004; Nilsson and Nilsson, 
1984). While alternative pathway activity is greatly restored at 10% concentration (1/10 
dilution) (Nilsson and Nilsson, 1984). Additional experimental evidence for the activity of all 
three pathways at 10% concentration and inhibition of the alternative pathway at 2% 
concentration, can be gleaned from the results C3b/iC3b and C5b-9 deposition on M. 
smegmatis using complement pre-incubated with C1q (Figure 5.4.1). M. smegmatis showed 
no deposition at 2% complement concentration with the classical pathway inhibited but 
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showed deposition at 10% complement concentration with the classical pathway inhibited. M. 
smegmatis only weakly triggers lectin pathway activation (Bartlomiejczyk et al., 2014). 
Therefore this suggests the remaining deposition at 10% complement concentration when the 
classical pathway was inhibited with C1q was attributable to the alternative pathway. The 
absence of this deposition at 2% complement concentration shows the alternative pathway 
was inhibited at this concentration. 
The C2a binding experiment did not show C2a binding to M. tuberculosis but there was 
direct binding of the anti-human C2a pAb to mycobacteria (Figure 5.6.2). The reason for this 
binding is unclear. However, the most likely answer is that the antibodies were raised in 
rabbits using human C2a in Freund's complete adjuvant (FCA), which contains mycobacteria 
proteins (Leenaars et al., 2005). If this were the case it would explain the binding to 
mycobacteria and a different anti-C2a antibody that was not raised using FCA should be used 
in this assay. Were direct anti-C2a binding still to be shown in mycobacteria using an 
antibody confirmed to be raised without FCA, this could suggest a novel host modulation 
mechanism. The IgG antibodies are unlikely to bind to mycobacteria via their Fc domains, as 
seen in pathogenic bacteria such as Streptococcus pyogenes (Nordenfelt et al., 2012) since 
this has not been previously reported in the literature. Pathogenic mycobacteria are suggested 
to have a C4b-like protein that binds with free C2a to create a functioning convertase 
(Lachmann, 1998; Schorey et al., 1997). If a C2a-like protein is also present on the surface of 
mycobacteria, could mycobacteria also bind C4b to create functioning convertases? 
Alternatively could pathogenic mycobacteria secrete fully functioning C3 convertases? Prior 
to further investigation, an anti-C2a antibody confirmed not to have been raised using FCA 
should be sourced. Also SDS-PAGE of the purified C1s, C2 and C2-C1s combination could 
be performed to confirm that the purified C1s enzyme cleaves C2. The experiment could then 
be repeated. 
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The biological replicates of the carbohydrates used in the complement ELISAs showed wide-
ranging variability in the amount of C5b-9 and MBL deposition (Figure 5.7.2). As mentioned 
during the technical discussion of whole blood stimulation with carbohydrate extracts, this 
variability could have been reduced by obtaining additional biological replicates. The M. 
tuberculosis planktonic carbohydrate extracts functioned as the control to the biofilm 
carbohydrate extracts. Yet it would have been preferable to include a positive control such as 
zymosan, known for its induction of complement activity, to assess whether the levels of 
complement deposition induced by M. tuberculosis carbohydrate extracts were high, as seen 
with dispersed live whole cells (Figure 5.4.1).  
In most of the standard curves generated for the ELISAs, and especially for the MBL 
standard curves, the highest levels of well-bound standard were above the limit of detection 
of the plate reader. Therefore, for further optimisation of the assay, standard curves should be 
generated starting from lower concentrations of standard. If for example MBL binding to M. 
tuberculosis carbohydrate was then above the new standard curve range, lower concentrations 
of MBL could be incubated with the carbohydrate samples. For the ELISAs using 2% and 
10% complement incubation, instead of altering complement concentration, the amount of 
carbohydrate bound to the bottom of each well could be reduced to ensure plate readings 
were within the range of the instrument.  
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6 DISCUSSION 
6.1 Biofilm and planktonic growth of bacteria in vivo 
Biofilms represent the predominant lifestyle of microbes (Watnick and Kolter, 2000) and 
there is strong evidence that biofilm formation is a key factor in many diseases, including 
chronic bacterial infections of the cystic fibrosis lung, in which Pseudomonas aeruginosa and 
Burkholderia cenocepacia biofilms can cause significant lung damage and increased 
mortality (Tomlin et al., 2001). Aggregates of bacteria in chronic infections are types of 
biofilms with increased antibiotic tolerance and resistance to host defences compared to 
dispersed planktonic bacteria (Bjarnsholt, 2013). There are numerous advantages to bacteria 
in chronic infections adopting a biofilm phenotype. Firstly the size of the biofilm can lead to 
‘frustrated phagocytosis’ where failure of phagocytes such as neutrophils to engulf the 
biofilm result in their release of proteolytic enzymes and cytotoxic effectors (Wagner et al., 
2003) which drives host tissue damage, releasing nutrients for bacterial growth. Secondly the 
oxygen/nutrient gradients in the biofilm slow the metabolism of bacteria located in the core 
turning them into persisters, which can survive antimicrobial therapy and reactivate, resulting 
in treatment failure as seen with P. aeruginosa biofilms (Walters et al., 2003). Thirdly 
extracellular DNA in the EPS of P. aeruginosa biofilms has been shown to sequester cations 
and inhibit the effectiveness of cationic antimicrobial peptides (Mulcahy et al., 2008). M. 
tuberculosis biofilms in tuberculosis cavities, isolated from adaptive immune responses 
through fibrosis of the cavity rim (Hunter, 2011) may not require such mechanisms to persist. 
However, pellicles are easily dislodged from their surface and may be the predominant 
phenotype of expectorated bacteria during transmission in untreated cavitary tuberculosis 
cases, as sputum samples suggest similarities between the transmissible bacteria and in vitro 
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pellicles (Arora et al., 2016). Following transmission, mechanisms similar to those described 
above, may allow M. tuberculosis to resist host defences and establish infection.  
M. tuberculosis replication is asymmetric, with faster growth at the old pole creating two 
daughter cells of different sizes (Kieser and Rubin, 2014) . Asymmetric division may 
promote directional interlocking growth of mycobacteria as serpentine cords. The 
spontaneous tendency of M. tuberculosis to form a biofilm in addition to the absence of any 
non-passive motility mechanism begs the question, is there any point during M. tuberculosis 
pathogenesis when the bacteria do not aggregate as some type of biofilm?  
Planktonic M. tuberculosis can be observed in vivo. Extracellular bacteria within the caseum 
of granulomas of infected C3HeB/FeJ mice have been shown to be more dispersed than 
intracellular aggregates at the rim of granulomas (Irwin et al., 2015). As previously 
mentioned in section 1.3, aerosols of expectorated M. tuberculosis can harbour single cells 
during transmission (Fennelly and Jones-López, 2015). These may be shed from pellicle-like 
biofilms growing in M. tuberculosis cavities (Hunter, 2011) and therefore share similar 
phenotypic characteristics to dispersed in vitro pellicle biofilm cultures. Planktonic 
intracellular M. tuberculosis may only occur in phagocytes able to control infection and 
prevent replication. M. tuberculosis H37Rv requires a multiplicity of infection >10 bacteria 
to replicate in macrophages (Welin et al., 2011) implying only M. tuberculosis bacteria in 
close proximity, such as biofilms, may be able to induce disease progression. Thus M. 
tuberculosis exists in heterogeneous growth states, since intracellular, extracellular 
planktonic and biofilm (aggregates) phenotypes have been documented in vivo using animal 
models (Driver, 2014; Hoff et al., 2011; Irwin et al., 2015; Lenaerts et al., 2007; Ryan et al., 
2010). In vivo planktonic M. tuberculosis might be most prevalent when replication is 
prevented through lack of nutrients/oxygen or via host bacteriostatic immune mechanisms 
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and the action of pulmonary surfactants. The source of these bacteria could be shed from 
actively replicating biofilms at the focal site of infection.  
6.2 Biofilm culture 
The comparison of in vitro shaken cultures and pellicles is useful principally because the 
specific type of biofilm being assessed for its immunological effects (pellicles) consists of 
bacteria encased in a type of EPS which is not present until week 4 of pellicle culture (Figure 
2.3.1e). SEM of intact pellicles provided evidence that the pellicles are in an organised 
structure (Figure 2.4.1). Historically, pellicle formation has been dismissed as a benign 
process of aggregation by mycobacterial cell wall hydrophobicity (Ojha and Hatfull, 2012). 
While hydrophobicity is an obvious pre-requisite to biofilm formation on a liquid surface, if 
pellicles are merely disorganised aggregations on liquid surface, one would expect a 
confluent spread of bacteria with no discernible macrostructural features. Whereas true 
biofilm formation would have distinct morphology and three-dimensional architecture, such 
as filaments or mushroom-shaped macrocolonies (Flemming and Wingender, 2010). The 
results presented in this thesis show that M. tuberculosis replication in non-perturbed cultures 
produces organised biofilms with serpentine cords encased in copious quantities of EPS 
(Figure 2.4.1). The delay to pellicle EPS production was until around week four of culture 
(Figure 2.3.1) and could be due to unrestrictive replication of M. tuberculosis until 
confluence is reached on the surface of the medium. The pellicle biofilms contained regions 
of confluence speckled with cording regions (Figure 2.4.2, Figure 2.4.3). Within the cords, 
M. tuberculosis bacteria were oriented pole to pole which may provide a much greater 
surface area to volume ratio than a confluent mass of cells, possibly improving diffusion 
efficiency during mycobacterial respiration, as gases may be able to penetrate deep into the 
3D structure. 
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Cording is an innate phenomena seen in M. tuberculosis and other mycobacteria (Caceres et 
al., 2013; Julián et al., 2010). M. tuberculosis cords enhance macrophage extracellular trap 
formation (Kalsum et al., 2017). Extracellular trap formation is a controlled cell-death 
process where the phagocyte releases its chromatin lined with antimicrobial proteins (Boe et 
al., 2015). But their formation does not affect intracellular mycobacterial growth (Wong et 
al., 2013). It is now becoming clear that M. tuberculosis biofilm formation is an important 
tuberculosis disease driver involved in all stages of the disease, including intracellular 
replication. M. tuberculosis replication within macrophages aggregate via an ESX-1 
dependent process, which is further enhanced by IFN-γ (Wong et al., 2013). After infected 
macrophage necrosis, the M. tuberculosis aggregate may continue to grow, increasing its 
cytotoxicity to facilitate serial phagocytosis and necrosis and disease progression (Mahamed 
et al., 2017). Since large aggregates are more cytotoxic than multiple smaller phagocytosis 
events of the same quantity of bacteria, this suggests that the EPS binding the aggregates 
plays an important role in cytotoxicity.  
Immuno gold EM labelling of α(1,2) mannospyranose residues using anti-PIM/LAM 
antibody revealed the capsule of M. tuberculosis (Figure 2.4.1c,d) as has been previously 
observed (Sani et al., 2010). Furthermore, labelling of the planktonic and biofilm culture 
aggregates showed EPS also has α(1,2) mannospyranose residues (Figure 2.4.4), found in M. 
tuberculosis PIMs, LM, and LAM (Mishra et al., 2011). While these lipoglycans are thought 
to be anchored to the inner and outer mycobacterial membranes, hydrolysis of the lipid 
anchor of LM and LAM allows export of mannans and arabinomannans to form the capsule 
(Angala et al., 2014). It is therefore likely that these polysaccharides are also constituents of 
EPS. The distinction between capsule and EPS becomes more challenging because M. 
tuberculosis pellicle biofilm cultures have been used to characterise the capsule surrounding 
each bacterium (Ortalo-Magné et al., 1995). This study utilised the mechanical force of 
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agitation with glass beads to extract extracellular material without lysing cells but did not 
acknowledge that a pellicle is a biofilm. Therefore the extracellular material extracted was 
classed as ‘capsule’ regardless of whether it was a distinct layer encompassing each 
bacterium or EPS. Ortalo-Magné et al., (1995) determined the ‘outermost cellular material’ 
hereto referred to as EPS, was comprised of 1 – 6% lipids with the remaining 94-99% being a 
mixture of carbohydrates (arabinomannan, mannan and α-glucan) and proteins. 
M. tuberculosis pellicle biofilm cells were significantly longer that planktonic cells (Figure 
2.4.1e). This contrasts with observations made during M. smegmatis biofilm formation, in 
which the bacteria became smaller over time as the pellicle matures (Sochorová et al., 2014). 
Increased cell size is indicative of arrested cell division but continued cell elongation. It could 
be indicate of changes to the cell wall components during phenotypic adaptation to pellicle 
biofilm-conducive conditions. Such conditions may include depletion of phosphate which has 
been shown to cause cell elongation (Rifat et al., 2009). It would be interesting to investigate 
whether there is a relationship between cell length and location within the biofilm using 
microscopy. In addition, to look at how the average cell length of M. tuberculosis in biofilms 
changes over time in relation to alterations to the environment. 
The EPS constituents of M. tuberculosis could be further characterised by labelling with 
fluorescent dyes, lectins and antibodies to look for extracellular DNA, specific 
polysaccharides and proteins respectively (Flemming and Wingender, 2010). Extracellular 
DNA, a key component of biofilms in many bacterial species, such as Pseudomonas 
aeruginosa (Montanaro et al., 2011), and M. avium (Rose et al., 2015) where it contributes to 
the stability of the biofilm, could be identified on M. tuberculosis pellicles following DNase 
treatment and a crystal violet assay. Alternatively EPS extracted from pellicles (without lysis 
of the bacteria and leakage of intracellular material) (Ortalo-Magné et al., 1995) could be 
subjected to additional biochemical analyses to what has already been performed here, such 
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as liquid chromatography-mass spectrometry, to identify proteins by peptide sequencing and 
linkage analysis of carbohydrates for accurate identification. It is possible that M. 
tuberculosis pellicle EPS contains ESX-1 secreted proteins, such as the ESAT6 as seen in 
studies of the capsule of M. marinum (Sani et al., 2010). ESAT6 is an immunodominant 
antigen that directly modulates the immune responses since it has been implicated in M. 
tuberculosis phagosomal escape into the cytosol of infected phagocytes (Houben et al., 
2012), 
6.3 M. tuberculosis biofilm phenotype lipid alterations 
The growth state M. tuberculosis directly modulates the anabolism of carbohydrates and 
lipids, influencing the quantities expressed, as shown in this thesis, and can also modulate the 
structure of the macromolecules, as seen with the increased arabinosylation of LAM in NRP 
M. tuberculosis cultures (Bacon et al., 2014). Such alterations are phenotypic adaptations to 
the environment, sensed by mechanisms such as two component systems to detect oxygen 
availability (Honaker et al., 2010) and influenced by levels of secondary messengers such as 
c-di-GMP (Hengge, 2009). M. tuberculosis is able to colonise and survive in a wide array of 
heterogeneous host environments from cavities to necrotising and non-necrotising 
granulomas (Lenaerts et al., 2015). Large scale changes to the pathogen surface PAMPs in 
turn alter host immune responses, as seen clearly in other bacteria such as Neisseria 
meningitides, which regulates expression of its virulence factor capsule via the MisS/R two 
component system (Tzeng et al., 2016). The synthesis of capsule imparts anti-adherence and 
anti-opsonophagocytic properties to N. meningitides cells, and also enhances its intracellular 
survival (Tzeng et al., 2016). While M. tuberculosis doesn’t show simple switching from 
highly virulent capsulated and commensal non-capsulated forms, its complex cell wall has 
numerous components shown to influence the immune response (Angala et al., 2014; Lopez-
Marin, 2012; Mishra et al., 2011).  
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While the EPS of M. tuberculosis biofilm and planktonic cultures described in this thesis 
were not separated from the bacteria for biochemical analysis, lipoglycans and carbohydrates 
were separated from the mycolyl-arabinogalactan-peptidoglycan cell wall core. These would 
include carbohydrates located in EPS. Organic soluble lipids were also extracted from the cell 
envelope and EPS of M. tuberculosis. These techniques are well established and are applied 
to total dried biomass (Besra, 1998). Accurate analysis of EPS would depend on high 
extraction efficiency, whereas analysis of cell wall extracts include total EPS. However, a 
drawback of this approach is that the location of specific changes seen in carbohydrates and 
lipids cannot be delineated between the cell envelope or EPS. It would be preferable in future 
to optimise EPS extraction efficiency without contamination of intracellular or cell envelope 
constituents using established techniques (Nielsen and Jahn, 1999). However, since the cell 
envelope contains free lipids of the outer membrane outer leaflet (predominately TAG, 
glycopeptidolipids, TDM and diacyl gycerols in M. smegmatis) (Bansal-Mutalik and Nikaido, 
2014) and capsular carbohydrates (Daffé and Etienne, 1999), complete extraction of EPS 
without cell envelope contamination may not be achievable.  
Triacylglycerol (TAG) was seen as a smear in the biofilm lipid extract, which was reduced to 
a faint spot in the planktonic lipid extract (Figure 3.3.1). Ojha et al., (2008) has previously 
identified alterations to the lipid profiles of M. tuberculosis biofilms compared to planktonic 
cultures. Specifically, it was shown that biofilms have reduced TAG and increased free 
mycolic acids. However, Ojha et al., cultured biofilms with Sauton’s medium and planktonic 
M. tuberculosis using Middlebrook 7H9+OADC 0.05% Tween 80 and therefore differences 
in extractable lipids may be due to available nutrients and not specific to pellicle biofilm 
formation. Furthermore the use of detergent sheds lipids into the culture filtrate (Wheeler, 
2009). Notably an increase in TAG can be seen when comparing M. tuberculosis cultured in 
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Sauton’s and Middlebrook 7H9 (Dobson et al., 1985). TAG may have been reduced in 
planktonic lipid extracts cultured for this thesis due to the shedding of lipid into the medium 
by the shearing forces of the shaken flask. Alternatively TAG could be a constituent of 
biofilm EPS. TAG has been shown to be in the outer membrane (OM) of M. smegmatis 
(Bansal-Mutalik and Nikaido, 2014). If the M. tuberculosis OM also contains TAG, the 
proportion of OM comprising of TAG may increase under biofilm culture conditions. The 
increased TAG could also be from increased intracellular lipid bodies or extracellular vesicles 
used for storage (Garton et al., 2002; Rastogi et al., 2017). 
Menaquinones (MK) are a group of mycobacterial lipids present in the plasma membrane and 
central to the electron transport chain, which have been found to decrease during oxygen 
limitation (Honaker et al., 2010). The biofilm cultures used in this thesis were in sealed boxes 
with limited oxygen, yet MK was increased in the biofilm phenotype (Figure 3.3.1). This 
suggests that the available oxygen may not have been fully used up in the biofilm culture. 
Alternatively the conditions for biofilm formation may also trigger increase biosynthesis of 
MK. MK may also be shed into the culture medium of planktonic M. tuberculosis accounting 
for the reduction in planktonic cells compared to biofilm cells. 
The unidentified lipid ?1 and an additional spot at the solvent front (Figure 3.3.1) are also not 
annotated in older reviews of mycobacterial lipid analysis (Besra, 1998; Dobson et al., 1985). 
The most recent review labels these spots as cholesterol esters (Wheeler, 2009). While M. 
tuberculosis has been shown to be able to metabolise host cholesterol (Pandey and Sassetti, 
2008), it was not present in the medium of the cultures used in this thesis. M. tuberculosis, 
like all other prokaryotes, does not synthesise cholesterol (Mouritsen and Zuckermann, 
2004). Therefore the identity of this apolar lipids remains to be determined. 
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Solvent system B revealed free fatty acid (FFA) to be increased in the biofilm phenotype 
(Figure 3.3.2). This spot is also annotated in Besra et al., (2008) in solvent system C which 
was later identified as free mycolate overlapping FFA (Ojha et al., 2008). Unidentified lipid 
?3 was present just to the right of FFA in system B. Another unidentified lipid ?2 was only 
seen on 2/3 of the biofilm replicates. The reason why it did not show up on a simultaneous 
extraction and TLC analysis of a biological replicate is unclear. It is worth repeating the lipid 
analysis of M. tuberculosis biofilms to determine whether the presence/absence of ?3 is an 
artefact or a novel unidentified lipid unique to the biofilm phenotype. Notably there was no 
reduction in free lipid trehalose mycolipenates (TMPs) between planktonic and biofilm 
phenotype, suggesting that the shedding of mycobacterial lipids into the medium may not be 
a significant issue in the shaken planktonic cultures. 
Free mycolates are a major component of M. tuberculosis pellicle biofilm EPS (Ojha et al., 
2008) and were increased in M. tuberculosis biofilm cultures compared to planktonic cultures 
(Figure 3.3.3) as previously described by (Ojha et al., 2008). The effect size did not appear 
as significant as the earlier publication and this may be due to the absence of detergent in the 
planktonic medium of cultures used in this thesis compared to Ojha et al., (2008). Free 
mycolate is thought to be a major constituent of the pellicle biofilm matrix (Zambrano and 
Kolter, 2005), with keto mycolic acids essential for its formation (Sambandan et al., 2013). 
Mycolic acids introduced into the airways of mice have been shown to induce foamy-like 
macrophages similar to those found in tuberculosis granulomas and modulate cytokine 
expression (Korf et al., 2005). This suggests that in vitro infection of macrophages with 
biofilm phenotype M. tuberculosis may better reflect the in vivo transformation of alveolar 
macrophages into foam cells during tuberculosis infection compared to infection with 
planktonic M. tuberculosis.  
193 
 
Additional unidentified lipids were present in solvent system C, ?4, ?5 and ?6 (Figure 3.3.3). 
These have not been annotated in systematic M. tuberculosis lipid reviews (Besra, 1998; 
Wheeler, 2009).Wheeler annotated phenolic glycolipids in solvent system C but the 
additional spots in the system C TLCs presented in this thesis are not phenolic glycolipids as 
the H37Rv strain does not synthesise phenolic glycolipids (Pang et al., 2012). ?6 appeared in 
2/3 biofilm replicates and could be an artefact or a biofilm phenotype specific lipid, whereas 
?4 and ?5 were present in all planktonic and biofilm M. tuberculosis replicates. 
System D can be used to analyse both polar and apolar lipids (Besra, 1998). Recently an 
improved system D has been developed (Wheeler, 2009) which allows visualisation of 
glycolipids trehalose dimycolate (TDM), trehalose monomycolate (TMM) and sulfolipid (SL-
I) in apolar lipid mycobacterial extracts. TDM and TMM have also been seen in the polar 
extract of M. bovis (Pirson et al., 2012). There was no obvious trend of increased or 
decreased TMM or TDM between planktonic and biofilm samples in apolar lipid extracts 
(Figure 3.3.4) or polar lipid extracts (Figure 3.3.5). Total levels were surprisingly low 
considering that TDM is a major component of M. tuberculosis pellicles (Robert Lee Hunter 
et al., 2006). SL-I was increased in biofilm phenotype M. tuberculosis. Regarding innate 
immunity, one study showed a genetic M. tuberculosis mutant that couldn’t produce SL-I had 
increased intracellular growth and survival and was more resistant to antimicrobial peptide 
LL-37 (Gilmore et al., 2012). The reason why M. tuberculosis evolution has conserved a lipid 
that negatively regulates growth and survival is unclear, yet it may be involved in phenotypic 
change into non-replicating persisters, as seen with the upregulation of TAG containing 
extracellular vesicles in low iron medium (Rastogi et al., 2017). Further studies are required 
to elucidate the localisation and role of SL-I during infection. There remains a possibility that 
the lipids in system D have been incorrectly annotated. For example, SL-I could be TDM. To 
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confirm the identity of the spot labelled SL-I, H-NMR could be performed as described for 
the identification of free mycolates by Ojah et al., (2008).  
No differences were seen between planktonic and biofilm phenotype M. tuberculosis in 
system E (Figure 3.3.7) Annotations were based on Pirson et al., (2012) who were able to 
discriminate not only between dimannoside and hexamannoside PIMs but also the mono and 
diacyl derivatives. Diphosphatidylglycerol can be seen in MPA stained system E. However 
the system E TLCs in this thesis were stained with α-napthol for glycolipids. Therefore the 
identities of glycolipids ?6 and ?7, which can be seen in planktonic and biofilm phenotype M. 
tuberculosis remain to be elucidated. All unidentified lipids could potentially be identified 
using comprehensive lipidomics analysis by separation simplification (CLASS) or shotgun 
lipidomics mass spectrometry approaches (Harkewicz and Dennis, 2011). Mass spectrometry 
could also be used to investigate potential structural differences, such as proximal 
cyclopropanation (Glickman et al., 2000) in the cell wall mycolic acids from biofilm and 
planktonic extracts (MAMES). 
6.4 M. tuberculosis biofilm phenotype carbohydrate alterations 
Non-replicating M. tuberculosis in batch cultures have previously been shown to gradually 
extend LAM through arabinosylisation visible over the course of >200 days and with visible 
extension during late stationary phase compared to exponential phase (Bacon et al., 2014). 
Extension of LAM in the 35 day mature biofilm cultures was not seen compared to 7 day 
exponential phase planktonic cultures (Figure 3.4.1). This suggests the pellicle model of 
biofilm phenotype differs from the biofilms produced by NRP M. tuberculosis and may 
therefore have a different infectivity profile in the guinea pig infection model.  
The reduced constituent sugar glucose in the carbohydrate extracts of biofilm M. tuberculosis 
(Figure 3.4.3) suggest either M. tuberculosis α-glucan (Ortalo-Magné et al., 1995) or 
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cellulose (Trivedi et al., 2016) or both are less prevalent in biofilm phenotype M. 
tuberculosis. Future analysis of biofilm phenotype carbohydrates should include linkage 
studies to determine from which carbohydrate the sugar is derived from. This approach was 
unsuccessfully attempted with one of the extracts produced for this thesis. However it can be 
inferred that the most likely carbohydrate is α-glucan since Ortalo-Magné et al., (1995) used 
Sauton’s medium pellicle biofilms in their linkage study and only identified α-glucan, while 
cellulose has only been observed in surface attached biofilms induced by exposure to 
dithiothreitol (Trivedi et al., 2016).  
If α-glucan and/or cellulose prevalence depletes during M. tuberculosis biofilm maturation, it 
is worth discussing how this may occur. One possibility is the upregulation of glucoside 
hydrolases to recycle glucose residues stored in carbohydrates. M. tuberculosis has been 
shown to harbour β-glucanases (Varrot et al., 2005) which could be upregulated if cellulose is 
metabolised during biofilm maturation. Also M. tuberculosis harbours the gene treX which 
encodes a malto-oligosyltrehalose synthase thought to target the α(1-6) branch linkages of α-
glucans. While TreYZ acts on linear α(1-4) glucans to convert them into trehalose, and can be 
further hydrolysed to glucose by Rv2402. Additionally gene Rv2471 encodes a putative α-
glucosidase which may target terminal α(1,4) residues of α-glucans (Van Wyk et al., 2017). 
Another possibility is the downregulation of genes involved in the synthesis of α-glucan via 
the GlgC-GlgA, the Rv3032 and the TreS-Pep2-GlgE pathways (Koliwer-Brandl et al., 
2016). The expression of glucose metabolism genes during biofilm formation and maturation 
could be assessed using RNA-Seq at specific time points in conjunction with corresponding 
carbohydrate/lipoglycan extractions to reveal the pathways responsible for the reduction in 
glucose in M. tuberculosis biofilm carbohydrate extracts.  
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6.5 Cytokines and chemokines involved in tuberculosis 
Cytokines and chemokines direct much of the host response to pathogens by regulating 
inflammation and recruiting immune cells to the site of infection. Modulation of cytokine and 
chemokine responses can have a profound effect on the immune responses in tuberculosis 
(Hossain and Norazmi, 2013), as outlined in the paragraphs below. The subversion of 
immune signalling mechanisms by M. tuberculosis through dynamic changes in pathogen 
PAMPs and host PRRs at the host pathogen interface in the tuberculosis lung can result 
ultimately in cavitation and the transmission of the bacteria from an immunocompetent, 
ambulatory individual (Orme et al., 2014). Should biofilm formation be a key factor in 
tuberculosis pathogenesis, the functional result of biofilm-specific cytokine and chemokine 
responses may help elucidate those that offer protection and those that contribute to 
pathology.  
IFN-γ release is the hallmark of a Th1 adaptive immune response, thought to be fundamental 
for a control of M. tuberculosis infection (Torrado and Cooper, 2013). However it can also be 
secreted after recognition by innate immune cells. Natural killer T cell (NKT) expressing 
Valpha19-Jalpha33 T cell receptor alpha chain circulate in blood and recognise MHC-related 
protein 1 (MR1) presented α-mannosyl phosphatidyl inositols, which form part of the 
structure of mycobacterial PIMs, LAM and LM and induce IFN-γ secretion (Shimamura, 
2008). The carbohydrate extracts contained these lipoglycans and therefore could 
conceivably induce IFN-γ secretion after whole blood stimulation. NKT cell activation has 
been shown to produce IFN-γ, recognise M. tuberculosis infected macrophages, and reduce 
bacterial load (Sada-Ovalle et al., 2008). In addition, natural killer (NK) cells produce IFN-γ 
rapidly in response to M. tuberculosis exposure (Feng et al., 2006). TLR4 and TLR2 
recognise mycobacterial lipoglycans (Jones et al., 2001) and both of these receptors are 
expressed by NK cells (Adib-Conquy et al., 2014). Finally γδ T Cells recognise CD1b 
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presented lipoglycans (Sieling et al., 1995) and also produce IFN-γ in response to TB 
infection (Gioia et al., 2003). Figure 4.3.7 showed IFN-γ was not induced by M. tuberculosis 
carbohydrate extracts. This suggests NK, specific NKT and γδ T cells may have been present 
in whole blood at levels too low to allow detection of their activation. Another possibility is 
that the process of the loading lipoglycan fragments for antigen presentation and innate t-cell 
activation required more than 24 hours stimulation. Zymosan strongly induced IFN-γ in all 
three donors suggesting that there were sufficient populations of innate cells in whole blood 
capable of inducing IFN-γ secretion.  
Paradoxically, the experiment stimulating whole blood with capsule extracts suggested 
Zymosan did not induce an IFN-γ response Figure 4.6.1. This difference may be due to the 
higher concentration of Zymosan used, which could be a sub-optimal concentration for 
measuring IFN-γ response after cytokine stimulation. Alternatively, donor blood responses to 
Zymosan stimulation may depend on previous exposure to the substance and/or their genetic 
background. M. tuberculosis capsule extracts induced an IFN-γ response, the extent of which 
varied widely between biological replicates. The crude method of material extraction using 
glass beads and filtration may account for this variability as the extracts could contain 
varying proportions of lipids, proteins and carbohydrates. Secondly the response was much 
larger in one of the donors and this could be due to recent exposure to environmental 
mycobacteria in the high responder, as seen in false positive tuberculin skin tests (O’Garra et 
al., 2013).  
None of the stimulants induced IL-12p70 (Figure 9.2.1) above the lower limit of detection 
(25 pg mL
-1
). The standard curve fit was only 90% with the lowest dilution excluded from the 
curve and this may have contributed to IL-12p70 results below the LLOQ. IL12p70 
comprises of two subunits IL12p40 and IL12p35 and this cytokine is thought to be vital for 
inducing the generation of IFN-γ producing in T cells (Torrado and Cooper, 2013) and NK 
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cells (Ye et al., 1995). Although there have been conflicting studies, in general studies have 
shown that Man-LAM causes no change in IL-12 secretion in monocyte/macrophage cell 
cultures while LM has been found to increase IL-12 production and PIMs cause no change 
(Källenius et al., 2015). The carbohydrate samples used in this thesis were a mixture of these 
compounds, with varying proportions (Figure 3.4.1, Figure 3.4.2) and additionally α-glucan. 
The variability between samples complicates interpretation of the complex interplay between 
the M. tuberculosis carbohydrate extracts and the immune response in whole blood and may 
have masked phenotype-specific changes in the relative proportions of constituent glucose.  
Some but not all M. tuberculosis carbohydrate extracts induced an IL-1β response with the 
highest levels induced by planktonic M. tuberculosis in donor 1, although this was not 
statistically higher than the level induced by M. tuberculosis biofilm carbohydrate extracts 
(Figure 4.3.8). It is possibly that with a larger number of biological replicates a significant 
difference would be seen however the biological significance of this difference would remain 
unclear. The amount of IL-1β secretion induced by M. tuberculosis carbohydrate extracts was 
considerably less than the zymosan positive control. Since M. tuberculosis is an obligate 
human pathogen and IL-1β has been shown to direct killing of M. tuberculosis (Master et al., 
2008) there would be a strong selection pressure for M. tuberculosis carbohydrate 
synthesising enzymes and exporting proteins to create outermost carbohydrates which induce 
minimal IL-1β. The ability of M. tuberculosis carbohydrates to induce IL-1β in vivo may be 
masked by the action of proteins such as zmp1, which inhibits inflammasome activation 
(Master et al., 2008). In addition, excessive IL-1β production induces pyroptosis, which M. 
tuberculosis is able to subvert via secretion of Rv3365c, which inhibits downstream 
activation of caspase-1 required for IL-1β production (Danelishvili et al., 2011).  
IL-2 is secreted by activated CD4
+
 T cells (Nelson, 2004) but can also be produced by naïve 
dendritic cells (Granucci et al., 2001) and naïve CD8
+
 T cells (Cheng et al., 2002) and 
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primarily acts to induce the proliferation of T cells. Dendritic cells and naïve CD8
+
 T cells 
make up <1% and <3% of leukocytes in whole blood respectively (Technologies, 2010). 
Concerning innate immunity, presumably early secretion of IL-2 would be beneficial to the 
host since it may promote the rapid onset of CD4
+
 T cell mediated immunity (Nelson, 2004) 
for M. tuberculosis control. Within the 24 hour stimulation period there was no significant 
change in IL-2 secretion (Figure 4.3.9) implying that none of the donors had active adaptive 
immunity to tuberculosis with CD4
+
 T cells secreting IL-2 and endogenous innate expression 
of IL-2 in naïve whole blood does not respond to PRR recognition of M. tuberculosis 
carbohydrate extracts.
 
IL-4 is a key Th2 cytokine often associated with the response generated in hosts after chronic 
infection by large parasites such as helminths (van Panhuys et al., 2011). It has anti-
inflammatory effect and inhibits IFN-γ production (Powrie et al., 1993). IL-4 secretion by 
CD4
+
 and CD8
+
 T cells is higher in tuberculosis patients, especially those with cavitary 
tuberculosis compared to controls. Tuberculosis cavities are where pellicle-like biofilms are 
thought to exist (Hunter, 2011; Hunter et al., 2014). NKT cells and basophils in whole blood 
are able to produce IL-4 after stimulation (Seder et al., 1991; Yoshimoto and Paul, 1994). 
The experiment measuring IL-4 response after 24 hour stimulation with carbohydrate extracts 
showed levels of IL-4 were only clearly above the LLOQ in one of the 3 donors. This 
suggests the variation between donors has a larger effect on IL-4 secretion compared to 
carbohydrate stimulation. Furthermore, even with donor 3, zymosan and M. tuberculosis 
stimulated whole blood induced a less than 1-fold response suggesting innate IL-4 producing 
cells e.g. basophils rely on different pathogen associated molecular patterns (PAMPS) than 
those present on the carbohydrate extracts in this assay. 
IL-5 is a Th2 cytokine which stimulates the activation and proliferation of eosinophils and 
primarily expressed by T cells and mast cells (Matthaei et al., 1997; Murphy, 2012). One 
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study looking at SIV and TB coinfection in the cynomologus macaque model showed SIV-
induced IL-5 production in monocytes reduced the frequency of M. tuberculosis specific CD4 
T cells (Diedrich et al., 2013). If biofilm M. tuberculosis carbohydrates promoted a Th2 like 
response  similar to large organism parasitic infections then IL-5 could be a biomarker. 
However no evidence was seen for this after whole blood stimulation with biofilm 
carbohydrate extracts. 
IL-6 was one of the cytokines which showed the largest responses after exposure to 
planktonic and biofilm M. tuberculosis capsule and carbohydrate extracts. IL-6 has been 
shown to be the only consistent cytokine biomarker of M. tuberculosis infected murine 
peritoneal macrophages (Singh and Goyal, 2013). IL-6 has also been shown to inhibit 
effective IFN-γ dependent macrophage activation, which may contribute to impaired 
mycobacterial clearance (Nagabhushanam et al., 2003). Since capsule extracts induced far 
greater IL-6 production than carbohydrate extracts, the major source of IL-6 induction could 
be mycobacterial EPS lipids or proteins. 
TNFα is secreted after exposure of macrophages to M. tuberculosis LAM (Källenius et al., 
2015). The release of TNFα can trigger IFNγ dependent reactive nitrogen intermediate 
production and mycobacterial killing (Chan et al., 1992). Yet TNFα production in alveolar 
macrophages has been shown to permit M. tuberculosis growth (Engele et al., 2002) 
Tuberculosis diseased mice that cannot produce TNFα receptors have reduced survival 
(Flynn et al., 1995) showing TNFα production to be a broadly protective. The results in this 
thesis do not suggest carbohydrates from M. tuberculosis biofilm phenotype modulate TNFα 
secretion any differently to planktonic phenotype. However removal of capsular 
polysaccharides using Tween 80 has been shown to modulate TNFα production (Sani et al., 
2010). It is therefore possible that TNFα induction is primarily caused by arabinomannans 
and mannans, which are not altered between planktonic and biofilm phenotypes.  
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GM-CSF is constitutively expressed in the lung and has been shown to enhance protection 
against tuberculosis in mice and improves the effectiveness of tuberculosis vaccines 
(Chroneos and Jagannath, 2012). Over expression of Th2 cytokine IL-13 in mice infected 
with M. tuberculosis produced necrotizing granulomas similar to human pathology which 
would otherwise be absent in mice (Heitmann et al., 2014). Since these cytokines modulate 
disease progression in tuberculosis their induction by M. tuberculosis warrant further study. 
However the whole blood stimulation technique used in this thesis failed to show detectable 
levels of GM-CSF and IL-13 suggesting it may not be an appropriate assay for detection of 
these cytokines. IL-18 enhances the protective Th1 response against tuberculosis in mice 
(Schneider et al., 2010) yet its production in M. tuberculosis carbohydrate stimulated whole 
blood does not appear to be affected by phenotype.  
CCL11 is increased in M. tuberculosis patients (Sharifabadi et al., 2014), CXCL1 is secreted 
early on in the M. tuberculosis mouse infection model (Kang et al., 2011). CXCL8 can 
directly bind to M. tuberculosis and enhance phagocytosis and M. tuberculosis killing (Krupa 
et al., 2015). CXCL10 has been touted as a potential biomarker for M. tuberculosis infection 
(Ruhwald et al., 2012). Humans with CCL2-2518 (A/G) polymorphisms which increases 
expression of CCL2 are more susceptible to active TB (Feng et al., 2012) . While a similar 
type of study found no association with CCL3 and CCL4 with susceptibility to pulmonary 
TB (Singh et al., 2014), they may still be involved in orchestrating innate immune responses 
to tuberculosis (Monin and Khader, 2014). CXCL12 is another potential biomarker of 
tuberculosis disease (Kohmo et al., 2012). Finally CCL5 knockout mice have been shown to 
have delayed IFNγ responses and poor control of M. tuberculosis growth indicating a role in 
innate immunity to tuberculosis (Vesosky et al., 2010). Despite these the involvement of 
these chemokines in tuberculosis disease, their expression appears broadly generic when 
comparing the responses generated between planktonic and biofilm phenotype M. 
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tuberculosis. An alternative complementary approach to the one taken in this thesis could 
utilise M. tuberculosis mutants with completely inhibited biofilm formation grown under the 
same conditions. This approach taken with titration of a broader range of carbohydrate 
stimulant concentrations may highlight interesting biofilm-specific innate responses not seen 
in the data presented in this thesis. Undoubtedly, comparison of planktonic and biofilm lipid 
extracts, EPS extract and whole biomass would also be of interest. 
MMP-1 the primary collagenolytic MMP in TB, is the most likely protease to be responsible 
for triggering cavitation, which is essential for M. tuberculosis transmission (Elkington et al., 
2011). Since pellicle biofilms are associated with tuberculosis cavities, biofilm capsule may 
also be a more potent inducer of MMP-1 than planktonic capsule. The results presented in 
this study suggest that neither planktonic or biofilm capsule were able to trigger MMP-1 
secretion. Since cavitation can appear suddenly after years of control, it may be that MMP-1 
secretion at levels significant enough to form a lung cavity is only triggered in a 
hypersensitivity reaction once a threshold in the accumulation of mycobacterial antigens has 
been reached (Hunter et al., 2014). The data presented in this thesis suggests that MMP-1 
secretion may not be involved in the establishment of infection. However, it cannot be ruled 
out because it would be preferable to observe MMP-1 secretion in human alveolar 
macrophages or BAL fluid after stimulation with M. tuberculosis extracts to better model the 
establishment of infection.  
6.6 Biofilm formation and the complement system 
The complement system is an innate immune surveillance system as well as regulating the 
clearance of apoptotic host cells (Merle et al., 2015). There are three primary immunologic 
outcomes from complement activation are opsonisation by covalent attachment of C3b to the 
surface of bacteria, deposition of the C5b-9 membrane attack complex and the release of 
anaphylatoxins C3a and C5a to regulate inflammation (Murphy, 2012). There is also cross-
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talk with adaptive immunity via antibody-dependent activation of complement via the 
classical pathway and C3aR and C5aR expressed on the surface of activated T cells, 
contributing to recruitment and development of a Th1 response (Merle et al., 2015). 
Complement deposition and activity has been shown to be modulated by biofilm formation 
compared to the planktonic growth state in many species of bacteria. For instance, 
Streptococcus pneumoniae biofilms impair C3b and C1q deposition with increased factor H 
recruitment, which downregulates the alternative pathway (Domenech et al., 2013). While 
Mycoplasma pulmonis biofilms are more resistant to complement killing (Simmons and 
Dybvig, 2007). Staphylococcus epidermidis biofilms promote more C3 cleavage than 
planktonic cells yet less C3b binds to the bacteria embedded in the biofilm (Kristian et al., 
2008). Also, Acinetobacter baumannii strains that produce more biofilm are more resistant to 
complement mediated killing than strains that produce less biofilm (King et al., 2009). 
Similarly the EPS of M. tuberculosis pellicle biofilms could modulate complement 
deposition. Furthermore, the changes seen in M. tuberculosis carbohydrate extracts may 
directly influence the affinity of lectin pathway complement activators.  
The results from this thesis agreed with the published literature that complement deposition 
on M. tuberculosis complex can be activated by direct binding of C1q, MBL and ficolin-3 to 
M. tuberculosis (Figure 5.5.1) (Bartlomiejczyk et al., 2014; Carroll et al., 2009), and by the 
three major complement pathways (Figure 5.4.2) (Bartlomiejczyk et al., 2014; Ferguson et 
al., 2004; Schlesinger et al., 1990). However, the M. tuberculosis C2 pathway of complement 
deposition was not observed (Figure 5.6.1)  
Flow cytometry revealed a significantly reduced magnitude of C3b/iC3b and C5b-9 
deposition on M. tuberculosis biofilm cells compared to planktonic cells (Figure 5.4.2), yet 
quantitative ELISA of sugar extracts only showed significantly reduced C3b/iC3b deposition 
at 2% complement concentration (Figure 5.7.2). There are several possible reasons which 
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may explain why. Firstly, the method of quantification for ELISAs differed to the flow 
cytometry experiments, although there is evidence that there may be a linear correlation from 
other studies (Shooshtari et al., 2010). Secondly, whole cells contain lipids and proteins, 
which are also modified in the biofilm phenotype, and may result in altered affinity to 
complement activators. For example, surface expressed proteins and free lipids may provide 
additional direct binding sites for C1q. C1q has been shown to bind to bacterial proteins, 
lipopolysaccharide and phospholipids (Kishore et al., 2004). Additionally the as yet 
unidentified C4b-like protein present on surface of pathogenic mycobacteria that is able to 
form a convertase with host C2a (Schorey et al., 1997), may have altered expression on 
biofilm phenotype cells. The C5b-9 complex only forms where C3b has already bound. The 
availability of C5 convertases on 2% complement incubated biofilm M. tuberculosis may not 
be a rate limiting factor for C5b-9 assembly, accounting for similar quantities of C5b-9 
deposition on planktonic and biofilm carbohydrate extracts. The phenotype dependent 
interference of lipids and proteins on C5b-9 deposition may account for reduced deposition 
on biofilm whole cells. Thus the absence of the full spectrum of complement activator 
epitopes in the planktonic and biofilm M. tuberculosis carbohydrate extracts is the most likely 
reason why there was no significant reduction in C5b-9 deposition at 2% and 10% 
complement concentration and C3b/iC3b deposition at 10% concentration on biofilm M. 
tuberculosis carbohydrate extracts. Additionally the alternative pathway, which is a positive 
feedback loop that amplifies complement deposition, may mask any differences in 
complement activation triggered by the lectin pathway on the planktonic and biofilm 
carbohydrate extracts incubated with 10% complement concentration. 
A significant reduction in C3b/iC3b deposition onto biofilm M. tuberculosis carbohydrate 
extract was observed when the alternative pathway was inactive (Figure 5.7.2a). This is 
physiologically relevant as the alternative pathway is not active in the human lung (Watford 
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et al., 2000). The reason why biofilm carbohydrate extracts showed reduced C3b/iC3b 
deposition at 2% concentration is unlikely to be due to reduced affinity to MBL, since MBL 
deposition on biofilm phenotype carbohydrate extracts is not significantly different from 
planktonic MBL deposition (Figure 5.7.2e). Reduced affinity of other complement activators 
in the IgG-depleted complement source, such as C1q or serum ficolin-2 (Ren et al., 2014) to 
biofilm carbohydrate extracts are more likely to account for the reduced C3b/iC3b deposition 
seen on biofilm carbohydrate extracts at 2% complement concentration.  
Since there is redundancy in the mechanisms M. tuberculosis utilises to enter cells 
(Schlesinger, 1996), it may be that reduced complement activation would have little effect on 
phagocytosis efficiency. This could be assessed using a macrophage infection assay. 
However the cleavage of C3 also releases anaphylatoxin C3a. C3a is an inflammatory 
modulator and is proinflammatory in chronic inflammation where monocytes and 
macrophages predominate, inducing the production of IL-1β, TNF-a and IL-6 (Coulthard and 
Woodruff, 2015). C3a induced IL-1β production and subsequent inflammasome activation 
(Asgari et al., 2013) may enhance early clearance of M. tuberculosis bacteria (Master et al., 
2008). Since the sight of establishment of infection is the alveoli, rich in alveolar 
macrophages, it may be advantageous for the establishment of tuberculosis infection if C3a 
activation was low. C3a release after incubation of carbohydrate extracts with complement 
could be measured directly with a fluorescent anti-C3a antibody following aspiration of the 
supernatant. A study utilising C3aR deficient mice has shown C3aR enhances early clearance 
of intracellular pathogen Chlamydia psittaci in the mouse lung and increases recruitment and 
proliferation of CD4
+
 T cells (Dutow et al., 2014).   
Notably direct C1q binding to biofilm phenotype M. tuberculosis was reduced (Figure 
5.5.2b) despite the C3b/iC3b and C5b-9 deposition assay suggesting greater dependence on 
the classical (C1q) pathway for C3b/iC3b and C5b-9 deposition onto biofilm cells (Figure 
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5.4.2e,f). This could be due to a number of reasons. Firstly natural antibodies in the 
complement source may have interacted to a greater extent with M. tuberculosis biofilm 
phenotype compared to planktonic phenotype and C1q bound via these secondary sites. 
Conversely, another explanation is that this discrepancy is due to the lectin pathway and/or 
C2 pathway. Figure 5.5.2a shows that MBL deposition is increased on planktonic bacteria 
compared to biofilm bacteria. The effect size is also greater than with C1q. MBL that is 
present in the complement source would interact to a greater extent with planktonic M. 
tuberculosis compared to biofilm grown bacteria and therefore reduce the relative 
contribution of the classical pathway in C3b/iC3b deposition in planktonic phenotype 
compared to biofilm phenotype.  
MBL binds to mannose and glucose residues (Weis et al., 1992) and therefore the reduced α-
glucan prevalence on biofilm phenotype M. tuberculosis may be the reason why deposition is 
higher on planktonic bacteria. However, although MBL deposition is higher on average on M. 
tuberculosis planktonic carbohydrate extracts compared to biofilm carbohydrate extracts, the 
difference was not statistically significant (Figure 5.7.2e). A potential reason why no 
statistical significance was seen could be because a relative reduction in the proportion of 
glucose coincides with a relative increase in the proportion of mannose in the biofilm extracts 
compared to planktonic extracts (see results section 3.4). 
The complement deposition experiments on live bacteria also included positive controls to 
guide interpretation of the results; specifically the inclusion of M. smegmatis, which is an 
environmental bacterium and would be less likely to have evolved complement evasion 
mechanisms. Whereas S. agalactiae evades complement activation in vivo (Jarva, 2003). S. 
agalactiae serotype Ia has been shown to recruit the negative regulator of complement 
activation Factor H to its surface protein Bac in order to avoid C3b deposition (Areschoug et 
al., 2002). Notably even M. tuberculosis biofilm phenotype bacteria show greater deposition 
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of C3b/iC3b and C5b-9 compared to M. smegmatis (Figure 5.4.1). The functional 
implications of the biofilm phenotype specific reduction in complement activation have not 
yet been assessed. It would be necessary to assess M. tuberculosis survival and replication 
and immunological parameters in a macrophage infection model using non-opsonised and 
complement opsonised planktonic and biofilm cells to determine this in future. 
The biological implications differential C3b/iC3b binding between planktonic and biofilm 
phenotypes may not be in the subsequent efficiency of phagocytosis and intracellular fate of 
the bacteria, since M. tuberculosis uptake and intracellular survival is efficient with or 
without complement activation (Schlesinger, 1996). Equally C5b-9 deposition to lyse the 
bacterial membrane is considered to be a useless host defence against Gram positive bacteria, 
yet shows distinct localisation in a controlled manner on Gram positive bacteria such as 
Streptococcus pyogenes and Bacillus subtilis, implying other immunological roles for the 
C5b-9 complex (Berends et al., 2013). While the function of localised binding to either the 
septum or poles respectively of these bacteria remain undefined, the localisation of C5b-9 
deposition on planktonic and biofilm phenotype could be similarly investigated. The effects 
of complement activation are not limited to opsonisation and lysis of Gram negative bacteria. 
Complement acts as an extracellular surveillance and alarm system which interacts with 
innate and adaptive elements and regulates inflammation (Triantafilou et al., 2015). The 
effect of C5b-9 deposition on M. tuberculosis viability could not be found in a literature 
search although its deposition may be beneficial to the pathogen since the lungs of C7 
deficient mice show reduced pathology (Welsh et al., 2012). C5b-9 has been shown to 
deposit onto M. leprae LAM to a far greater extent than M. tuberculosis LAM and it is 
postulated that C5b-9 assembly and complement activation is associated with nerve damage 
(Bahia El Idrissi et al., 2015). Therefore C5b-9 deposition on M. tuberculosis may be 
associated with other components of the M. tuberculosis cell envelope and EPS.  
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In tandem with complement deposition is the release of anaphylatoxins C3a and C5a. While 
little work has been published on C3a and tuberculosis, gene expression and serum levels of 
C3 have been shown to be higher in wild boars without active bovine tuberculosis (Naranjo et 
al., 2006a, 2006b). There have been extensive studies about the protective role of C5a. A/J 
mice deficient in C5 showed enhanced M. tuberculosis growth in the lungs and reduced 
TNFα, IL-1β, IL-6, IL-12 CXCL1, CXCL2 and CCL3 compared to C5 sufficient B10 mice 
(Jagannath et al., 2000). Congenic C5 sufficient and deficient mice were then tested and C5 
deficient mice were found to have decreased IL-12p40 transcription and reduced CXCL1, 
CXCL2, CXCL10 and CCL2 transcription as well as increased bacterial load in the lung 
(Actor et al., 2001). TDM injection into C5aR deficient mice were unable to form 
granulomas and showed excessive inflammation with, contrary to the Actor et al., study, 
increased CCL3, CXCL1, IL-β and TNF-α secretion (Borders et al., 2005). Interestingly, 
viable delipidated and TDM reconstituted M. tuberculosis have been introduced into C5a 
sufficient and deficient macrophages. Wild type M. tuberculosis and TDM reconstituted M. 
tuberculosis showed greater TNFα and IL-6 production compared to delipidated M, 
tuberculosis and the response was always greater in C5a sufficient macrophages compared to 
C5a deficient macrophages (Welsh et al., 2008). Finally regarding adaptive immunity, 
purified C5 deficient mouse T cells secrete less IFNγ after exposure to M. tuberculosis 
infected macrophages (Mashruwala et al., 2011). 
Levels of C3 and C4 do not correlate with TST status in populations with TB high disease 
burden (Araujo et al., 2006), yet TST status is often not indicative of M. tuberculosis 
infection (O’Garra et al., 2013). While ficolin-2, ficolin 3 and MASP-2 serum levels do not 
correlate with TB incidence, MBL levels are increased (Chalmers et al., 2015). Similarly C1q 
levels are also increased in patients with active TB (Cai et al., 2014). Taken together with the 
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comprehensive analysis of C5 in mice, the complement system clearly interacts and 
modulates the host-pathogen interaction in tuberculosis disease. 
Therefore in the context of TB pathogenesis, excessive complement-driven inflammation 
may be detrimental to the pathogen during the establishment of infection, but also contribute 
towards disease progression during its chronic phase, augmenting granuloma formation and 
perhaps contributing towards cavitation. Inhaled pellicle biofilm phenotype M. tuberculosis 
that enter a new host lung environment where the alternative pathway is not active (Ferguson 
et al., 2004; Watford et al., 2000) may therefore induce less inflammation and be more 
infectious than inhalation of equivalent quantities of planktonic phenotype bacteria from 
shaken flasks. The results presented in this thesis suggest the presence of pellicle EPS, high 
in arabinomannans, mannans and free mycolates but low in α-glucan may partially shield the 
bacteria complement activation predominantly initiated by modulation of direct C1q and 
MBL binding. This may impair early clearance of the establishing infection by reducing the 
release of immunomodulatory C5a and the formation of C5b-9 at the site of infection.  
6.7 Future work 
The results presented in this thesis point to a new hypothesis that M. tuberculosis biofilms 
limit complement activation (compared to planktonic phenotype), which contributes to the 
establishment of infection (Figure 6.7.1). To test this hypothesis in future, researchers could 
utilise both EPS extraction techniques and/or mutant M. tuberculosis strains with inhibited 
biofilm formation.
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Figure 6.7.1: Hypothesis: M. tuberculosis biofilm formation reduces complement activation, which aids in the establishment of infection. 
Biofilm phenotype M. tuberculosis (expectorated from tuberculosis cavities (Arora et al., 2016)) enters the lung of a new host, where the 
alternative pathway of complement activation is absent (Watford et al., 2000). Results from this thesis suggest that biofilm phenotype M. 
tuberculosis shows reduced complement deposition via the, lectin and classical pathways. Biofilm formation may also affect the C2 pathway 
(Schorey et al., 1997). This reduces the release of anaphylatoxins C3a and C5a and also the formation of the C5b-9 complex, which all modulate 
inflammation (Bahia El Idrissi et al., 2015; Merle et al., 2015) and may promote early clearance of the infection. Despite the overall reduction in 
complement activation, there is still sufficient C3b/iC3b deposition (in addition to non-C3b/iC3b mediated pathogen recognition) to promote 
phagocytosis (Schlesinger, 1996). M. tuberculosis biofilms enter cells and escape into the cytosol leading to necrosis (Simeone et al., 2012). 
Biofilms grow and trigger serial phagocytosis-necrosis cycles to establish infection (Mahamed et al., 2017). The cycle of M. tuberculosis biofilm 
growth, phagocyte necrosis and low-level complement activation continues until the onset of adaptive immunity controls the infection.  
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EPS could be extracted by utilising petroleum ether extraction to remove lipids such as TDM 
from M. tuberculosis biofilms without affecting viability (Bloch, 1950) followed by 
extraction with a cation exchange resin to extract carbohydrates and proteins (Frølund et al., 
1996). The viability and intracellular leakage of EPS depleted M. tuberculosis could be 
assessed through viable counts and glucose-6-phophate dehydrogenase assays respectively 
(Nielsen and Jahn, 1999). The extracted EPS components could be identified and M. 
tuberculosis pellicle biofilm, EPS-depleted and EPS reconstituted bacteria could be used in in 
vitro innate immunoassays to assess EPS effects.  
Alternatively, genetic manipulation of c-di-GMP synthesis in M. tuberculosis may inhibit 
pellicle biofilm formation. For example, the culture of wild type M. tuberculosis H37Rv as 
pellicle biofilms, M. tuberculosis H37RvΔ Rv1354c with a truncated GGDEF domain (the 
only known diguanylate cyclase encoding gene in M. tuberculosis) and the complemented 
strain (Hong et al., 2013). Since deletion of this gene eliminates c-di-GMP synthesis, and 
high c-di-GMP levels are associated with biofilms (Hengge, 2009) it may inhibit pellicle 
biofilm formation.  
If either approach was successful, all cultures could be grown in pellicle biofilm-promoting 
conditions. Furthermore, the humidified cultures could be aerated in 5% CO2 chambers to 
better resemble human cavities. Dispersal of bacteria for experiments could be performed by 
light agitation using a vortex and low-speed centrifugation since the use of glass beads should 
be avoided to reduce EPS shedding of the EPS associated bacteria. Equal absorbance/CFU 
cultures could be opsonised with human complement at 2% and 10% concentrations and 
complement deposition could be assessed by labelling with fluorescent antibodies and flow 
cytometry as described in this thesis. 
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In addition, using an in vitro granuloma model of healthy donor human peripheral blood 
mononuclear cells (Guirado et al., 2015) and exogenous IgG-depleted human complement, 
the survival and proliferation of complement opsonised M. tuberculosis biofilm cells versus 
complement opsonised M. tuberculosisΔRv1354c/EPS-depleted planktonic cells could be 
assessed. The location, aggregation and proliferation of M. tuberculosis bacteria could be 
measured by acid-fast SYBR Gold staining (Ryan et al., 2014) and microscopy at specific 
time points. Furthermore, secreted levels of anaphylatoxins C3a and C5a could be measured 
using ELISAs. 
Significantly greater proliferation of complement opsonised biofilm M. tuberculosis 
compared to complement opsonised planktonic M. tuberculosis within in vitro granulomas, in 
conjunction with reduced anaphylatoxin release and complement deposition on biofilm 
bacteria would suggest biofilm formation by M. tuberculosis reduces complement activation 
and enhances the ability of M. tuberculosis to establish infection. It may even suggest 
adjuvant therapies which target biofilm formation and/or complement activation at the site of 
infection could assist host clearance and shorten the lengthy treatment regimen required for 
tuberculosis patients.  
Regarding the generation of an improved tuberculosis vaccine compared to the current BCG 
vaccine (itself mostly manufactured as a pellicle biofilms), novel vaccines containing 
attenuated M. tuberculosis complex biofilm phenotype bacteria or their components have 
been suggested (Flores-Valdez, 2016). Furthermore an M. bovis BCG strain that shows 
enhanced pellicle production, due to accumulation of c-di-GMP by deletion of the 
phosphodiesterase encoding gene BCG1419c, has shown improved efficacy in a mouse 
model (Pedroza-Roldán et al., 2016). Such developments suggest that understanding how the 
immune response is altered by M. tuberculosis biofilm formation may be a key factor to 
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developing better vaccines and drug regimens to significantly reduce tuberculosis disease 
prevalence and mortality worldwide.  
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7 MATERIALS AND METHODS 
7.1 Mycobacterial culture 
All mycobacterial strains were cultured in Sauton’s medium (Parish et al., 2009; Sauton, 
1912) with a 1/10 reduction in KH2PO4 hereafter referred to as Modified Sauton’s medium. 
M. tuberculosis H37Rv was inoculated at 0.05 OD540 nm from steady state chemostat cultures 
grown in Mod2 medium (Bacon and Hatch, 2009). M. smegmatis ATCC 700084/mc
2
155 
cultures were inoculated from 24 hour cultures grown in Middlebrook 7H9 + OADC + 0.05% 
Tween 80 or Tryptic Soy Broth + 0.05% Tween 80 at 0.05 OD540 nm. Planktonic cultures were 
grown in aerated flasks shaken at 200 rpm at 37
o
C for 24 hours (M. smegmatis) or 7 days (M. 
tuberculosis). Biofilms were grown as pellicles in 24-well microplates, static at 37
o
C in an 
airtight 5.5L plastic box for large batches of 8-12 plates or a 550mL box for smaller batches 
(1 plate) (Lock & Lock HPL836 and HPL815 respectively). Cultures were grown 7 days (M. 
smegmatis) or 5 weeks (M. tuberculosis). Streptococcus agalactiae serotype Ia was grown in 
aerated flasks in Todd Hewitt broth at 37
o
C 180 rpm for 2 hours after suspending seed stock 
plates in PBS and inoculating at 0.1 OD540 nm.  
7.2 Biofilm viable counts 
Replicate donor chemostats were used to inoculate two independent cultures A and B in 
modified Sauton’s medium at 0.05 OD540 nm. These cultures were used to seed biofilms in 24 
well plates. x12 1 mL A cultures and x12 1 mL B cultures were aliquoted per plate for a total 
of 5 plates. These were placed in separate Lock & Lock HPL815 550 mL containers and 
incubated statically at 37
o
C. One plate was used for sampling on weeks 3, 4, 5, 6 and 7.  
Viable counts were performed by removing the medium from the wells minimising disruption 
of the biofilms by using a P200 pipette tip. Biofilms were then scraped from the bottom of the 
wells into pre-weighed 1.7 mL cryotubes within universal containers (double contained) 
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using sterile disposable spatulas. For each sample point, x6 technical replicates per biological 
replicate were scraped into cryotubes. Universals were sprayed out of the CL3 cabinet and 
weighed in a CL3 lab to allow for calculation of wet-weight biomass. Samples were placed 
back in the cabinet and suspended in 1mL of filter-sterilised PBS-1% Tween 80 and vortexed 
for 30 seconds to attempt to disperse the biofilms as much as possible. Samples were then 
serial diluted to 10
-6
 and dilutions 10
-2
 to 10
-6
 were plated using the spread plate method onto 
Middlebrook 7H10 + OADC plates. The viable count of the inoculum was determined by 
pipetting 1 mL of innoculum into pre-weighed tubes within Universals, pelleted and weighed 
again to calculate biomass. After weighing, the samples were re-suspended in PBS 1% 
Tween 80 and plating was performed as described for the biofilm samples. Plates were 
incubated at 37
o
C for 3 weeks before counting colonies. Data was analysed using Microsoft 
Excel 2010 and Graph Pad Prism 6. 
7.3 Biofilm crystal violet assay 
Replicate donor chemostats A and B were used to inoculate two independent cultures A and 
B in modified Sauton’s medium at 0.05 OD540 nm. These cultures were used to seed biofilms 
in 24 well plates. x12 1 mL A cultures and x12 1 mL B cultures were aliquoted per plate for a 
total of 5 plates. These were placed in separate Lock & Lock HPL815 550 mL containers and 
incubated statically at 37
o
C. One plate was used for sampling on weeks 3, 4, 5, 6 and 7.  
The crystal violet assay was performed by removing the medium from the wells minimising 
disruption of the biofilms by using a P200 pipette. For each sample point 6 technical 
replicates per biological replicate per plate were air dried overnight in a CL3 cabinet. 
Samples were immersed in 1mL of 1% crystal violet solution (Sigma, V5265) for 10 minutes. 
The crystal violet was removed using a P1000 pipette (air-dried biofilms stayed on the base 
of the wells.) Samples were washed x3 times in 1 mL of sterile water which was swilled 
before removing. Wells were then immersed in 95% ethanol to de-stain for 10 minutes. 
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Samples were then pipetted into empty bijous and serial diluted in 95% ethanol to 10
-3
. Serial 
dilutions and neat samples were read on a spectrophotometer and OD600 values were 
recorded. For the T0 initial time point, samples were centrifuged to pellet bacteria at 3060g 
for 5 minutes at each step. Finally the OD600 of blank wells treated the same as the biofilm 
samples (negative control) was calculated and subtracted from each biofilm sample. Data was 
analysed using Microsoft Excel 2010 and Graph Pad Prism 6. 
7.4 M. tuberculosis planktonic growth curve 
Three independent cultures (12 mL) in universal containers were fitted with a sampling line 
and vent and incubated at 37
o
C 200 rpm for 14 days. Approximately 1mL of culture was 
sampled. Viable counts were taken on day 0, 4, 10 and 14. Serial dilutions of the cultures in 
PBS-Tween 0.05% were made and plated using the spread plate method (100 µL on each 
plate). Plates were incubated and counted after 3 weeks. Data was analysed using Microsoft 
Excel 2010 and Graph Pad Prism. Generation time was calculated using the equations n = 
3.3(log N - log N0), where n is the number of generations during the period of exponential 
growth, N is the final cell number and N0 is the initial cell number. g = t/n where g is the 
generation time and t is the duration of exponential growth (time) (Madigan et al., 2010).  
7.5 SEM of intact M. tuberculosis biofilms 
M. tuberculosis biofilms were cultured in 24-well plates containing 70% ethanol sterilised 
plastic coverslips (VWR, 48376-049) cut to size and placed into each well were set up and 
fixed with 4% formaldehyde. X6 samples were taken to the Electron Microscopy department 
at Public Health England where they were prepared using the following 2 methods: 
Ethanol/solvent dehydration: Formaldehyde was carefully removed and replaced with 2% 
Osmium tetroxide for 2 hours at room temperature for secondary fixation. Biofilms were then 
dehydrated through graded ethanol solutions for 15 min at room temperature sequentially at 
217 
 
25%, 50%, 75%  and 100% concentration. Next the coverslips were dehydrated with 100% 
Hexamethyldisilazane for 15 min at room temperature and this step was repeated. Coverslips 
were then air dried. Coverslips were mounted on to SEM stubs using double sided adhesive 
carbon discs. The mounted coverslips/pellicles were then conductive coated with 
approximately 10nm thickness of gold using an ion beam sputter coater (AtomTech 700 
series Ultra Fine Grain Coating Unit). 
Air drying method: Coverslips were removed from wells using forceps, placed on absorbent 
tissue and allowed to air-dry. The coverslips were then mounted on to SEM stubs and gold 
coated as described above. Samples were then examined in a Philips XL30 FEG SEM. 
7.6 Immuno gold α(1-2) mannosyl residue labelling of M. tuberculosis 
M. tuberculosis planktonic and biofilm phenotypes were cultured as described in section 7.1. 
The samples were split into non-treated and glass bead treated sub-groups. Dispersion with 
glass beads followed by low speed centrifugation was performed as described in section 7.22. 
1 mL Samples were diluted or concentrated to absorbance 0.5 OD540 nm. EM grade 
formaldehyde was added to the x4 samples to a final concentration of 4%. Samples were 
stored at room temperature and sent to Dr. Nicole N van der Wel, University of Amsterdam. 
Samples were immuno gold labelled with anti-PIM/LAM antibody which binds to α(1-2) 
mannosyl residues and individual bacilli were imaged using electron microscopy by Zehui 
Zhang. The images were retuned and analysed using FIJI (Schindelin et al., 2012). Images of 
large bacilli were stitched using MosaicJ plugin, the length of each bacilli was measured as 
well as the number of gold particles present on the bacilli. Data analysis was performed with 
GraphPad Prism 6. 
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7.7 Preparation of heat-inactivated planktonic and biofilm M. tuberculosis biomass 
Biofilms were scraped using sterilised disposable spatulas into glass universals, planktonic 
cultures were spun at 3060g for 10 minutes, consolidated and pelleted into glass universals. 
Samples were inactivated by autoclaving at 126
o
C for 30 minutes, evaporated to dryness 
using a Genevac EZ-2 Plus evaporator (Genevac Ltd, UK) and frozen at -80
o
C until required. 
7.8 M. tuberculosis polar and apolar lipid extractions 
Apolar and polar lipids were extracted from planktonic and biofilm heat-inactivated M. 
tuberculosis biomass according to the method described in (Besra 1998). Briefly, 50 mg of 
biomass was resuspended in 2mL methanol-0.3% NaCl (100:10) and 1 mL or Petroleum 
Ether was added. Samples were mixed overnight. The upper petroleum layer was removed 
and 1 mL of petroleum ether was added again, mixed for 15 minutes and combined. These 
were evaporated to yield apolar lipids which were re-suspended in 250µL dichloromethane. 
2.3 mL of chloroform-methanol-0.3% NaCl (9:10:3) was added to the methanolic saline 
extract and mixed for an hour, spun for 15 minutes at 3500g and the supernatant was retained. 
The pellet was further extracted with 0.75 mL of chloroform-methanol-0.3% NaCl (5:10:4) 
for 1 hour, spun and combined with the previous supernatant. 1.3mL of chloroform and 1.3 
mL of 0.3% NaCl was added and mixed for 2 hours until a biphase had formed. Samples 
were centrifuged and the lower organic layer was evaporated to yield polar lipids. These were 
suspended in 300µL chloroform-methanol (2:1).  
7.9 Analysis of M. tuberculosis planktonic and biofilm phenotype polar and apolar 
lipids 
Apolar and polar lipids were analysed by two-dimensional thin-layer chromatography (2d-
TLC) using the solvent systems described in (Besra, 1998) (Systems A- C) and (Wheeler, 
2009) (systems D and E). Aluminium backed silicon TLC sheets were divided into 9 squares 
each 6.6 cm by 6.6 cm. Solvent systems A-E were set-up as described in Table 3.3-1. 
219 
 
Solvent mixtures were agitated and left to form an atmosphere in TLC developing tanks for 5 
minutes before TLC analysis. 20µL of lipids were spotted on TLC plates 1cm X 1cm from 
the bottom left corner using a capillary tube, allowed to dry and placed in the correct 
orientation into developing tanks. Once completed the plates was dried using a heat gun 
(lowest setting) and run in direction 2 at the correct orientation. After a second period of 
drying the TLCs were sprayed with 5% ethanolic molybdophosphoric acid (MPA) and 
charred with a heat-gun to visualise the lipids. Alternatively they were sprayed with α-
naphthol-sulphuric acid to visualise glycolipids. 
7.10 Imaging and analysis of apolar and polar TLC plates 
TLC plates were scanned into TIFF images in sets relating to solvent system and stain 
applied. For preparation of figures, the brightness and contrast of each image was uniformly 
optimised for each set and the plates were cropped, rotated and compiled using GIMP 2.8 
software. For densitometry analysis, raw scanned image sets were analysed using FIJI 
software (Schindelin et al., 2012). Images were converted to greyscale and the background 
was subtracted. The image was inverted and the integrated density was measured in equal 
size circular selections over each spot replicate. Raw integrated density data was imported to 
Microsoft Excel and for each biological replicate, the relative density of planktonic and 
biofilm lipid spots was calculated. Statistical analysis was performed using Graph Pad Prism 
6 software. 
7.11 mAGP extraction 
 2% SDS in PBS was added to planktonic and biofilm pellets left over from the ethanol reflux 
step of the carbohydrate and lipoglycan extraction (see section 7.13). This was heated under 
reflux at 95
o
C overnight. The following day the samples were washed with water, pelleted, 
washed with 80% acetone, pelleted and washed with 100% acetone and dried. 
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7.12 Extraction and analysis of fatty acid and mycolic acid methyl esters (FAMES and 
MAMES) 
As described in (Besra, 1998). 2mL of 15% Tetrabutylammonium hydroxide (TABH) was 
added to 50mg of planktonic and biofilm mAGP extracts. Samples were heated at 95
o
C 
overnight and allowed to cool. 2 mL of water was added to the samples followed by 1 mL of 
dichloromethane and 250 µL of idomethane and mixed for 1 hour. The samples were 
centrifuged at 3000g for 10 minutes. The lower layer was retained and 3ml of water was 
added. These were mixed and centrifuged again and the water wash step was repeated 
another 2 times. Samples were suspended in 0.5 mL dichloromethane and evaporated. 0.2 mL 
toluene and 0.3 mL acetonitrile were added and the samples were left for an hour. FAMES 
and MAMES were centrifuged at 3000g for 15 minutes and resuspended in dichloromethane. 
FAMES and MAMES were analysed by spotting 20µL and running in 1 direction in a solvent 
system of hexane.ethyl acetate (95:5) three times and charred using a heat gun after spraying 
with 5% MPA.  
7.13 Extraction of carbohydrate and lipoglycan extracts 
As described in (Besra, 1998). Equal biomass samples of planktonic or biofilm heat-
inactivated biomass were heated under reflux with 10mL ethanol-water (1:1) at 75
o
C for 4 
hours. Samples were then left to cool to room temperature, spun at 3000g for 15 minutes and 
the supernatant was removed into fresh tubes. The pellet was topped up to with 10mL 
ethanol-water (1:1) and the heating step and centrifugation was repeated. The supernatants 
were vacuum dried overnight in an EZ-2 personal evaporator to give dried pellets. The 
remaining pellet from the ethanol reflux was used for mAGP extraction (section 7.11). To the 
dried supernatants, 1 mL PBS was added to the smaller pellet which was resuspended by 
sonicating for 10 minutes. The suspensions were pipetted into the tubes containing the larger 
pellet and sonicated again for another 10 minutes. An equal volume of phenol saturated with 
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PBS was added to the tubes. The tubes were heated at 75
o
C for 30 minutes. The tubes were 
left to stand and cool to room temperature. The phenol and aqueous layers were separated by 
centrifugation at 3000g. The aqueous layer was removed into a semi-permeable dialysis 
membrane (MWCO 3500) which was wetted and sealed at one end with a mediclip using a 
plastic Pasteur pipette. The samples were dialysed overnight with running tap water and left 
in distilled water for 1 hour to remove salts from the tap water. Samples were transferred into 
clean pre-weighed glass tubes and were subsequently vacuum dried using the aqueous setting 
on the EZ-2 overnight. The tubes were weighed again and the biomass of the crude 
lipoglycan fraction was calculated.  
7.14 Carbohydrate and lipoglycan gel 
Planktonic and biofilm carbohydrate/lipoglycan extracts were suspended in water at 15 µg 
mL
-1
. 150µg (10 µL) was added to Eppendorf tubes along with 10 µL M. smegmatis LAM 
standard. Subsequently 10µL of x2 concentrated SDS loading buffer was added. Samples 
were added to a Mini Protean TGX Precast Gel (Bio-Rad, USA) submerged in 1% SDS 
buffer (National diagnostics Ultra-pure 10X Tris, Glycine, SDS diluted 1/10) and the samples 
were run with PageRuler pre-stained protein ladder and CandyCane molecular weight 
standards (Life Technologies, USA). The gel was run for 45 minutes 200V 30mA. The gel 
was stained to visualise lipoglycans using Pro-Q emerald stain kit (P21857) and the gel was 
processed according to the manufacturer’s instructions (Life Technologies, USA). The gel 
was viewed on a Molecular imager with image-lab software Gel Doc XRT (Bio-Rad, USA).  
7.15 Total sugar analysis 
Planktonic and biofilm phenotype carbohydrate/lipoglycan extracts and mAGP fractions were 
treated with 2M trifluoroacetic acid (TFA). 200µL of 2M TFA was added to 0.5 mg mAGP 
extracts and 3µg of carbohydrate/lipoglycans. Samples were heated to 120
o
C for 1.5 hours 
under reflux and allowed to cool to room temperature. The acid was evaporated using a 
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sample concentrator. 100 µL of 10 mg mL-1 NaBH4 in 1:1 ethanol:NH4OH (1M) was added 
to each sample and left capped at room temperature overnight. 3 drops of glacial acetic acid 
were added to each sample and evaporated. 3 drops of 10% glacial acetic acid in methanol 
were added then evaporated. This step was repeated once. Next 3 drops of 100% methanol 
was added and evaporated. This step was repeated once. 100µL acetic anhydride was added 
and this was heated at 120
o
C for 1 hour. After allowing the sample to cool to room 
temperature, 100 µL of toluene was added to the samples and was evaporated. 2 mL of 
chloroform and 2 mL of H2O was added to each sample. The lower organic layer of each 
sample was transferred into a fresh tube using a glass pipette and dried using a sample 
concentrator, ready for gas chromatography analysis. Gas chromatography was carried out by 
the University of Birmingham Chemistry department. Percentage of constituent sugars was 
determined after identifying arabinose, mannose, glucose peaks for carbohydrate/lipoglycan 
fraction and rhamnose, arabinose and galactose peaks for mAGP extract from planktonic and 
biofilm cultures. 
7.16 Whole blood stimulation with M. tuberculosis planktonic and biofilm phenotype 
carbohydrate extracts 
x3 planktonic and x3 biofilm M. tuberculosis carbohydrate extracts were resuspended in 
RPMI 2mM L-glutamine at 1000 and 2500 µg mL
-1
 and zymosan at 1000 µg mL
-1
. 5µL of 
stock solutions was added to 495 µL of blood from x3 donors (PIP039, PIP027 and PIP004) 
for final concentrations of 10 µg mL
-1
 and 25 µg mL
-1
. After 24 hours incubation at 37
o
C 5% 
CO2, plasma was collected after centrifugation of the samples at 1000g for 10 minutes. 
Samples were either stored at -80
o
C until required or filtered using 0.2 µm spin-X centrifuge 
tube filters (Sigma, CLS8160) and analysed for cytokine secretion using a 20-plex 
eBioscience Procartaplex Human Th1/Th2 & Chemokine Panel 1 (EPX200-12173-901) kit 
which detected secreted IL-12p70, CCL2 (MCP-1), CCL5 (RANTES), CXCL1 (GRO α), 
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CXCL12 α (SDF-1 α), CXCL10 (IP-10), CCL11 (Eotaxin), GM-CSF, IFN gamma, IL-1 β, 
IL-13, IL-18, IL-2, IL-4, IL-5, IL-6, IL-8, CCL3 (MIP-1 α), and CCL4 (MIP-1 β) and TNF α. 
The kit was used according to manufacturer’s instructions using the plate layout in Table 
7.16-1. The kit was run on a MAGPIX instrument and standard curves were developed using 
Procartaplex analyst software to calculate the amount of secreted cytokines in each sample in 
pg mL
-1
.
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 Standards Donor1 Donor2 Donor3  
1 2       9 10 11 12 
A 
 
Std1 Std1 Unstim PK2 BF3 Unstim PK2 BF3 Unstim PK2 BF3 BF1(25) 
B 
 
Std2 Std2 Unstim PK2 BF3 Unstim PK2 BF3 Unstim PK2 BF3 BF1(25) 
C 
 
Std3 Std3 Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) BF1(25) 
D 
 
Std4 Std4 Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) Unstim 
RPMI 
PK3 PK1(25) BF1(25) 
E 
 
Std5 Std5 Zy BF1 PK2(25) Zy BF1 PK2(25) Zy BF1 PK2(25) BF1(25) 
F 
 
Std6 Std6 Zy BF1 PK2(25) Zy BF1 PK2(25) Zy BF1 PK2(25) BF1(25) 
G 
 
Std7 Std7 PK1 BF2 BF1(25) PK1 BF2 BF1(25) PK1 BF2 BF1(25)  
H 
 
Std8 Std8 PK1 BF2 BF1(25) PK1 BF2 BF1(25) PK1 BF2 BF1(25)  
Table 7.16-1: Plate layout M. tuberculosis whole blood stimulation with carbohydrate extracts. Std, standards; Unstim, unstimulated plasma; 
Unstim RPMI, plasma stimulated with RPMI 2mM L-glutamine only; Zy, zymosam 10 µg mL
-1
; PK1-PK3, planktonic M. tuberculosis 
carbohydrate extracts 10 µg mL
-1
; BF1-BF3 biofilm M. tuberculosis carbohydrate extracts 10 µg mL
-1
; (25) 25 µg mL
-1
.
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7.17 Generation of M. tuberculosis planktonic capsule and biofilm extracts 
 x6 planktonic capsule extracts were prepared from biological replicate planktonic cultures 
set-up as described in methods section (7.1). To harvest, each culture was spun at 3060g for 
10 min in x2 50 mL tubes, the supernatants were discarded and pellets combined resulting in 
x6 planktonic pellets. x6 biofilm capsule extracts were prepared from biological replicate M. 
tuberculosis biofilm cultures as described in methods section (7.1) with x4 24-well plate 
technical replicates per biological replicate. To harvest, biofilms were scraped off the surface 
of the wells into x6 50 mL falcon tubes. 
Approximately x5 pellet volume sterilised 4mm glass beads were added to the wet cells and 
vortexed for 1 minute. 3 mL of distilled water was added to each bead-treated sample and 
briefly vortexed and passed through a 0.2µm sterile filter using a syringe. The filtrates were 
transported to a non-toxic CL3 cabinet and filtered a second time to ensure the contents were 
sterile, into pre-weighed glass tubes. Capsule extracts were dried down using the aqueous 
setting on a Genevac EZ-2 personal evaporator and dried capsule biomass was calculated. 
Dried capsule extracts were frozen at -80
o
C until required. 
7.18 Whole blood stimulation with capsule extracts 
x6 planktonic and x6 biofilm dried capsule extracts were suspended in distilled water to 
10mg/mL and heavily vortexed until sufficiently dissolved. The samples were then added to 
RPMI 2mM L-glutamine to give a final concentration of 200µg/mL. Additional controls were 
also dissolved in RPMI 2mM L-glutamine at the following concentrations: pre-activated 
Zymosan (CompTech, B400) 50 µg mL
-1
 and Tuberculin PPD RT 23 (Statens Serum Institut) 
200 µg mL
-1
. 12-O-Tetradecanoylphorbol-13-acetate (PMA) (4.8 µg mL
-1
) combined with 
Ionomycin (95 µg mL
-1
) dissolved in DMSO was also used as a positive control. 5 µL of 
capsule or controls were added to 495 µL of fresh heparinised human blood from 2 donors 
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PIP004 and PIP027 in 5mL dual- position capped sterile tubes. Additionally 5 µL of RPMI 
2mM L-glutamine without antigen was added to one sample as a negative control and 500µL 
of unstimulated blood were also included as an additional negative control. Tubes (caps in 
loose position to allow ventilation) were incubated statically at 37
o
C 5% CO2
 
for 24 hours. 
After incubation, tubes were spun at 1000g for 10 min and the plasma was collected into 
cryovials which were frozen at -80
o
C until required.  
A Procartaplex custom kit (eBiosciences) measuring human IFN-γ, IL-6, CCL2 and MMP-1 
was set up with the plate layout shown in Table 7.18-1. The assay was performed as 
described in the multiplex instruction manual. However, prior to their addition, the plasma 
samples were thawed and pipetted into 0.2µm Spin-X centrifuge tube filters which were spun 
at a 2000g for 10 minutes to remove aggregates. The plasma samples were incubated with the 
beads overnight and analysed on a MAGPIX (Luminex). The .csv results file was exported 
and imported on to ProcartaPlex Analyst 1.0 software. The standards and lot numbers were 
added and the software was used to generate standard curves and results for each secreted 
cytokine/chemokine/enzyme in pg/mL. Standard curves were exported as well as the re-
analysed results in a .csv file into Microsoft Excel to generate graphs. 
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 Standards Donor 1 PIP027 Donor 2 PIP004 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
Std1 Std1 Unstim PPD PKD BFB BFF Unstim PPD PKD BFB BFF 
B 
 
Std2 Std2 Unstim PPD PKD BFB BFF Unstim PPD PKD BFB BFF 
C 
 
Std3 Std3 Unstim 
RPMI 
PKA PKE BFC  Unstim 
RPMI 
PKA PKE BFC  
D 
 
Std4 Std4 Unstim 
RPMI 
PKA PKE BFC  Unstim 
RPMI 
PKA PKE BFC  
E 
 
Std5 Std5 Zy PKB PKF BFD  Zy PKB PKF BFD  
F 
 
Std6 Std6 Zy PKB PKF BFD  Zy PKB PKF BFD  
G 
 
Std7 Std7 PMA PKC BFA BFE  PMA PKC BFA BFE  
H 
 
Std8 Std8 PMA PKC BFA BFE  PMA PKC BFA BFE  
Table 7.18-1: Whole blood stimulation with M. tuberculosis capsule extracts. Std, standards; Unstim, unstimulated plasma; Unstim RPMI, 
plasma stimulated with RPMI 2mM L-glutamine only; Zy, zymosam 10 µg mL
-1
; PK1-PK3, planktonic M. tuberculosis carbohydrate extracts 10 
µg mL
-1
; BF1-BF3 biofilm M. tuberculosis carbohydrate extracts 10 µg mL
-1
; (25) 25 µg mL
-1
. 
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7.19 C3b/iC3b ELISA 
x3 planktonic and x3 biofilm phenotype carbohydrate extracts were diluted in 1 mL 
carbonate/bicarbonate buffer capsule (Sigma, C3041) in 100 mL distilled water to a final 
concentration of 25 µg mL
-1
. 100 µL was added to to ensure 2.5 µg of carbohydrate per well 
in Microlon high-affinity binding plates (Sigma, M4561). A 7 point standard curve of human 
purified C3 (CompTech, A113) was generated after diluting neat purified human C3 in to 12 
µg mL
-1
 in carbonate buffer before serial diluting 1/4. Likewise a second 7-point standard 
curve was generated after diluting C3 to 300 µg mL
-1
 in carbonate buffer followed by 1/4 
serial dilutions. 50 µL of standards was placed in respective wells. 
The plate was sealed and left in the fridge overnight to bind the carbohydrate extracts to the 
bottom of the plate. The buffer was removed by inverting the plate over the sink and dabbing 
the plate with paper towels. The plate was blocked by adding 100 µL of 10% BSA in PBS to 
each well and incubating for 1 hour. The plate was washed by inverting the plate over the 
sink and dabbing the plate with paper towels, 100 µL PBS 0.05% Tween 20 was added to 
each well and the plate was inverted over the sink and dabbed with paper towels. Exogenous 
IgG depleted human complement (In house PHE) was thawed. Complement binding buffer 
(CBB) was made by dissolving a complement fixation diluent tablet (Thermo Scientific, 
BR0016) in 2% bovine serum albumen. CBB contained 1.76 mM MgCl2, 0.25 mM CaCl2, 
145.4mM NaCl. 2% complement in CBB, and 10% complement in CBB, or control CBB 
only was added to respective wells and incubated for 1 hour at 37
o
C.  
For labelling, the plate was washed as previously described and 100 µL of (1:500) pAb anti-
C3c HRP (Abcam, ab4212) in CBB or CBB control was added to respective wells.  
The plate was sealed and incubated for 1 hour at room temperature. The plate was washed x3 
times and developed by adding 100 µL of tetramethylbenzidine (TMB) (Abcam, ab171527) 
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to each well for 15 minutes. The reaction was stopped by adding 100 µL of stop solution 
(Abcam, ab171529). After 10 minutes to ensure equal diffusion of colour throughout the 
well, the plate was read using a Multiskan EX plate reader at 450 nm with Ascent software. 
 
7.20 C5b-9 ELISA 
x3 planktonic and x3 biofilm phenotype carbohydrate extracts were seeded to ensure 2.5 µg 
of carbohydrate per well as described in section 7.19. A seven point standard curve was 
generated by diluting neat purified human C5b-9 (CompTech) in carbonate buffer to 10.8 µg 
mL
-1
 before serial diluting ¼. A second 7 point standard curve was generated by diluting neat 
human C5b-9 in carbonate buffer to 270 µg mL
-1 
and performing ¼ serial dilutions. 100 µL 
of standards was placed into respective wells. The plate was sealed and left in the fridge 
overnight to bind the carbohydrate extracts to the bottom of the plate.  
The ELISA was performed as described in section 7.19 until labelling. For labelling, the plate 
was washed and 100 µL of (1:100) pAb Mouse anti-Human C5b-9 Clone aE11 (DAKO, 
M0777) in CBB was added to each well. The plate was sealed and incubated for 1 hour at 
room temperature. The plate was washed as previously described and 100 µL of (1:2000) 
pAb Goat anti Mouse HRP (DAKO, P0447) in CBB was added to each well. Following 
labelling, the ELISA was continued as described in section 7.19 
7.21 MBL ELISA  
x3 planktonic and x3 biofilm phenotype carbohydrate extracts were seeded to ensure 2.5 µg 
of carbohydrate per well as described in section 7.19. A seven point standard curves was 
generated by serial diluting ¼ starting from 10 µg mL
-1
 recombinant human MBL (R&D 
systems, 2307-MB) in in carbonate buffer. 100 µL of standards were added to respective 
wells. The plate was sealed and left in the fridge overnight to bind the carbohydrate extracts 
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to the bottom of the plate. The buffer was removed by inverting the plate over the sink and 
dabbing the plate with paper towels. The plate was blocked by adding 100 µL of 10% BSA in 
PBS to each well and incubating for 1 hour. The plate was washed by inverting the plate over 
the sink and dabbing the plate with paper towels, 100 µL PBS 0.05% Tween 20 was added to 
each well and the plate was inverted over the sink and dabbed with paper towels. 100 µL of 
10 µg mL
-1
 MBL in CBB, or control CBB only was added to respective wells and incubated 
for 1 hour at 37
o
C. 
For labelling, the plate was washed as previously described and 100 µL of mouse anti-human 
MBL mAb 3E7 (Hycult, HM2061) (1:100) in CBB or CBB only was added to respective 
wells. The plate was sealed and incubated for 1 hour at room temperature. The plate was 
washed as previously described and 100 µL of (1:2000) pAb Goat anti Mouse HRP (DAKO, 
P0447) in CBB was added to each well. Following labelling, the ELISA was continued as 
described in section 7.19 
7.22 Dispersal of M. tuberculosis using glass beads. 
Agitation with 4 mm glass beads was performed similarly to as described in published studies 
(N’Diaye et al., 1998; Villeneuve et al., 2003). Live M. tuberculosis planktonic pellets or 
scraped biofilms were agitated with sterile 4 mm glass beads which had been added at a ratio 
of approximately 5:1 bead volume:pellet volume. The samples were vortexed for 30 seconds, 
suspended in PBS and left to sediment for 10 minutes. The liquid was poured into fresh tubes 
and the suspension was spun at 200g. The supernatant (dispersed whole cell fraction) was 
aliquoted into cryovials and frozen at -80
o
C until required. 
7.23 Assessment of M. smegmatis viability before and after dispersal using glass beads. 
7 day biofilms were cultured as previously described (7.1). These were weighed and 
dispersed non-mechanically by suspending in PBS-0.1% Tween 80 at 100 mg mL
-1
 (wet 
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weight) and vortexing. Serial dilutions to 10
-6
 in PBS-0.1% Tween 80 and viable counts were 
performed using the spread plate method. Subsequently M. smegmatis Tween-80-dispersed 
fractions were pelleted and treated by vortexing for 30 seconds with or without beads (5g 
beads for every 1g wet weight) and re-suspended in PBS-0.1% Tween-80 to 100 mg mL
-1
. 
Samples were serial diluted again and viable counts were performed. Middlebrook 7H10 + 
OADC plates were counted after 3 days incubation at 37
o
C. 
7.24 C3b/iC3b and C5b-9 deposition ± mAb C1q assay 
Viable, thawed planktonic and biofilm phenotype M. tuberculosis from glass-bead treated 
stocks, were diluted to 0.2 OD540 nm Complement binding buffer (CBB). IgG-depleted 
exogenous pooled human complement was pre-incubated for 20 minutes at 4
o
C with PBS 
(control) or mouse anti-human C1q mAb JL-1 (Hycult, HM1096) at 1/5 dilution. To 
bacteria/zymosan control wells, 55 μL of CBB was added. To 2% complement wells, 2.5 μL 
of IgG-depleted exogenous pooled human complement-PBS/mAb anti C1q (4:1) was added 
along with 52.5 μL of CBB. To 10% complement wells, 12.5 μL of IgG-depleted exogenous 
pooled human complement-PBS/mAb anti C1q (4:1) was added along with 42.5 μL CBB.  
 
The plate was incubated at 37
o
C for 45 mins 900 rpm. The plate was centrifuged at 3060g for 
5min and each well was washed with 200 μL CBB. The plate was spun again at 3060g and 
re-suspended in 4% PBS-formaldehyde. The plate was sealed and left in a fumigating cabinet 
overnight to inactivate M. tuberculosis. The following day at containment level 2 the plate 
was spun and re-suspended in CBB. The plate was spun again at 3060g and re-suspended in 
200 μL of CBB containing rabbit anti-human C3c pAb FITC (Abcam, ab4212) and 
Alexafluor 647 nm conjugated mouse anti-human SC5b-9 (Quidel, A239) at 1/500 and 
1/4000 dilutions respectively. The plate was incubated at 4°C for 20mins, centrifuged at 
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3060g for 5min and washed with 200μl PBS twice before being analysed on a CyAN ADP 
Analyzer flow cytometer (Beckman-Coulter, USA) using the gating strategy described in 
Figure 5.3.2.  
After running the plate, compensation was performed using Summit 4.3 software (Beckman-
Coulter, USA) from single conjugate sample FCS files and the magnitude of either C3b/iC3b 
or C5b-9 deposition was measured by calculating integrated median fluorescence intensity 
(iMFI) (Darrah et al., 2007) (median fluorescence*% positive cells) for each sample. The 
iMFI of bacteria + conjugate only negative control wells were subtracted from each sample to 
remove the contribution of background fluorescence to net iMFI values. For statistical 
analysis, ≥3 biological replicate planktonic and biofilm samples were compared by 
performing t-tests corrected for multiple comparisons by false discovery rate (Benjamini et 
al., 2006) with Q = 5% using GraphPad Prism software. 
7.25 MBL, C1q and Ficolin-3 binding assay 
Viable, thawed planktonic and biofilm phenotype M. tuberculosis from glass-bead treated 
stocks, were diluted to 0.2 OD540 nm in CBB. 55 µL of CBB was added to control wells and 54 
µL added to MBL/C1q/Ficolin-3 wells. 45 µL of bacteria was added to designated wells. In 
separate experiments, recombinant (R&D systems, 2307-MB) (100 µg mL
-1
) or recombinant 
ficolin-3 (R&D systems, 2367-FC-050) or human purified C1q (Comp Tech, A099) was 
added to designated wells to give a final concentration of 1µg mL
-1
 in 100 µL. Plates were 
incubated at 900 rpm 37
o
C for 45 min. Plates were spun at 3060g for 5min and washed with 
200 µL CBB per well. Plates were spun at 3060g for 5 min and re-suspended in either 1:100 
mouse anti-human MBL 3E7 (Hycult, HM2061), 1:500 mouse anti-human C1q JL-1 (Hycult, 
HM1096) or 1:100 mouse anti-human Ficolin-3 4H5 (Hycult, HM2089) in CBB or CBB only 
and incubated for 20 min at room temperature. Plates were spun at 3060g 5 min and washed 
with 200 µL CBB per well. Plates were spun at 3060g 5min and re-suspended in 1:500 Goat 
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Anti-Mouse IgG (H+L) Fluorescein (FITC)-AffiniPure F(ab')2 Fragment antibody (Stratech, 
115-096-062-JIR) in CBB or CBB only and incubated for 20 min at room temperature. Plates 
were spun at 3060g 5min and washed with 200 µL filter sterilised PBS per well and this step 
was repeated. Plates were spun at 3060g for 5 min and re-suspended in 200 µL 4% 
formaldehyde in PBS per well and sealed with 70% ethanol-soaked plate sealers. Plates were 
sprayed with 70% ethanol and incubated at room temperature for 1 hour to inactivate the 
bacteria in the wells. For statistical analyses of the MBL, C1q and ficolin-3 experiments, ≥3 
biological replicate M. tuberculosis planktonic and biofilm samples were compared by 
performing two-tailed Welch’s t-tests using GraphPad Prism software. 
7.26 C2a binding assay 
Live bead-treated M. tuberculosis planktonic, biofilm, M. smegmatis, S. agalactiae and 
Zymosan stocks were diluted to 0.2 OD540 nm in CBB. 55 µL of CBB was added to control 
wells and 52 µL was added to C2 and C2a wells. Human purified C2 (Comp Tech, A112) and 
activated C1s (CompTech, A104) were fast thawed to 37
o
C. 44 µL of 1/10 diluted activated 
C1s or PBS was added to 55 µL of C2. The x2 vials were vortexed and incubated at 37
o
C for 
20 min. 3 µL of PBS-C2 or C1s-C2 was added to designated wells and the plate was 
incubated for 45 minutes 900 rpm. The plate was spun at 3060g for 5 min and washed with 
200 µL CBB per well. The plate was resuspended in 1:200 Rabbit anti-human C2a FITC pAb 
(Bioss Antibodies, bs-10428R-FITC) and incubated at room temp for 20 min. The plate was 
washed x2 with 200 µL PBS per well and resuspended a final time in PBS-4% formaldehyde. 
An ethanol sprayed plate sealer was placed over the plate and it was incubated for 1 hour at 
room temp to inactivate bacteria. The plate was sprayed out the cabinet and run on the flow 
cytometer. 
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9 APPENDICES 
 
9.1 Standard curves of cytokines/chemokines tested in planktonic and biofilm 
carbohydrate stimulations with whole blood
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Figure 9.1.1: Standard curves of secreted cytokines generated using Procartaplex Th1/Th2 
Panel and Procartaplex analyst software. (Affymetrics, eBiosience, USA). 7-point standard 
curves generated from means of duplicate standard samples, using a 5 parameter logistic fit 
curve. Green dotted lines show lower limit of quantitation (LLOQ) and upper limit of 
quantitation (ULOQ) after setting the cut-off at 30% bias (acceptable percentage variation 
form the ideal standard curve.) (A) IFN-γ, (B) IL-12p70, (C) IL-1b, (D) IL-2, (E) IL-4. 
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Figure 9.1.2: Standard curves of secreted cytokines generated using Procartaplex Th1/Th2 
Panel and Procartaplex analyst software. 7-point standard curves generated from means of 
duplicate standard samples, using a 5 parameter logistic fit curve. Green dotted lines show 
lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ) after setting the 
cut-off at 30% bias (acceptable percentage variation form the ideal standard curve.) (A) IL-5, 
(B) IL-6, (C) TNF-α, (D) GM-CSF, (E) IL-18. 
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Figure 9.1.3: Standard curves of secreted chemokines generated using Procartaplex Th1/Th2 
Panel and Procartaplex analyst software. 7-point standard curves generated from means of 
duplicate standard samples, using a 5 parameter logistic fit curve. Green dotted lines show 
lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ) after setting the 
cut-off at 30% bias (acceptable percentage variation form the ideal standard curve.) (A) 
CCL11, (B) CXCL1, (C) CXCL8, (D) CXCL10, (E) CCL2. 
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Figure 9.1.4: Standard curves of secreted cytokine/chemokines generated using Procartaplex 
Th1/Th2 Panel and Procartaplex analyst software. 7-point standard curves generated from 
means of duplicate standard samples, using a 5 parameter logistic fit curve. Green dotted 
lines show lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ) after 
setting the cut-off at 30% bias (acceptable percentage variation form the ideal standard 
curve.) (A) CCL3, (B) CCL4, (C) CXCL12α, (D) IL-13, (E) CCL5 
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9.2 Appendix results and figures from planktonic and biofilm carbohydrate 
stimulations with whole blood 
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Figure 9.2.1: IL-12p70 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-12p70 (A) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted IL-12p70 (B) in whole blood after 24h 
stimulation with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 
µg mL
-1
). Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg 
mL
-1
). The horizontal dotted line on each graph represents the lower limit of quantitation. 
Each donor blood stimulation is presented separately by vertical dotted lines. Error bars = 
standard deviation. 
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Figure 9.2.2: IL-4 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-4 (A) in whole blood 
after 24h stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
). Total secreted IL-4 (B) in whole blood after 24h stimulation with x2 
biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) and x2 
biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). Negative 
control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). The 
horizontal dotted line on each graph represents the lower limit of quantitation. Each donor 
blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation.
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Figure 9.2.3: IL-5 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-5 (A) in whole blood 
after 24h stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
). Total secreted IL-5 (B) in whole blood after 24h stimulation with x2 
biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) and x2 
biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). Negative 
control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). The 
horizontal dotted line on each graph represents the lower limit of quantitation. Each donor 
blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation.
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Figure 9.2.4: GM-CSF response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted GM-CSF (A) in whole 
blood after 24h stimulation with x3 biological replicate planktonic M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis 
carbohydrate extracts (10 µg mL
-1
). Total secreted GM-CSF (B) in whole blood after 24h 
stimulation with x2 biological replicate planktonic M. tuberculosis carbohydrate extracts 
(25 µg mL
-1
) and x2 biological replicate biofilm M. tuberculosis carbohydrate extracts (25 
µg mL
-1
). Negative control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg 
mL
-1
). The horizontal dotted line on each graph represents the lower limit of quantitation. 
Each donor blood stimulation is presented separately by vertical dotted lines. Error bars = 
standard deviation.
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Figure 9.2.5: IL-13 response in whole blood stimulated with carbohydrate extracts from 
planktonic and biofilm phenotype M. tuberculosis. Total secreted IL-13 (A) in whole blood 
after 24h stimulation with x3 biological replicate planktonic M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
) and x3 biological replicate biofilm M. tuberculosis carbohydrate 
extracts (10 µg mL
-1
). Total secreted IL-13 (B) in whole blood after 24h stimulation with x2 
biological replicate planktonic M. tuberculosis carbohydrate extracts (25 µg mL
-1
) and x2 
biological replicate biofilm M. tuberculosis carbohydrate extracts (25 µg mL
-1
). Negative 
control RPMI response (Unstim RPMI), Positive control Zymosan (10 µg mL
-1
). The 
horizontal dotted line on each graph represents the lower limit of quantitation. Each donor 
blood stimulation is presented separately by vertical dotted lines. Error bars = standard 
deviation.
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9.3 Standard curves of cytokines/chemokines/protease tested in planktonic and 
biofilm capsule stimulations with whole blood
269 
 
 
Figure 9.3.1: Standard curves of secreted cytokine/chemokines/protease generated using 
Procartaplex custom 4-plex panel and Procartaplex analyst software. 7-point standard curves 
generated from means of duplicate standard samples, using a 5 parameter logistic fit curve. 
Green dotted lines show lower limit of quantitation (LLOQ) and upper limit of quantitation 
(ULOQ) after setting the cut-off at 30% bias (acceptable percentage variation form the ideal 
standard curve.) (A) IFN-γ, (B) IL-6, (C) CCL2, (D) MMP-1. 
